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Abstracts of the XII European Symposium on Platelet and Granulocyte Immunobiology
L1 Genetics of platelet responsiveness
Kunicki T.
CHOC Childrens Hospital/University of California Irvine,
Orange, CA, USA
Genetic and environmental factors contribute to a substantial va-
riation in platelet function among normal individuals. Candidate
gene association studies are an initial approach to define the ge-
netic component, but single nucleotide polymorphisms (SNPs)
identified in those studies can be validated by more objective and
comprehensive genome wide association studies (GWAS) of qu-
antitative functional traits in large cohorts of carefully selected
subjects. Platelet count and mean platelet volume (MPV) are
genetically maintained within narrow physiological ranges by
genes that regulate the maturation of the erythro-megakaryocy-
te lineage. Accumulated evidence from a number of laboratories
indicates that among normal individuals or patients with cardio-
vascular disease, MPV correlates with levels of functionally re-
levant platelet receptors, such as the fibrinogen receptor inte-
grin aIIbb3, the collagen receptor integrin a2b1, and the von Wille-
brand Factor receptor GPIba, and the same is likely to be true
for the collagen receptor GPVI. In certain cases, notably the col-
lagen receptor a2b1 or GPIba, the variation in receptor level is
even more pronounced because of an additional effect of recep-
tor gene alleles. By the same token, allelic gene variation certa-
inly contributes to megakaryocyte maturation and platelet pro-
duction. Thus, recent data suggest that allelic variation in the in-
tegrin a2 subunit gene ITGA2 itself contributes to variation in
platelet size and MPV, such that an inverse correlation exists
between MPV and the rs1126643 minor allele. Increased levels
of platelet receptors related to increased MPV contribute in lar-
ge part to the resultant increase in platelet reactivity. Larger pla-
telets are hyperactive, owing in large part to the increased sur-
face expression of these receptors, which play a key role in ini-
tiation of platelet activation and perpetuation of the nascent
thrombus.
L2 The role of complement in mobilization
and engraftment of hematopoietic stem/
/progenitor cells — a novel link between
innate immunity and hematopoiesis
Ratajczak M.Z.
Stem Cell Biology Program at the James Graham Brown Cancer
Center, University of Louisville, Louisville, Kentucky, USA and
Department of Physiology, Pomeranian Medical University,
Szczecin, Poland
The retention of hematopoietic stem/progenitor cells (HSPCs)
in bone marrow (BM) is mainly regulated by interaction betwe-
en stroma cell-secreted stromal derived factor-1 (SDF-1) — and
CXCR4 receptor expressed on HSPCs. Mounting evidence ac-
cumulates that this process is modulated by elements of innate
immunity (e.g, complement cascade, and granulocytes). Accor-
dingly, complement cascade (CC) becomes activated in bone
marrow (BM) during both granulocyte colony stimulating factor
(G-CSF)-induced mobilization of HSPCs as well as after condi-
tioning for hematopoietic transplantation by lethal irradiation.
Research from my laboratory indicates also that CC and granu-
locytes are major regulators of both processes.
In mobilization process of HSPCs the activation of CC leads first
to release from BM-residing granulocytes/monocytes of several
proteolytic enzymes (MMP-2, MMP-9, catepsin G, neutrophil
elastase) that impair SDF-1-CXCR4 mediated retention of HSPCs
in BM niches. We also noticed that activation/cleavage of CC
releases C3a and C5a anaphylatoxins that differently regulate
mobilization. Accordingly, C3a, by enhancing responsiveness of
HSPCs to decreasing concentrations of SDF-1 in BM, prevents
mobilization and promotes their BM-retention. On other hand
C5a-mediated pro-mobilization effects are mediated by granulo-
cytes. Accordingly, C5aR+ granulocytes are chemoattracted by
plasma C5 cleavage fragments, being the first wave of cells le-
aving BM. This facilitates subsequent egress of HSPCs. It expla-
ins why granulocytopenic mice or C5 deficient mice are poor
mobilizers.
In an opposite process of HSPCs homing to the BM activation of
CC leads to release several factors in BM microenvironment that
increase responsiveness of HSPCs to SDF-1 gradient and facili-
tate engraftment of HSPCs such as C3 complement cascade cle-
avage fragments and antimicrobial cationic peptides, such as ca-
thelicidin/LL-37 or b2-defensin.
Based on this it is proposed a novel paradigm that activation of
CC play an important and underappreciated role in trafficking of
HSPCs. Our data also indicate that modulation of CC as a novel
strategy to optimize and accelerate both mobilization and homing
of HSPCs.
Autoimmune thrombocytopenia
and genetic disorders — session 1
L3 TPO mimetics in children with chronic
immune thrombocytopenia
Nugent D.
CHOC Children’s Hospital/University of California Irvine,
Orange, CA, USA
Although TPO-mimetics have been shown to be useful in adults
with severe chronic ITP, the experience in children is very limi-
ted due in large part to the higher rate of spontaneous resolu-
tion and less bleeding in this age group. In this presentation, we
will review the reports available describing randomized and con-
trolled studies in children with chronic ITP. In the adult popula-
tion, concerns have been raised with the occurrence of throm-
bosis and bone marrow changes while on TPO-mimetics such as
increased fibrosis and reticulin deposition. This has not yet been
observed in children, and in an open label trial at our center all
children have base line bone marrow biopsy and cytogenetic stu-
dies performed for comparison at 6 and 12 months while on the-
se agents. Many pediatric pathologists do not score bone mar-
rows routinely, and when asked to report on blinded samples,
reported scores of 2 and 3 on samples previously reported as
normal. This has resulted in a new protocol for the pediatric pa-
thologists in our center when reading marrows in chronic ITP
and points to a need for baseline studies prior to the institution
of TPO-mimetics. Although, most adults are dependent on TPO-
mimetics, we have had some success in weaning pediatric pa-
tients off of these agents and found certain patients appear to have
resolved their ITP. The benefit of these agents is primarily seen
in the ability to eliminate steroids and chronic immune suppres-
sion in young children while maintaining a fully active and mar-
kedly improved quality of life for both parents and patient.
L4 Management of primary immune
thrombocytopenia in 2012
Windyga J.
Institute of Hematology and Transfusion Medicine, Warsaw,
Poland
Primary immune thrombocytopenia (ITP) is an autoimmune di-
sorder characterized by isolated thrombocytopenia, defined as
a peripheral blood platelet count below 100 × 109/l, and the absen-
ce of any obvious underlying cause of thrombocytopenia. ITP may
be acute (< 6 months), or chronic (> 6 months). Recent studies
indicate that ITP is not only a disease of autoantibody-mediated
platelet destruction but also a disease of impaired platelet pro-
duction. The latter is thought to be a direct effect of autoantibo-
dies on the megakaryocyte. Epidemiologic data suggest that the
incidence of ITP in adults ranges from 1.6 to 3.9 per 100,000
persons per year, with a prevalence ranging from 9.5 to 23.6 per
100,000 persons. Clinical manifestations are related to the seve-
rity of thrombocytopenia. In general, ITP patients with platelet
counts of 50–100 × 109/l are asymptomatic. Platelet counts be-
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tween 20 and 50 × 109/l are associated with excessive bruising,
petechiae and ecchymoses with minor trauma. Patients with pla-
telet counts below 20 × 109/l can develop spontaneous bleeding
episodes, including life-threatening bleeds such as intracranial
haemorrhage or other internal bleeds. The risk of severe ble-
eding has been estimated to increase with increasing patient age
and with platelet counts persistently below < 20–30 × 109/l. In
chronic ITP, the goal of treatment is to achieve a platelet count
that prevents major bleeds. Management must be tailored to the
individual patient, taking into account clinical course of the dise-
ase, lifestyle and risk factors for severe bleeding. Patients with
platelet counts > 30 × 109/l usually do not require treatment
unless they are undergoing procedures likely to result in blood
loss (e.g. surgery). Corticosteroids are the standard first-line tre-
atment. They are effective in as much as 2/3 of patients, but are
associated with significant short- and long-term side effects (e.g.
hypertension, glaucoma, Cushing’s syndrome). Intravenous im-
munoglobulin is reserved for “rescue” treatment of acute ble-
eding episodes and for patients who are refractory to steroids.
Other alternative treatments include among others anti-D, im-
munosupressants (azathioprine, danazol, cyclosporine, anti-CD20
agent rituximab), vinca alkaloids. Splenectomy is often perfor-
med in patients who are refractory to corticosteroids or in whom
corticosteroid-dependence has developed. Eighty percent of ITP
patients respond to splenectomy, and response is sustained in
66% with no additional therapy for at least 5 years. Newly ap-
proved agents for use in patients with ITP are thrombopoietin
receptor agonists romiplostim and eltrombopag.
L5 Pathophysiology, laboratory
diagnosis and treatment of Glanzmann’s
Thrombasthenia
Chojnowski K.
Department of Hematology, Medical University of Lodz,
Łódź, Poland
Glanzmann’s Thrombasthenia (GT) is a rare autosomal recessi-
ve disorder, characterized by quantitative or qualitative defect
of the platelet membrane glycoprotein (GP) IIb/IIIa (aIIbb3 inte-
grin). It is named for Eduard Glanzmann (1887–1959), the Swiss
pediatrician who originally described this disease. The hallmark
of GT is severely reduced or absent  platelet aggregation in re-
sponse to multiple physiological agonists.
Epidemiology: GT is very rare disorder with a worldwide di-
stribution but precise epidemiologic data is not available. The
highest frequency of GT is found in certain ethnic populations
with an increased incidence of consanguinity.
Pathophysiology: GPIIb and GPIIIa form a complex in the pla-
telet membrane which functions as a receptor for fibrinogen and
other adhesive glycoproteins. An abnormality in the GPIIb/IIIa
complex results in a failure of platelet plug formation at sites of
vascular injury leading to easy bruising and excessive bleeding.
A large number of mutations in genes encoding GPIIb and GPIIIa
that are causative for GT have been described. To date Glan-
zmann Thrombasthenia Database includes 101 mutations in the
ITGA2B gene and 66 mutations in the ITGB3 gene. Majority of
them are missens and nonsense mutations.
Clinical features: Patients with GT show a mucocutaneous
pattern of bleeding. Clinical manifestation include easy bruising,
purpura, ecchymoses, epistaxis, gingival bleeding, gastrointesti-
nal bleeding and hematuria. Women may experience heavy or
prolonged menstrual bleeding and bleeding at the time of child-
birth. Haemarthroses and muscle haematomas, common in se-
vere haemophilia seldom occur in the course of GT.  Bleeding
manifestation may vary in severity and frequency but majority
of patients have a history of red cell and/or platelet transfusion.
Laboratory diagnosis: First line tests in patients with suspec-
ted inherited platelet disorders include complete blood count with
platelet morphology and PFA-100. Platelet count and size in pa-
tients with GT are within normal ranges whereas closure time
in PFA-100 method is usually prolonged. Sensitivity of PFA-100
in GT is very high (~ 97%) but specificity of this test is low.
Diagnosis of GT can be confirmed by platelet aggregation stu-
dies that show markedly diminished or absent aggregation in
response to all platelet stimuli except for ristocetin. A definitive
laboratory diagnosis of GT is based on flow cytometric analysis
employing monoclonal antibodies specific for GPIIb (CD41) and
GPIIIa (CD61).
Management: Presently no specific guideline/algorithm for cli-
nical management for GT is available because of the rarity of this
disease. Management of patients with GT includes: patient edu-
cation, local measures, antifibrinolytic agents, hormonal thera-
py, platelet transfusions and recombinant activated factor VII
(rFVIIa). Desmopressin (DDAVP) is not recommended for GT
patients.  Platelet transfusions are the first-choice treatment for
severe hemorrhage and for haemostatic cover of major invasive
procedures. However, repeated transfusion of platelets carries
the risk of alloimmunization to human leukocyte antigens (HLA)
and/or platelet membrane GPIIb/IIIa with possible refractoriness
to future platelet transfusion. Recombinant activated factor VII
was found to be a safe and mostly effective alternative to plate-
let transfusion. In 2003, the EMEA approved rFVIIa for treat-
ment and prevention of bleeding in GT patients with platelet
refractoriness and/or past or present antiplatelet antibodies.
The prognosis in GT is usually good with adequate supportive
care but severe bleeding episodes can occur with menses, trau-
ma and surgical procedures.
O1 Mouse models of anti-platelet
autoimmunity
Detalle L., Su D., Coutelier J.P.
de Duve Institute, Université Catholique de Louvain, Brussels,
Belgium
Background: The development of clinical autoimmune throm-
bocytopenia may require two successive steps: initiation of the
autoantibody response and activation of macrophages that may
be related to stimuli independent from the initial cause of the
autoimmune response, including viral infections.
Methods: We therefore developed different mouse models of
immunization and infection to analyze the successive mechani-
sms that could explain disease development.
Results: Immunization of normal mice with rat erythrocytes or
platelets results in the production of autoantibodies that reco-
gnize antigens on the mouse cells. Analysis of autoantibodies
elicited by this immunization showed the production of IgM di-
rected against ± 95 and 150 kDa autoantigens that could induce
both platelet destruction in vivo and impairment of their func-
tion. Production of these autoantibodies was dependent on CD4+
T helper lymphocytes reacting with rat but not with mouse pla-
telets, and was controlled by CD4+CD25+FoxP3+ regulatory
T cells that developed progressively after immunization. Howe-
ver, these autoantibodies triggered only moderate in vivo drop
in platelet counts. Infection with a common and non-pathogenic
mouse virus, namely lactate dehydrogenase-elevating virus, trig-
gered dramatic thrombocytopenia when autoantibodies were at
high levels. This resulted from macrophage activation, which was
under the control of interferons, leading to exacerbated phago-
cytosis of target cells opsonized with autoantibodies. An incre-
ased expression of Fc-gamma receptors following viral infection
could partly explain this increased phagocytic activity.
Conclusion: These mouse models of anti-platelet autoimmuni-
ty may help to understand the sequence of events leading to pa-
thologic thrombocytopenia and therefore to define targets for new
treatments.
Key words: autoimmune thrombocytopenia, mouse, platelet,
autoantibody, helper T lymphocyte, regulatory T lymphocyte,
macrophage, phagocytosis, Fcgamma receptor, virus, lacate de-
hydrogenase-elevating virus
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O2 Leucocyte adhesion deficiency type III
due to a novel mutation in the FERMT3
gene
Shah B.F.S., Taaning E., Schejbel L., Marquart H.V.,
Ryder L.P., Ifversen M., Heilmann C., Müller K.
Rigshospitalet Copenhagen, Copenhagen, Denmark
Background: Leucocyte-adhesion deficiency type III (LADIII)
is a rare autosomal recessive disorder with a Glanzmann-like
bleeding syndrome combined with a leucocyte-adhesion deficien-
cy, characterized by multiple integrin signalling dysfunctions in
leucocytes and platelets. Mutations in the FERMT3 gene have
been proposed as the main cause of the disease. The gene enco-
des the hematopoietic specific integrin-activating cytoplasmic
protein Fermitin family homolog 3 (kindlin-3), found to be im-
portant in integrin activation.
Aim: We report on a patient with LADIII syndrome caused by
a novel mutation in the FERMT3 gene.
Methods and material: The patient was a 3-week old boy with
consanguineous Afghan parents who presented with petecchial
bleedings. Blood counts showed highly elevated white blood cells,
moderate thrombocytopenia and anaemia. The patient was ad-
mitted with opportunistic infections including pneumocystiis ji-
roveci pneumonia. Fourteen months old he underwent success-
ful stem cell transplantation with an unrelated cord blood donor.
Results: Thromboelastography showed decreased maximum
amplitude, indicating defective GPIIb-IIIa activation signalling
cascade. Flow cytometry showed expression of GPIIb-IIIa on the
patient´s platelets and no platelet antibodies were detected in
serum. Leucocyte studies revealed impaired chemotaxis, sugge-
sting leucocyte adhesion deficiency. Molecular investigations sho-
wed normal CGH-array. Sequencing revealed a homozygous one-
base deletion in the start of exon 15 (c.21667del-G, NG_016360)
in the FERMT3 gene, leading to skipping of the original stop co-
don, which is likely to destroy normal protein function.
Conclusions: The combination of thrombastenic bleeding and
opportunistic infections should raise the suspicion of LADIII
syndrome and further investigation of the kindlin3-expression,
hence FERMT3 gene.
Key words: leucocyte-adhesion deficiency, thrombasthenia
Diagnosis and etiology of transfusion-
-related acute lung injury — session 2
L6 Non-immune TRALI
Fung Y.L., Tung J.P., Minchinton R.M., Fraser J.F.
University of Queensland & the Prince Charles’ Hospital,
Brisbane, Australia
Background: Reviews of laboratory results from TRALI cases
now confirm that over 20% of TRALI events have no associated
leukocyte antibody, and thus are non-immune TRALI events [1–
–3]. This form of TRALI is hypothesised to follow the two-event or
priming TRALI mechanism, where non-antibody factors (NAF) ac-
tivate the patient’s neutrophils (key effector cells) [4] which were
originally primed by the patient’s underlying clinical condition.
Experimental evidence for non-immune TRALI: Silliman
and colleagues were pioneers in demonstrating that lipids in sto-
red blood products could prime neutrophils [5]. Recently they
reported that non-polar lipids which accumulate during storage
of leukoreduced packed red blood cells (PRBC) may represent
the key agents provoking antibody-negative TRALI [6].
Animal models have been very useful for dissecting the mecha-
nism underlying non-immune TRALI. Ex vivo rat models sho-
wed that plasma from aged human platelet and aged human PRBC
could precipitate acute lung injury (ALI) [7, 8]. These findings
were confirmed in a syngeneic in vivo rat model which in addi-
tion to ALI provoked coagulopathy [9, 10]. To investigate in de-
tail the pathophysiology of non-immune TRALI, we used an in
vivo ovine model [11]. By comparing the TRALI triggered by aged
platelet supernatant versus aged PRBC supernatant in this mo-
del we found that PRBC produced more severe symptoms and
signs of TRALI [12].
Conclusions: While the use of male predominant plasma rich
blood components will minimise the incidence of antibody me-
diated TRALI, there are currently no consistent strategies in
place to minimise non-immune TRALI. The cumulative eviden-
ce from careful laboratory investigation of TRALI cases together
with in vitro, ex vivo and in vivo data confirm the existence of
non-immune TRALI. This knowledge base is also fundamental
to elucidating the mechanisms of transfusion-related immuno-
modulation (TRIM). Both lines of investigations provide ideal
platforms for developing strategies to make blood transfusion
safer for patients.
References:
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cytes causes lung inflammation and coagulopathy in a ”two-hit”
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lets causes lung inflammation and coagulopathy in a novel in vivo
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L7 A threshold model for the susceptibility
to transfusion-related acute lung injury
Sachs U.J.
Justus Liebig University Giessen, Giessen, Germany
Contaminants present in blood components are capable of indu-
cing TRALI in a transfusion recipient by interacting with the
recipient’s leukocytes and/or endothelial cells. Whether or not
such contaminants lead to the breakdown of the endothelial bar-
rier depends on the patient’s individual predisposition and on the
preactivation status of his leukocytes and endothelial cells. There
is evidence that the presence or absence of attenuators and/or
multipliers of activatory pathways may further modulate this in-
terplay. It is conceivable that in most TRALI patients, several
factors related to the transfusion event and related to the indivi-
dual predisposition act together in order to overcome an (arbi-
trary) activation threshold, a pathological concept known as the
threshold model of TRALI. Our knowledge about critical path-
ways determining the individual predisposition is still very limi-
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ted; excellent clinical trials have identified critical medical con-
ditions that can be integrated in the threshold model and may
hopefully soon help us to identify patient-focused strategies to
further decrease the incidence of TRALI. It is to be feared, ho-
wever, that the mechanism behind many of these medical condi-
tions will not be identified easily.
The capability of antibodies to precipitate TRALI is generally ack-
nowledged, even though how exactly they induce the increase in
endothelial permeability has not been pinpointed so far. It is witho-
ut question that we do see cases of TRALI in the absence of antibo-
dies (non-immune TRALI). Unfortunately, previously published,
promising results on mediators of non-immune TRALI could not
be confirmed both in experiments and most clinical studies, and the
mechanism of non-immune TRALI still awaits elucidation.
This presentation will summarize recent findings on TRALI pa-
thophysiology with a focus on newly discovered or disenchanted
recipient-related and transfusion-related risk factors for TRALI
and will present the threshold model as a unifying concept of how
TRALI develops.
L8 Immunological and non-immunological
factors implicated in TRALI — Polish
experience
Maślanka K., Żupańska B.
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
TRALI (transfusion-related acute lung injury) is recognized as
a serious transfusion related adverse reaction. Among numero-
us TRALI mediators, leukocytes antibodies have been identified
as most important factor for severe TRALI (‘immune’ TRALI).
Experimental evidence shows that TRALI can be induced by me-
tabolic products accumulated during blood component storage
such as bioactive lipids, cytokines and microparticles (‘non-im-
mune’ TRALI). This paper is a summary of 10 year experience
(2001–2011) in TRALI diagnostics in Poland including clinical
observation of TRALI and results of leukocyte antibody detec-
tion in both recipients and donors of blood components. We also
present our recent investigations on concentrations of lysopho-
sphatidylcholine, cytokines and microparticles released from ery-
throcytes, platelets and leukocytes during storage of blood com-
ponents.
O3 Transfusion-related acute lung injury
induced by HNA-3a antibody: new insight
Bayat B., Tjahjono Y., Sydykov A., Hippenstiel S.,
Weissmann N., Sachs U.J., Santoso S.
Clinical Immunology and Transfusion Medicine, Giessen, Germany
Background: Accumulated evidence demonstrates that antibo-
dies against human neutrophil antigens (HNA)-3a play a major role
in fatal TRALI incidence. The mechanism underlying this reac-
tion, however, is unknown. In this study, we investigated the role
of endothelial cells (ECs) in pathomechanism of anti HNA-3a allo-
antibody mediated TRALI under in vitro and in vivo conditions.
Results and conclusions: Analysis of endothelial cells and diffe-
rent blood cells revealed presence of abundant copies of CTL-2
transcripts in ECs in comparison to neutrophils and platelets. This
result was confirmed by immunochemical analysis using anti-HNA-
3a alloantibodies. Treatment of HNA-3a phenotyped EC with anti-
HNA-3a alloantibodies induced reactive oxygen species (ROS) pro-
duction, reduced transendothelial electrical resistance, and incre-
ased albumin-influx through EC monolayer, drastic stress actin fiber
formation and VE-cadherin phosphorylation that lead to cell junc-
tion disturbance and gap formation. This observation indicates that
anti-HNA-3a alloantibodies induce EC barrier failure via ROS-me-
diated destabilization of VE-cadherin in cell junctions.
In an in vivo murine model of TRALI, injection of anti-HNA-3a
alloantibodies in LPS-pretreated C57BL/6 mice induced eleva-
ted concentration of albumin, and number of neutrophils in the
bronchoalveolar lavage and significant increase in lung weight.
Interestingly, although neutrophil depletion mitigated this effect
in mice, but failed to prevent TRALI. Our data demonstrate the
direct destructive effects for transfused HNA-3a antibodies on
endothelial barrier integrity in vitro as well as in vivo. This no-
vel mechanism of TRALI may be helpful to therapeutic strate-
gies in order to decrease transfusion mortality induced by this
antibody.
O4 Binding of HNA-3a antibodies to the
CTL2 isoforms heterologously expressed
on HEK 293T cells
Wesche J., Flesch B.K., Hundt M., Berthold T., Muschter S.,
Schubert N., Fürll B., Bux J., Reil A., Greinacher A.
Universitätsmedizin Greifswald, Inst. für Immunologie &
Transfusionsmedizin, Greifswald, Germany
Background: The choline transporter like protein 2 (CTL2)
expresses the human neutrophil alloantigen 3a (HNA-3a) which
plays an important role in severe cases of antibody mediated
transfusion-related acute lung injury (TRALI) [1]. Two isoforms
of CTL2, differing in the first 10-12 N-terminal amino acids, have
been described. Only the 706 amino acids long CTL2 variant TV1
(NM_020428.3) has been demonstrated to enable choline trans-
port across the cell membrane [2]. In humans, the shorter va-
riant TV2 (NM_001145056.1) seems to be expressed on periphe-
ral blood cells, whereas TV1 is expressed by alveolar type II cells
of the lung [3]. Our aim was to analyze, if binding of HNA-3a
antibodies differs between these two CTL2 variants.
Methods: HEK 293T cells were transfected with an IRES pla-
smid containing TV1 (pCTV1L-3a) or TV2 (pCTV2k-3a) inserts
of the full length CTL2. Cells were harvested and incubated with
plasma containing HNA-3a or HNA-3b antibodies or control pla-
sma and antibody-binding was analyzed by flow cytometry.
Results:. HNA-3a or -3b antibodies showed nearly the same affini-
ty for TV1 and TV2. However, two out of 14 HNA-3a plasmas sho-
wed 30–40% higher affinity for TV2, while one showed 60% higher
affinity for TV1. Results for control plasmas were all negative.
Conclusion: The two isoforms of CTL2 seem to weakly influ-
ence binding of HNA-3a antibodies. An effect in the development
of TRALI remains to be elucidated.
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Neonatal alloimmune thrombocyto-
penia mechanisms and prevention I
— session 3
L9 New approaches to detection of
antibodies causing neonatal alloimmune
thrombocytopenia (NAIT)
Peterson J.A.
Blood Research Institute, BloodCenter of Wisconsin, Milwaukee,
WI, USA
Background: In about two-thirds of suspected NAIT cases, it is
not possible to confirm the diagnosis by detecting a maternal anti-
body specific for an HPA antigen carried by the fetus. One reason
for this is that the mother may be immunized against one of many
low frequency HPA antigens not ordinarily tested in a standard
evaluation. A second, recently recognized cause is that some ma-
ternal antibodies capable of causing NAIT react with low avidity
(LA) antibodies that are difficult to detect in conventional assays.
Methods: Surface plasmon resonance (SPR) assays were used
to detect low avidity antibodies. Purified platelet GPIIb/IIIa (gro-
up O) and recombinant versions of platelet GPs were immobili-
zed on a CM5 sensor chip. Pathogenicity of detected antibodies
was assessed using the NOD/scid mouse model which enables
destruction of human platelets by human antibodies to be tracked
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in vivo with high sensitivity. Modified antigen capture ELISA and
flow cytometry were used to detect maternal antibodies specific
for low frequency antigens using CHO cells expressing recom-
binant antigens and recombinant GP fragments as targets.
Results: Eleven of 61 “antibody-negative” maternal IgG sam-
ples recognized HPA-1a-positive, but not HPA-1a-negative
GPIIb/IIIa using SPR for detection. Three of four LA antibodies
tested caused clearance of human HPA-1a/a platelets but not
HPA-1b/b platelets in the NOD/scid mouse. Soluble recombinant
versions of the GPIIb calf-2 domain were used in SPR to analyze
the binding of IgG from 23 mothers of unresolved NAIT cases
whose baby carried an incompatibility for the HPA-3 antigen. In
one of these 23 cases a low avidity HPA-3a-specific antibody was
identified. CHO cells expressing recombinant HPA antigens were
convenient for detection of antibodies recognizing low frequen-
cy HPA antigens. Soluble recombinant GPIIb calf-2 constructs
engineered to carry HPA-3a and 3b were found (using ELISA)
to be significantly more sensitive than intact platelets for detec-
tion of HPA-3a and -3b antibodies in ELISA.
Conclusions: Low avidity antibodies could account for many
cases of unresolved NAIT triggered by HPA-1a and other human
platelet antigens. They are pathogenic it the mouse and by im-
plication are pathogenic in humans. Recombinant platelet glyco-
protein domains and cell lines expressing platelet glycoproteins
may prove to be of considerable value for detection of HPA anti-
bodies as part of an NAIT evaluation.
O5 Differential IgG-responses
against human platelets through
IgG-Fc-glycosylation
Kapur R.1, Vestrheim A.2, Koeleman C.A.M.3,
Porcelijn L.4, Jackson D.5, Kumpel B.5, Deelder A.M.3,
Michaelsen T.E.2, de Haas M.1, van der Schoot C.E.1,
Wuhrer W.3, Vidarsson G.1
1Department of Experimental Immunohematology, Sanquin
Research, Amsterdam, and Landsteiner Laboratory, Academic
Medical Centre, University of Amsterdam, Amsterdam, The
Netherlands, 2Norwegian Institute of Public Health, Oslo, Norway,
3Biomolecular Mass Spectrometry Unit, Department of Parasitology,
Leiden University Medical Center, Leiden,The Netherlands,
4Thrombocyte and leukocyte serology, Sanquin, Amsterdam, The
Netherlands, 5Bristol Institute for Transfusion Sciences, NHS
Blood and Transplant, Bristol, UK
IgG-antibody responses during pregnancy against human plate-
let antigens (HPA) of the fetus (fetal or neonatal alloimmune
thrombocytopenia, FNAIT) can result in various clinical scena-
rios, as patients can be asymptomatic, suffer from petechiae,
major organ bleedings or even intracranial hemorrhages. Our aim
is to determine what signifies a clinically relevant IgG-response
against platelets. Various biological activities of IgG including
antibody-dependent cellular cytotoxicity (ADCC) can be modu-
lated by the structural features of the N-glycans in the Fc-part.
The extent of sialylation, galactosylation, and in particular fuco-
sylation has been described to affect the binding of IgG to
Fc-receptors. By extensively analyzing the Fc-glycosylation of
the pathogenic IgG formed in FNAIT using mass spectrometry
we found markedly increased levels of core-afucosylation com-
pared to the total IgG1 in the same patients. This led us to qu-
estion whether this skewing in afucosylation of anti-platelet an-
tibodies was due to the immune response during pregnancy or
due to allo- or autoimmunity. Interestingly, when analyzing anti-
HLA antibodies in refractory thrombocytopenia (lack of adequ-
ate post-transfusion platelet-count increments, in which anti-
HLA antibodies are frequently implicated), we did not observe
any changes in IgG afucosylation. To gain more insight in these
phenomenons, we are currently investigating IgG glycosylation
patterns of anti-HLA antibodies from FNAIT sera, as well as from
antibodies from autoimmune thrombocytopenia (ITP). Our stu-
dies indicate that IgG glycosylation including core-fucosylation
is regulated at a clonal level in patients. This is expected to in-
fluence IgG effector functions including ADCC activity and may
have a profound effect on disease severity and prognosis.
O6 Kinetic analysis of anti-HPA-1a reveals
that affinity is indicative of the severity of
neonatal alloimmune thrombocytopenia
Bessos H.1, Moss M.1, Urbaniak S.1, 2, Tomac G.3, Brown P.4
1Immunohaematology R&D, Scottish National Blood Transfusion
Service, Edinburgh and Aberdeen, 2Division of Applied Medicine,
University of Aberdeen, 3Transfusion Medicine and Transplanta-
tion Biology, Clinical Hospital Centre, Zagreb, Croatia, 4Biomole-
cular Core Small University Research Facility, University of
Edinburgh, MRC Centre for Reproductive Health
Background: Antibody performance, specifically kinetic proper-
ties rather than antibody titre, may be more meaningful and re-
levant to severity of NAIT. In this study we assessed the kine-
tics of anti-HPA-1a in 11 women who had delivered babies with
or without mild or severe NAIT.
Methods: Recombinant PSI domain of HPA-1a GPIIIa (rec-HPA-
-1a) was obtained by conventional cloning techniques and coupled
to CNBr activated Sepharose 4B. The immobilised rec-HPA-1a
was used to purify anti-HPA-1a directly from patient and control
sera. IgG was recovered from sera using Melon gel. The puri-
fied samples were assessed by various methods including surfa-
ce plasmon resonance technique (SPRT) using CM5 sensor chips
bound with HPA-1a1a or HPA-1b1b GPIIIa.
Results: In SPRT, control AP3 Mab bound to both HPA-1a &-
-1b chips, while control r-anti-1a bound specifically to HPA-1a
chips. The IgG samples gave high background precluding their
determination of ka and kd values. In contrast, purified anti-HPA-
-1a bound specifically to HPA-1a which enabled the determina-
tion of their ka and kd values. Patients with mild or no NAIT gave
an average affinity of 320 ± 100 nM (n = 5), while patients with
severe NAIT gave an average affinity of 50 ± 22 nM (n = 6)
**p < 0.018. Plotting ka against kd stratified patients who had
delivered babies with severe NAIT from mild or no NAIT.
Conclusion: Our results show that (a) unlike the IgG fraction of
serum, antibody purified using immobilised r-HPA-1a enables ki-
netic evaluation and measurement of antibody affinity by SPRT; and
(b) NAIT severity appears to be associated with antibody affinity.
O7 The implementation of surface plasmon
resonance technique in monitoring
pregnancies with expected fetomaternal/
/neonatal alloimmune thrombocytopenia
Bakchoul T., Bertrand G., Krautwurst A., Kroll H.,
Bein G., Sachs U.J., Santoso S., Kaplan-Gouet C.
Universitatmedizine Greifswald, Greifswald, Germany
Background: Maternal anti-HPA-1a antibodies (abs) are respon-
sible for the most severe cases of fetal/neonatal alloimmune
thrombocytopenia (FNAIT). Controversial conclusions were
obtained in the past on the role of anti-HPA-1a quantification
using MAIPA in predicting the severity of NAIT. Surface plasmon
resonance (SPR) enables standardized immobilization of antigens
and provides additional data such as determining antibody quan-
tification in real-time and binding avidity.
Methods: Sera from mothers with expected FNAIT were inve-
stigated by SPR during pregnancy. Anenatal treatment included
maternal ivIgG with steroids (group I: n = 6) or intrauterine pla-
telet transfusion (group II, n = 4). Ab-quantification was perfor-
med at the end of the association phase (B350) and at the end of
the dissociation phase (B700) using an HPA-1a specific monoc-
lonal antibody. Additionally, antibody-avidity was determined and
the area under antibody-binding curve (AUC) was calculated.
Results: During the pregnancy, thirty and twenty samples were
collected from group I and II, respectively. Remarkable reduc-
tion of anti-HPA-1a concentration was observed in group I (me-
dian of reduction: B350: 11 ng/mL, B700: 7 ng/mL/ week of the-
rapy) but not in group II (median of reduction: B350: 0.55 ng/
/mL, B700: 0.14 ng/mL/ week of therapy). Interestingly, a pro-
gressive reduction of antibody avidity was observed during two
pregnancies from group I. The best correlation with fetal and
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neonatal PLT-count was found with AUC of maternal antibody
(spearman r: 0.79).
Conclusion: Analysis of maternal antibodies using SPR provi-
des a precise tool in monitoring different therapies of pregnan-
cies with expected FNAIT may be helpful to avoid unnecessary
aggressive intervention.
O8 T cell responses associated with fetal/
/neonatal alloimmune thrombocytopenia
(FNAIT): HPA-1a-specific CD4+ T cells
can be identified and isolated by monitoring
proliferation and TNF production following
cognate antigen stimulation
Killie I.L.1, Ahlen M.T.2, Husebekk A.1, 2,
Skogen B.1, 2, Stuge T.1, 2
1Division of Immunology, Institute of Medical Biology, University
of Tromsø, Norway, 2Department of Laboratory Medicine,
University Hospital North Norway, Tromsø, Norway.
Background: FNAIT is most commonly caused by destruction
of foetal platelets by maternal anti-HPA-1a IgG antibodies that
cross the placenta and opsonise foetal HPA-1a-postitive plate-
lets. Production of anti-HPA-1a antibodies is most likely depen-
dent on HPA-1a-specific T cell responses, and the study of such
responses is therefore needed in order to understand the ma-
ternal immune responses that result in FNAIT. Currently, qu-
alitative and quantitative assessment of in vivo HPA-1a-specific
T cell responses is hampered by the lack of optimal methods and
reagents to identify and isolate such cells. Here, we describe one
method for identification and isolation of newly activated HPA-
1a-specific T cells.
Methods: PBMCs from an immunized woman who had given birth
to a child with FNAIT were labelled with CFSE and stimulated
with HPA-1a (L33) peptide in culture. On day 11, the cells were
restimulated with L33 peptide in the presence of the TNF alpha
protease inhibitor TAPI-0 for 4.5 hours and assayed for prolifera-
tion and TNF production by flow cytometry. Proliferating (CFSE-
low) CD4+ TNF-producing individual cells were sorted by Fluore-
scent Activated Cell Sorting (FACS) and expanded with anti-CD3.
Results: Thirteen proliferating clones sorted from the CFSElow
TNFhigh population were tested in ELISPOT and 6 of these clo-
nes (46%) were specific for the L33 (HPA-1a) epitope.
Conclusion: Combining CFSE proliferation assay with a second
stimulation with antigen and subsequent assay for surface de-
tection of TNF production allows for efficient detection and iso-
lation of HPA-1a-specific TH1 cells associated with FNAIT.
Key words (MSH Index Medicus): T-lymphocytes, thrombo-
cytopenia, foetal neonatal alloimmune
O9 Usefulness of maternal anti-HPA-1a
antibody quantitation to predict severity of
fetomaternal alloimmune thrombocytopenia
Sainio S., Javela K., Tuimala J.,
Koikkalainen P., Koskinen S.
Finnish Red Cross Blood Service, Helsinki, Finland
Background: Recent studies using an international anti-HPA-
1a standard have showed correlation between maternal antibo-
dy levels and neonatal thrombocytopenia. Cut-off values inden-
tifying high risk pregnancies have been introduced. The useful-
ness of these in clinical practice remains uncertain.
Materials: During 1986-2010 HPA-1a alloimmunisation was con-
firmed in 84 women with 132 pregnancies. Maternal samples ava-
ilable for this study were obtained at delivery (n = 77) and at dif-
ferent stages of the subsequent pregnancy (n = 35). Anti-HPA-1a
was quantified using a MAIPA assay with a detection limit of 0.8
IU/l (WHO reference serum 03/152). Antibody levels were com-
pared with severity of neonatal disease in the index pregnancy and
with the lowest fetal platelet count in the subsequent pregnancy.
Results: The index cases are presented in the Table 1. The cor-
relation between anti-HPA-1a level and neonatal platelet count
did not reach statistical significance in this group. The platelet
counts and antibody levels in cases with mild (cutaneous) and
severe bleeding complications (intracranial hemorrhage) were
significantly different from cases with no evidence of bleeding
(Fig. 1). In the subsequent pregnancy, the positive predictive va-
lue of maternal anti-HPA-1a obtained in the second trimester for
a fetal platelet count < 20 × 109/l was 90%, but the negative pre-
dictive value only 33%.
Figure 1. Distribution of neonatal platelet count (A) and maternal anti-HPA-1a concentration at delivery (B) according
the severity of the neonatal disease in the index cases (09)
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Table 1. Characteristics of the index cases of HPA-1a alloimmunisations (09)
n ICH IUD Neonatal platelet Mean neonatal Mean maternal
Count < 20 × 109/l Platelet count Anti-HPA-1a level
n × 109/l ± SD at delivery IU/l
Primiparous 19 (23%) 2 1 5 35 ± 24 35.7 ± 23.7
Multiparous (range 2–6) 65 (77%) 6 4 25 29 ± 20 60.4 ± 70.2
Total 84 8* 5 30 32 ± 25 53.6 ± 67.8
p** 0.4198 0.3317 0.008
*platelet count < 20 × 109/l in 7/8 cases of ICH, one newborn with a platelet count of 48 × 109/l had subdural hematoma in association with severe asphyxia;
**p-values from Fisher’s exact test or Wilcoxon rank sum test; ICH — intracranial hemorrhage; IUD — intrauterine death
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Conclusion: Although anti-HPA-1a level correlated statistical-
ly with severity of neonatal disease, barely detectable levels of
antibody were observed in most severely affected pregnancies.
Cut-off values with sufficient sensitivity and specificity to iden-
tify these fetuses could not be found. Previous obstetric history
remains still the most useful predictive parameter for severe
NAIT in clinical practice.
Key words: HPA-1a, alloimmune thrombocytopenia, MAIPA
O10 Effect of HPA-1a peptides on in vivo
anti-HPA-1a responses
Jackson D.1, Keen L.2, Kumpel B.1
1Bristol Institute for Transfusion Sciences, NHS Blood and
Transplant, Bristol, UK, 2Histocompatibility and Immunogenetics,
NHS Blood and Transplant, Bristol, UK
Background: Feto-maternal alloimmune thrombocytopenia
(FMAIT) is commonly due to destruction of fetal HPA-1a+ plate-
lets by maternal HPA-1a alloantibodies. The immune response is
restricted to HPA-1b1b, HLA-DRB3*0101 [and DQB1*0201]
women. If the antibody response were modulated by peptide the-
rapy, risks and costs associated with present treatments might be
reduced. We used a pre-clinical humanised severe combined im-
munodeficient mouse model injected with human leucocytes, pla-
telets and peptides to study anti-HPA-1a responses.
Method: Peripheral blood mononuclear cells (PBMC) isolated
from blood of donors with a history of FMAIT were injected in-
traperitoneally (i.p.) into mice. A mix of soluble HPA-1a pepti-
des were injected by i.p. or intranasal (i.n.) route. HPA-1a+ pla-
telets were injected i.p. on days 14 and 21 to reimmunise. Four-
teen experiments were performed with seven donors. The
DRB3*0101 and DQB1*0201 sequences of the donors were iden-
tified by PCR-SBT.
Results: Human IgG anti-HPA-1a was produced in these mice
in 7 experiments. Mixes of short or long HPA-1a peptides (12,
14, 16, 20, 22 Mer) given i.p. or i.n. resulted in enhancement of
anti-HPA-1a in 5 of these 7 experiments. However, in 2 of the
remaining experiments, mice given all five HPA-1a peptides i.p.
(2 mg) had reduced anti-HPA-1a compared to mice given corre-
sponding HPA-1b peptides. All donors were DRB3*0101 and
DQB1*0201 positive.
Conclusion: HPA-1a peptides usually increased anti-HPA-1a.
The data suggests there may be a fine balance between stimula-
tion and inhibition, possibly dependent on peptide length, concen-
tration and binding to DRB3*0101 and DQB1*0201 molecules.
Platelet biology — session 4
L10 Interaction of integrins
with protein ligands
Cierniewski C.S.
Department of Molecular and Medical Biophysics, Medical University
of Lodz, Institute of Medical Biology, Polish Academy of Sciences, Poland
Integrins are heterodimeric, type I transmembrane adhesion and
signaling proteins. Interaction of an integrin with intracellular
proteins causes its switch from an inactive, low affinity to acti-
ve, high affinity state. On the structural level such transition in-
volves conversion from the bent to an extended intermediate
affinity conformation and then to a high affinity. They can rapi-
dly increase their affinity towards different extracellular ligands
in response to both intracellular signaling events and extracel-
lular modifications. Before integrins can be activated, inhibitory
proteins must be displaced from their cytoplasmic tails. Then,
the integrin activators (talin/kindlin) or activator complexes need
to be targeted to the integrins. Finally, the activators bind to the
integrins causing their transition into the ligand competent sta-
te. How these proteins cooperate is currently of high interest.
Any factors that can affect inhibitor displacement, talin/kindlin
targeting, or the capacity of talin/kindlin to bind and activate in-
tegrins likely can regulate integrin activation.
We and others showed that there is a non-canonical activation of
integrins as well. Several observations indicate that conforma-
tional changes induced by ligand interactions with integrin lead
to the exchange of disulfide bonds within the integrin molecule,
which stabilizes the altered conformation, thus enabling susta-
ined binding. The formation and rearrangement of disulfide bonds
is modulated by protein disulfide isomerase (PDI), which has been
found on the surface of several types of cells, including endothe-
lial cells, hepatocytes, pancreatic cells, B cells, and cancer cells.
PDI was also identified on the platelet surface, where it appears
to play an important role in platelet aggregation and secretion.
Both aIIbb3 and a2b1 were reported to be substrates of PDI, and
their sulfhydryl groups seem to be implicated in platelet adhesion.
Our data show that the induction of the high-affinity state of aVb3
involves the thiol-dependent step, which is clearly associated with
activation of the integrin and precedes its ligation. This process
depends upon association of PDI with the integrin, resulting in
disulfide exchange occurring in the integrin molecule, and is ne-
cessary for the step of conformational change that enables susta-
ined ligand binding. PDI alone is not sufficient to isomerize disul-
fide bonds and requires reoxidization. In recent study we showed
that oxidase Ero1a is bound to platelet membranes and colocali-
zes with aIIbb3 supporting PDI activity.
L11 Platelets as immune cells
Semple J.W.
Transfusion Medicine Research, Keenan Research Center of the Li
Ki Shing Knowledge Institute at St. Michael’s Hospital, Toronto,
ON, Canada
Platelets are the primary cellular mediators of hemostasis and this
function intimately acquaints them with a variety of inflammatory
processes. For example, when aggregated on damaged vessel walls,
activated platelets can capture circulating leukocytes and attract
them to inflamed tissue. As early as the 1970’s, several reports began
to demonstrate that platelets may play an active role in the direct
stimulation of innate and adaptive immune responses. For exam-
ple, platelets are known to secrete several pro- and anti-inflamma-
tory chemokines and cytokines that can affect local innate immune
responses by, for example, attracting neutrophils to sites of inflam-
mation. In addition, platelets may be able to directly regulate ada-
ptive humoral immune responses via their expression and secre-
tion of CD40/CD40L molecules. These studies have also suggested
that platelets represent an important linkage between inflammation
and thrombosis, which is important in the pathophysiology of athe-
rosclerosis. In addition, platelets can avidly bind to microorganisms
and several viral proteins have been shown to have cross-reactivi-
ty with platelet antigens which is potentially important in the deve-
lopment of autoimmune thrombocytopenia. Perhaps more surpri-
singly, platelets have been clearly shown by many laboratories to
express the entire family of Toll-like receptors (TLR) and platelets
may act as primary circulating sentinel cells that first encounter
bacterial products for presentation and activation of innate immune
responses. In particular, platelet TLR4 expression allows them to
present lipopolysaccharide to mononuclear cells which modulates
their phagocytic capabilities that this has implications for the deve-
lopment of both autoimmune and alloimmune platelet disorders.
Elucidating the role of platelets in sepsis and a better understan-
ding of the apparent central role that platelets play as defensive cells
may be important for the potential development of efficient thera-
peutic modalities against infectious agents or immune mediated pla-
telet disorders. This lecture will highlight the many attributes of
platelets that draw them into the realm of immunity and will discuss
how platelets may be responsible for directly and indirectly con-
trolling immune functions.
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O11 Human platelet NF-kappaB links
TLR2 and PAR1 to cytokine secretion
Damien P.1, Cognasse F.1, 2, Payrastre B.3, Spinelli S.L.4,
Blumberg N.4, Phipps R.P.4, McNicol A.5, Pozzetto B.1,
Garraud O.1, 2, Hamzeh-Cognasse H.1
1GIMAP-EA3064, Université de Lyon, 42023 Saint-Étienne,
France, 2EFS Auvergne-Loire, Saint-Etienne, France, 3Inserm,
U1048 and Université Toulouse 3, I2MC, CHU de Toulouse,
Laboratoire d’Hématologie, Toulouse, France, 4Department of
Pathology and Laboratory Medicine, University of Rochester School
of Medicine and Dentistry, Rochester, NY 14642, USA, 5Depart-
ment of Oral Biology, University of Manitoba, Winnipeg, Canada
Background: In immune cells the engagement of TLR2 initia-
tes signaling through the transcription factor nuclear factor kap-
pa B (NF-kB) after its release from the inhibitor kappa B (I-kB)
and translocation into the nucleus. Although platelets are non-
-nucleated, they express the NF-kB machinery whose role re-
mains poorly understood.
Methods: Here we investigated the contribution of NF-kB in the
release of cytokines and serotonin by human platelets following
selective stimulation of TLR2 and PAR1.
Results: Using a specific ELISA test we demonstrated that pla-
telet PAR1 activation drives oscillations of NF-kB phosphoryla-
tion, contrary to TLR2 activation which induces a slower phospho-
rylation process. Moreover, we found that engagement of TLR2
with its ligand, Pam3CSK4, significantly increases the release of
sCD62p, RANTES and sCD40L, an effect significantly attenuated
when platelets were pre-incubated with a blocking anti-TLR2
MoAb. No modulation of serotonin secretion was observed follo-
wing platelet TLR2 activation. The release of cytokines from pla-
telets following TLR2 or PAR1 triggering was no longer observed
in the presence of the NF-kB inhibitor Bay11-7082.
Conclusions: These data support the concept that, in addition
to its reported role in platelet aggregation, NF-kB is an impor-
tant player in platelet inflammatory functions, pointing to new
potential strategies based on the modulation of platelet transcrip-
tion factor activity.
Key words: Platelet, NF-kB, inflammation, TLR2, PAR1, cyto-
kines/chemokines
O12 Homopentameric and heteropentameric
acetylcholine receptors in megakaryopoiesis
and platelets
Schedel A., Besenfelder S., Lorenz F., Kaiser K.,
Starigk J., Klüter H., Bugert P.
Institute of Transfusion Medicine and Immunology, Medical
Faculty Mannheim, Heidelberg University; German Red Cross
Blood Service Baden-Württemberg- Hessen; Mannheim, Germany
Background: We previously showed that platelets have nicoti-
nic alpha7 acetylcoline receptors (nAChRa7) that form homopen-
tameric calcium channels and affect platelet function. We also
demonstrated that in-vitro megakarypoiesis by MEG-01 cells can
be modulated via the nAChRa7. In microarray-based RNA profi-
ling we found gene transcripts of further nAChR subunits such
as a4 and b2. In this study we were interested in the characteri-
zation of the heteropentameric sodium channel nAChRa4b2 in
platelets and precursor cells.
Methods: Expression of nAChRs was investigated on undiffe-
rentiated megakaryoblast cell lines (MEG-01, CMK, M07, Dami)
cell lines and platelets. In addition, nAChR expression was me-
asured during megakaryopoiesis using CD34+ cells isolated from
cord blood and differentiated under TPO-stimulation for up to 16
days. Quantitative real-time PCR (QRT-PCR) and Western blot
analysis was used to investigate nAChR expression. The effect
of nAChRs on platelet function was demonstrated by flow cyto-
metry assays and whole blood aggregometry.
Results: Significant amounts of the a4, a7 and b2 nAChR subu-
nits were identified in platelets and megakaryoblast cell lines on
the mRNA and protein level. Both, homopentameric nAChRa7
and heteropentameric nAChRa4b2, were also identified in cord
blood CD34+ cells with significant upregulation during TPO-in-
duced megakaryopoiesis. In platelet function assays selective
nAChRa4b2 antagonists significantly inhibited platelet activation
and aggregation.
Conclusions: In addition to the calcium channel nAChRa7 pla-
telets and precursor cells also express sodium channels of the
nAChRa4b2 type. Both nAChRs are upregulated during mega-
karyopoiesis. Because nAChRs are targets of nicotine and many
psychopharmaceuticals, effects on megakaryopoiesis and plate-
let function can be speculated.
O13 The platelet specific function of DCBLD2,
a newly identified blood platelet receptor
Nuyttens B.P.1, Broos K.1, Sadeghi M.M.2, Nie L.2,
Vanhauwaert S.1, Pareyn I.1, Vanhoorelbeke K.1,
Deckmyn H.1
1Laboratory for Thrombosis Research, IRC, KU Leuven campus
Kortrijk, Kortrijk, Belgium, 2Cardiovascular Molecular Imaging
Laboratory, Section of Cardiovascular Medicine, Yale University
School of Medicine, New Haven, CT, USA
Platelets play a central role in haemostasis, adhering to the sub-
endothelial matrix upon vascular injury and aggregating to form
a haemostatic plug. Deregulation of the process due to pathoge-
nic conditions or genetic disorders may result in occlusive throm-
bus formation or bleeding. Although many platelet receptors have
been described, recent genome wide association and -omics stu-
dies revealed new platelet proteins [1, 2], among them transmem-
brane receptors such as the discoidin, CUB and LCCL domain
containing 2 protein (DCBLD2) for which involvement in throm-
bus formation has been shown in a zebrafish model [3]. To fur-
ther characterize DCBLD2 and uncover its platelet specific func-
tion, the role of DCBLD2 in thrombosis and haemostasis is stu-
died in knock-out (KO) mice using the well established in vivo
murine FeCl3 thrombosis and tail clipping bleeding models.
Although DCBLD2 KO mice show normal platelet counts and no
profound phenotype, an in vivo FeCl3 thrombosis model clearly
indicated a significant (p < 0.01) decrease in the time to occlu-
sion upon vessel damage in these mice compared to control mice
(respectively 596 ± 33s versus 795 ± 60 s; n = 11). In contrast,
the bleeding time upon tail clipping was not significantly diffe-
rent from the one in controls (105 ± 14 s versus 106 ± 11 s;
n = 12, p > 0.1). Further in vitro agonist-induced platelet aggre-
gation experiments in platelet rich plasma from DCBLD2 KO
mice showed a significant stronger aggregation of 13 ± 0.5%
(n = 5; p < 0.01) and 10 ± 1% (n = 3; p < 0.01) compared to
controls when stimulated with ADP or collagen respectively. Sug-
gesting that the effect seen in vivo can be at least in part alloca-
ted to DCBLD2 on platelets. Further experiments also demon-
strated a similar role for DCBLD2 on human platelets, as the
addition of recombinant DCBLD2-extracellular domain to human
platelet rich plasma resulted in a 21.8 ± 4.6% (n = 8; p < 0.01)
and 23.0 ± 5.1% (n = 6; p < 0.001) stronger aggregation compa-
red to controls at threshold concentrations of ADP and collagen
respectively. Overall, these data are in agreement with the fin-
dings in the zebrafish model and confirm a function for DCBLD2
in the down regulation of platelet activation and control of plate-
let-dependent thrombus formation. We now aim to identify extra-
cellular ligands and the intracellular signalling pathways of
DCBLD2 in order to fully characterise its function in platelet
physiology which in the future may lead to better identification,
prevention and treatment of thrombotic events.
References:
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tive gene expression profiling of in vitro differentiated mega-
karyocytes and erythroblasts identifies novel activatory and in-
hibitory platelet membrane proteins. Blood 2007; 109: 3260–
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L12 Neonatal alloimmune neutropenia
Porcelijn L.1, Abbink F.2, Huiskes E.1, de Haas M.1, 3
1Sanquin Diagnostic Services, Amsterdam, the Netherlands,
2VU Medical Centre, Amsterdam, the Netherlands, 3Sanquin
Research and Landsteiner Laboratory, Academic Medical Center,
University of Amsterdam, Amsterdam, the Netherlands
Neonatal alloimmune neutropenia (NAIN) results from mater-
nal alloimmunization against neutrophil antigens present on fe-
tal neutrophils but absent from maternal neutrophils. The exact
incidence of NAIN is not known, but is estimated to be 1 in 1000
newborns. NAIN is known to cause severe neutropenia (< 0.5 ×
× 109/L) which can last for weeks to months. Clinical symptoms
can vary from none (neutropenia is detected by coincidence) to
omphalitis, skin infections and even (rare) meningitis or pneumo-
nia. Next to the symptomatic treatment with antibiotics, intraveno-
us immunoglobulines (IVIg) and Granulocyte-Colony Stimulating
Factor (G-CSF) are used to increase the neutrophil count. Litera-
ture search (1986–2010) shows six successful IVIg treatments in
19 NAIN cases (32%) and 18 successful G-CSF treatments in 20
NAIN cases (90%). Antibodies against Human Neutrophil Antigens
(HNA) -1a, 1b, 1c, 2a, 3a and 4a have been described as cause for
NAIN. Very recently we described a first case of NAIN due to anti-
bodies against HNA-5a. This concerned a term male neonate su-
spected for infection, with a pronounced neutropenia (0.6 × 109/L).
Although all bacterial cultures were negative, treatment with anti-
biotics was started. The presence of neutrophil antibodies was su-
spected four weeks post partum as the neutropenia persisted and
a bone marrow aspiration showed normal cellularity and no arrest
in the myeloid maturation. Neutrophil serology, using the granulo-
cyte agglutination test (GAT), the granulocyte immunofluorescen-
ce test (GIFT) and the monoclonal antibody immobilization of gra-
nulocyte antigens (MAIGA) assay, showed the presence of HNA-
5a antibodies in the maternal serum. Mother was typed HNA-1a+,
1b+, 1c–, 2a+, 3a+, 4a+, 4b–, 5a–, 5b+. Father was typed HNA-
-1a+, 1b+, 1c–, 2a+, 3a+, 4a+, 4b–, 5a+, 5b–.
No further treatment was necessary as the clinical situation was
improved. Four months later the neutropenia recovered and pro-
phylaxis with antibiotics was stopped. During this episode there
were no further complications.
Antibodies against lymphocyte function-associated antigen 1 (LFA-1,
CD11a) in a serum named ‘OND’ were first detected by Decary
et al. in 1979. This antigen, now termed HNA-5a, was found to be
due to a 2372 C > G substitution coding for an arginine instead of
a threonine at position 766 of the alpha-L chain of LFA-1. HNA-5a
genotyping showed frequencies between 79 and 88% in different
populations. LFA-1 is part of the family of leukocyte integrins that
are recognized by their common b-chains (CD18).
Although both neutrophils, lymphocytes and monocytes express
HNA-5a, only neutropenia developed in the neonate. With the mo-
dified MAIGA (MAIL/MA), using T cells and monocytes, reactivity
of the HNA-5a antibodies with these cell types was confirmed, ho-
wever both in the MAILA (only T cells reacted, B cells were nega-
tive) and in the flow cytometry-based test, reactivity with lympho-
cytes was lower compared to that with neutrophils. In the MAIMA,
the maternal antibodies showed only weak reactions with monocy-
tes. Therefore, there may be different binding characteristics of the
HNA-5a antibodies to these different cell types, which may influ-
ence the level of immune-mediated cell destruction.
References:
1. Bux J. Human neutrophil alloantigens. Vox Sang 2008; 94 (4):
277–285.
2. Simsek S, van der Schoot CE, Daams M, et al. Molecular charac-
terization of antigenic polymorphisms (Ond (a) and Mart (a))of the
beta 2 family recognized by human leukocyte alloantisera. Blood
1996; 88 (4): 1350–1358.
3. Muschter S, Berthold T, Greinacher A. Developments in the defi-
nition and clinical impact of human neutrophil antigens. Curr Opin
Hematol 2011: 452–460.
L13 Characteristics of human neutrophil
antigens — the important science
behind each antigen
Flesch B.K.
German Red Cross Blood Service West, Bad Kreuznach
and Hagen, Germany
Human neutrophil antigens (HNA) are implicated in a variety of
clinical conditions. Actually eight antigens are allocated to five
HNA groups.
The neutrophil specific HNA-1a, -1b and -1c antigens are loca-
ted on the FcgRIIIb, an immunoglobulin superfamily member
which is anchored to the neutrophil membrane by glycosylpho-
sphatidylinositol (GPI). Five nucleotide substitutions code for the
three antigens but gene recombination, deletion and nucleotide
exchanges are responsible for additional variant types.
The likewise GPI -anchored HNA-2/CD177 glycoprotein, which
is upregulated by inflammatory processes, is an isoantigen. In
HNA-2a positive individuals as a unique feature there are anti-
gen-positive as well as antigen-negative neutrophil subpopula-
tions. HNA-2 isoimmunisation, however, is only possible in in-
dividuals with a complete HNA-2 deficiency. CD177 enables
membrane binding of Proteinase-3 (PR-3) and is reported to be
co-localized with FcgRIIIb and CD11b/CD18 (HNA-4) in mem-
brane lipid rafts thus forming a potential signalling complex.
The HNA-3a/-3b antigens result from a G461A substitution on
the Choline transporter like protein 2 (CTL2) gene. The epitope
on the CTL2 molecule with ten hydrophobic membrane spanning
domains is extremely sensitive to conformational changes, which
hampers the development of cell-free antibody detection assays.
A further C457T exchange influences the affinity for some HNA-
-3a antibodies and can impair primer annealing in typing assays.
Of two variant transcripts which differ in the twelve N-terminal
cytoplasmic amino acids only the shorter TV2 form was demon-
strated in human peripheral blood cells. Thus new HNA-alleles,
negative phenotypes and the contributions of structure and func-
tion to the clinical conditions remain as future challenges.
L14 Clinical and laboratory aspects
of the immune neutropenias
Lucas G.
Department of Histocompatibility and Immunogenetics,
NHSBT-Filton, Bristol, UK
The immune neutropenias are a diverse range of clinical condi-
tions that can be divided into primary disorders, where the im-
mune neutropenia is the main clinical feature, and secondary di-
sorders associated with a systemic condition, where immune
destruction is usually only one of several causes of neutropenia.
The primary immune neutropenias include neonatal alloimmu-
ne neutropenia (NAIN), autoimmune neutropenia of infancy
(ANI), adult autoimmune neutropenia (AIN) and antibody media-
ted drug induced neutropenias. Secondary immune neutropenias
can occur together with systemic lupus erythematosus, Felty’s
syndrome, large granular lymphocyte leukaemia and other pro-
liferative diseases. Immune neutropenias associated with bone
marrow transplantation and following passive transfusion of HNA
antibodies (not necessarily associated with Transfusion Related
Acute Lung Injury) have also been described.
NAIN has been associated with antibodies reactive with human
neutrophil antigens (HNA) -1a, 1b, 1c, 2, 3a, 4a and 5a and CD16b.
Before the introduction of GCSF, some cases of NAIN were de-
scribed where the neutropenia persisted for up to 28 weeks. ANI
is a self-limiting autoimmune condition which typically presents
between 8 and 24 months of age but can develop earlier. ANI is
predominantly mediated by HNA-1a antibodies but HNA-1b,
CD11b/18 and CD35 specificities have also been detected. The
antibody specificity in ANI can develop during the course of the
disorder with anti-CD16b being detected early in the disease and
HNA specific antibodies developing later. In contrast, AIN is
usually a chronic condition that is less frequently associated with
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HNA reactive autoantibodies, although antibodies against the
carrier molecules CD16b and CD11/18 have been described. In
the secondary immune neutropenias, the antibody specificity is
usually unidentified. Granulocyte antibodies typically cause neu-
tropenia but may cause defects in neutrophil function.
Laboratory investigation of these conditions must be able to de-
tect and identify alloimmune and autoimmune antibodies that bind
HNA or their carrier molecules and also distinguish between
HNA and HLA antibody binding. Advances in granulocyte immu-
nobiology in the last 10 years have increased the scope of HNA
genotyping but until recently antibody detection has been based
on assays utilising freshly isolated granulocytes from HNA ty-
ped donors. The recent development of cell lines expressing re-
combinant HNA and soluble recombinant proteins has begun to
add a new dimension to antibody investigation strategies for the
immune neutropenias.
O14 Serologic and genetic studies
on the HNA-3a alleles SLC44A2*1:1
and SLC44A2*1:2
Winterstein K., Grabowski C., Jorks S., Kroll H.
Institute for Transfusion Medicine, Dessau, Germany
Introduction: Granulocyte reactive antibodies in particular anti-
HNA-3a in blood products can cause transfusion related acute
lung injury. Recently, a variant of SLC44A2 (SLC44A2*1: 2, 457C
> T) characterized by a single nucleotide substitution 4bp upstre-
am of the HNA-3 (461G > A) polymorphism was described. Here,
we analyzed the antibody binding pattern and the gene frequen-
cies of the SLC44A2 alleles.
Methods: A total of 436 unrelated healthy blood donors were
included into the study. Serologic analysis was done by granulo-
cyte agglutination test (GAT) and microscopic granulocyte im-
munofluorescence test (GIFT). DNA was extracted from EDTA-
-anticoagulated blood. SLC44A2 genotyping was performed by
PCR-SSP and pyro-sequencing.
Results: Among 436 donors, two individuals carried the
SLC44A2*1: 2 allele. Genotyping resulted in the following allele
frequencies: SLC44A2*1: 1: 0.808, SLC44A2*2: 0.189,
SLC44A2*1: 2: 0.002. An additional SNP in intron 7 was detected
that was linked to the HNA-3 polymorphism. Serologic HNA-3a
and -3b analysis was performed in 197 donors. The serology mat-
ched completely with molecular testing. Granulocytes carrying
the SLC44A2*1: 2 were analyzed with ten different HNA-3a an-
tisera. Interestingly SLC44A2*1: 2 granulocytes showed redu-
ced agglutination with two HNA-3a antibodies compared to
SLC44A2*1: 1 cells. These differences could not be were obse-
rved in immunofluorescence.
Conclusions: Granulocytes carrying the SLC44A2*1: 2 allele
showed a reduced reactivity with some HNA-3a antibodies. The-
refore such granulocytes should not be included into antibody
screening panels. Nothing is known about the immunogenicity
of the rare allele. Genotyping of the HNA-3 system can be impa-
ired by the SLC44A2*1: 2 polymorphism as well as the associated
SNP in intron 7. Genotype/phenotype discrepancy of HNA-1a
antigen typing in blood donor involved in TRALI leads to the
identification of FCGR3B variant.
O15 HNA-1d — a new epitope located
on Fc gamma Receptor IIIb (FcgRIIIb)
Reil A.1, Sachs U.J.2, Berghoefer H.2, Bux J.1
1German Red Cross Blood Service West, Hagen, Germany
2Justus Liebig University Giessen, Giessen, Germany
Background: The neutrophil-specific Fc gamma receptor IIIb
(FcgRIIIb) is a well-known target of allo- and autoantibody forma-
tion. Three alleles (FCGR3B*01, *02, *03) corresponding to the
epitopes HNA-1a, -1b, -1c have been described. The HNA-1b epi-
tope which is characterized by the amino acids Ser65 and Asn82, is
shared by the proteins encoded by the FCGR3B*02 and
FCGR3B*03 alleles. The HNA-1c epitope differs from HNA-1b in
an 78Ala > Asp exchange. Here we describe a new epitope located
on FcgRIIIb detected in a case of neonatal alloimmune neutropenia.
Methods: Sera of mother and infant were tested by granulocyte
immunofluorescence test, granulocyte agglutination test and
MAIGA assay. Genotyping was performed by PCR-SSP. Addi-
tionally, the mother’s serum was tested using recombinant hy-
brid proteins in the MAIGA assay.
Results and conclusions: In the mother’s serum we detected
antibodies which only reacted with FcgRIIIb encoded by
FCGR3B*02. There was no reaction with FcgRIIIb encoded by
FCGR3B*03. The mother was FCGR3B*01,*03, the infant
FCGR3B*01,*02. Since the protein encoded by FCGR3B*03 not
only shoes the HNA-1c but also the HNA-1b epitope, the new
epitope, called HNA-1d, must be different from HNA-1b but also
present on the protein encoded by FCGR3B*02. This is corro-
borated by the fact that the moab 3G8, which is regularly used
for immobilization of anti-HNA-1b, is not suitable for immobili-
zation of anti-HNA-1d, likely because of sterical hindrance.
MAIGA assays using hybrid proteins revealed that HNA-1d is
characterized by the amino acids Ala78 and Asn82 and indepen-
dent of the amino acid at position 65.
Key words: neutrophils, neonatal alloimmune neutropenia,
Fc gamma receptor IIIb, HNA antigen, HNA antibody
Microparticles — session 6
L15 Analysis of cell membrane
microparticles in blood — current
methods and future perspectives
Simak J.
Center for Biologics Evaluation and Research, U. S. Food
and Drug Administration, Rockville, Maryland, MD, United States
Upon various types of stimulation, platelets, blood cells and en-
dothelial cells release different types of phospholipid vesicles
ranging from tens of nanometers to micrometers in size which
can be found in circulating blood. The released phospholipid ve-
sicles have been implicated in intercellular communications in
various physiological and pathophysiological processes and may
also be useful as diagnostic biomarkers of vascular, hematologic
and some other diseases. Due to high heterogeneity and largely
submicron size, analysis of cell derived phospholipid vesicles in
blood remains challenging task, however (Simak & Gelderman,
Transf. Med. Rev. 2006). A small subset of large exocytic vesic-
les released from plasma membranes of platelets, blood and en-
dothelial cells is commonly called as membrane micropartic-
les (MPs), analyzed in blood or plasma mostly by flow cytometry
(FC). Initially, using analog FC, a number of MP counting and
immunophenotyping assays with a variety of preanalytical and
analytical variables have been developed. Generally, these FC
assays are able to detect MPs in the size range corresponding to
forward scatter (FS/FSC) signal of 500 nm–1 um standard poly-
styrene beads. Although polystyrene beads have different scat-
tering characteristics compared to MPs, their use as standards
in MP analysis is important for evaluation of the instrument re-
solution and intra- as well as inter-laboratory comparison of re-
sults (Gelderman & Simak, Methods. Mol. Biol. 2008). New sta-
te of the art digital flow cytometry instruments allow more pre-
cise resolution of MPs in the submicron range. Recent reports
from different laboratories, however, show controversial results
in size resolution of polystyrene beads and distribution of FS/FSC
values for populations of platelet MPs and platelets (Chandler
et al.; Mullier et al.; Robert et al, JTH 2011). Different types of
FC instruments differ in optical design for FS/FSC measurement
making these parameters difficult to compare. In addition, con-
troversies in performance of the same type cytometers may stem
from various hardware modifications, tuning, calibration, and
maintenance status of the individual instruments (Lacroix et al.,
JTH 2010). Although optimization and further standardization of
FC assays for MP analysis is needed and FC is proved to be use-
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ful method for counting and immunophenotyping of large MPs,
it is important to note that even the most advanced high sensitivity
FC today likely can not provide robust analysis of smaller particles
then FS/FSC equivalent to 300 nm polystyrene beads (Robert et
al., ATVB 2012). Our preliminary results of nanoparticle tracking
analysis (NTA) using Nanosight system showed that about 80% of
phospholipid vesicles released from TRAP-activated platelets have
hydrodynamic diameter less than 300 nm. Thus, along with FC opti-
mization, there is a need for a complementary high throughput me-
thod allowing analysis of phospholipid vesicles of less than 300 nm
in size. The NTA with a 30 nm lower size resolution limit for pho-
spholipid vesicles may be one of the promising candidate methods.
Disclaimer: The findings and conclusions in this presentation
have not been formally disseminated by the Food and Drug Ad-
ministration and should not be construed to represent any Agency
determination or policy.
L16 Stem cells — potential source
of bioactive microvesicles
Zuba-Surma E.
Department of Cell Biology, Faculty of Biochemistry, Biophysics
and Biotechnology, Jagiellonian University, Krakow, Poland
During the past decade, the attention of biomedical researchers
has increasingly been directed to stem cells (SCs) as potential
mediators of effective tissue repair in injured organs including
infarcted myocardium following ischemic events.
Although, several significant advances in pharmacotherapy have
been achieved, fully successful therapeutic approach for treat-
ment of ischemic heart patients has not been developed. Multi-
ple fractions of SCs have been tested in these patients to sup-
port traditional treatment; however, the outcomes of these stu-
dies are still insufficient.
However, vast promising results from animal studies  and clini-
cal trials indicate that experimental therapies employing stem
cells may improve LV function, ameliorate remodeling, and im-
prove heart perfusion and beneficial effects may in fact be a re-
sult of SC-induced angiogenesis, myogenesis, antiapoptotic ef-
fects, and a combination thereof, often termed “paracrine effects”.
Until recently, the major route of bioactive components’ activity
has been envisioned in their direct release into damaged tissue
following transplantation. However, the recent observations in-
dicate that bioactive protein components as well as nucleic acids
(microRNA, RNA) may be released from cells including SCs, via
microvesicles shed from their surface. Several studies have al-
ready proved that MVs act as “natural nanocarries” and may
transfer their bioactive content to other cells via fusion. Becau-
se of this phenomenon, MVs become considered as valid modu-
latory components of cell to cell communication.
Importantly, it have been shown that MVs may be also shed by stem
and progenitor cells and the SC- specific proteins and genetic com-
ponents may be transferred to other cells. For instance, MVs deri-
ved from human endothelial progenitors (EPCs) have been shown
to carry mRNA associated with pathways relevant for angiogenesis
and MVs from embryonic stem cells (ESCs) may functionally mo-
dify purified BM- derived hematopoietic progenitor cells (HPCs).
Thus, we envision that derived from stem cells may represent va-
luable source of bioactive factors important for tissue regeneration.
O16 Effects of placental microparticles
and platelets on in vitro cytokine profiles
and their ability to cause an anti-HPA-1a
antibody response in vivo
Eastlake J., Kumpel B.
Bristol Institute for Transfusion Sciences, NHS Blood
and Transplant, Bristol, UK. BS34 7QH
Background: Placental syncytiotrophoblast microparticles
(STMP) expressing fetal antigens are shed into maternal blood.
NAIT is due to maternal antibodies to fetal platelet antigens of
paternal origin. Anti-HPA-1a, commonly implicated, targets
a polymorphism on CD61 that is present on STMP and poten-
tially responsible for primary immune responses in NAIT. To in-
vestigate this a system to generate de novo anti-HPA-1a is being
developed.
Methods: STMP-13g and ultracentrifuged STMP-100g prepara-
tions were generated from fresh term placentas. Immunisation
of naive HPA-1b1b/HLA-DRB3*0101 leucocytes with HPA-1a+
STMP or platelets was performed. In vitro: dendritic cells were
immunised with antigen, matured, then cultured with ThCD4+/
/BCD19+/OtherCD4- cells for 30 days. Culture supernatants were
screened for cytokines by Luminex. In vivo: leucocytes and anti-
gen were injected i.p. into SCID mice. Culture supernatants and
mouse plasma were tested for human anti-HPA-1a by MAIPA
and/or PIFT and total IgG quantitated by ELISA.
Results: The most predominant cytokines were: IL-6, -8, -12,
-13 and TGF-b with very low levels of IL-1b, -2, -5, -10 and
IFN-g. No IL-15, -17, -21 or IFN-g  were detected. IL-4, GM-CSF
and TNF-a were found at levels correlating with supplemented
media. In all cases increased levels of cytokines were seen with
the addition of antigen except for IL-13, where levels decreased.
STMP-100 g were the most stimulatory, then STMP-13 g and
platelets. Platelets gave an equivalent or greater response for
IL-6 and IL-8 yet caused the greatest suppression of IL-13.
Leucocytes pre-mixed with IL-4, IL-21 and STMP-13 g produ-
ced anti-HPA-1a antibodies in 5/6 SCID mice.
Conclusions: Placental microparticles are immunomodulatory
and can initiate an anti-HPA-1a response.
O17 Microparticles in blood components
transfused to patients with dyspnea-asso-
ciated non-hemolytic transfusion reactions
Wróbel A., Maślanka K., Uhrynowska M., Łopacz P.,
Michur H., Ostas A., Brojer E.
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Introduction: Microparticles (MPs) are circulating 100 nm to
1µm vesicles, released from membranes of platelets (PMPs),
erythrocytes (EMPs) or leukocytes (LMPs) as result of cell ac-
tivation or apoptosis. Although their role in many pathophysio-
logical processes has been confirmed as crucial, the rate of their
release in blood components and effect on patients with dysp-
nea-associated transfusion reactions remains unknown.
Aim: Evaluation of PMPs, EMPs and LMPs in blood components
transfused to patients with dyspnea-associated non-hemolytic
transfusion reactions,
Material: MPs were evaluated in: 26 units of packed red blood
cells (RBCs), 17 units of leukoreduced RBCs (L-RBCs) and
3 units of platelet concentrates (PCs) transfused to 2 patients
who developed transfusion-related lung injury (TRALI), 12 pa-
tients with non-hemolytic transfusion-reactions ongoing with
dyspnea only (TRD) and 14 patients with transfusion-associated
circulatory overload (TACO).
Six RBCs, 26 L-RBCs and 9 PCs transfused to patients with no
transfusion reactions and plasma samples from 16 healthy do-
nors were used as controls.
Methods: Isolated MPs (Nieuwland et al., 2000) were labeled
with annexin V-PE and CD61-FITC for PMPs, CD235a-FITC for
EMPs and CD66c-FITC for LMPs (BD, San Jose, USA) and eva-
luated on BD FACSCanto II cytometer with FACSDiva softwa-
re. Statistical analysis was performed using Student’s t-test for
unequal sample sizes.
Results: In plasma samples from healthy donors MPs ranges
were: PMPs = 25.86 ± 15.18%, EMPs = 37.88 ± 15.27%, LMPs
= 13.76 ± 7.82%. In blood components transfused to patients
with no transfusion reactions, all MPs were within the range for
healthy donors.
Patients who developed TRALI were transfused with RBCs only.
In these blood components PMPs and LMPs values were within
the range of both control groups while EMP ranges were signifi-
cantly higher (84.8 ± 8.49%) (p < 0.05).
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Patients who developed TRD as well as TACO patients were
transfused with RBCs, L-RBCs and PCs. MPs ranges in these
blood components showed no statistically significant difference
as compared to healthy donors and control blood units.
Conclusions: Higher percentage of EMPs in blood components
involved in 2/2 TRALI cases implies their effect on the pathoge-
nesis of this reaction. Further investigation is necessary to es-
tablish their importance.
Insight into mechanism of thrombo-
cytopenia and thrombosis — session 7
L17 New insights on the pathophysiology
of heparin-induced thrombocytopenia
Gruel Y.
Department of Hematology-Hemostasis and UMR CNRS 7292
CHU Trousseau and University Francois Rabelais, Tours, France
Heparin-induced thrombocytopenia (HIT) is a unique model of
immune-mediated disorder due to the development of antibodies
(mainly IgG) specific to platelet factor 4 (PF4). PF4 is a C-X-C
chemokine abundant in platelet a granules and is released in pla-
sma as tetramers, which exposed an electropositive ring critical
for the binding of heparin, a negatively-charged molecule. The
risk of immunization towards PF4 and thus of HIT is lower with
low-molecular-weight heparins (LMWHs) than with unfractiona-
ted heparin (UFH). It was recently demonstrated after studying
the effects on PF4/HIT antibody interactions of variable oligo-
saccharides derived from enoxaparin by serotonin release assay
and surface plasmon resonance that LMWHs with fragments > 10
saccharides and a large number of sulfate groups are more likely
to be associated with a significant risk of HIT. PF4-heparin inte-
ractions induce the expression of neoepitopes involving several
aminoacids (including P37, R49, L55 and K61) that trigger the
humoral immune response associated with HIT. This anti-PF4/
/heparin immune response is atypical since rapid, transient with
simultaneous appearance of antibodies of different classes and
no IgM precedence, suggesting short-term activation of B cells
that have previously undergone Ig-class switching even without
previous pharmacologic heparin exposure. Recently, it was sho-
wed that prevalent infections such as periodontitis may induce
preimmunization to PF4/bacteria complexes, and likely contri-
buted to the early occurrence of anti-PF4/H-IgG in HIT. It was
suggested that IL10 promoter microsatellite polymorphisms
might also influence the immune response against PF4/heparin
and the risk of HIT.
Thrombocytopenia and thrombotic complications result from
a multicellular activation involving platelets, endothelial cells, and
monocytes. Platelet activation is mediated by the binding of HIT-
-IgG present within immune complexes to FcgRIIa receptors. Im-
portantly, a minority of sera containing antibodies to PF4/H exhi-
bits platelet-activating properties and all immunized patients do
not develop HIT. This variable clinical response can be related
in part to single nucleotide polymorphisms (SNPs) affecting ge-
nes coding for signaling proteins regulating FcgRIIa-dependent
activation. In this regard, we recently studied CD148 a recep-
tor-like protein tyrosine phosphatase that regulates Src family
kinases and FcgRIIa-platelet activation, and investigated whe-
ther 3 SNPs i.e. Q276P (rs1566734), R326Q (rs1503185), and
D872E (rs4752904) may influence the development of HIT. The
heterozygote status for the CD148 276P or 326Q alleles was fo-
und to be less frequent in patients with antibodies to H/PF4 but
without HIT. In addition, platelet aggregation tests demonstra-
ted that lag time was significantly longer when washed platelets
from donors heterozygous for the 276P/326Q alleles were acti-
vated by HIT plasma with heparin. Moreover, lower concentra-
tions of dasatinib, a SKF inhibitor, were required to abolish pla-
telet aggregation of platelets from carriers of the 276P/326Q al-
leles induced by ALB6, a monoclonal antibody that cross-links
FcgRIIa receptors. Finally, the phosphorylation of Src kinases,
LAT and PLCg2 regulating the proximal signaling of FcgRIIa pa-
thway was also delayed in platelets from heterozygotes for the
276P/326Q alleles compared to those of homozygous controls
276QQ/326RR, when activated by ALB6. These results therefore
support the 276P/326Q CD148 isoform exerts a protective effect
on the risk of HIT in patients with antibodies to PF4/ heparin.
HIT IgG/PF4/heparin complexes/FcgRIIa interaction leads to
platelet activation, granule release and the generation of proco-
agulant phospholipid-rich microparticles. HIT antibodies might
also activate endothelium by interacting with PF4-heparan sul-
fate complexes. A PF4-dependent binding of HIT IgG to mono-
cytes inducing a tissue factor synthesis has also been demonstra-
ted and this mechanism likely contributes to the generation of
thrombin associated with HIT and resulting thrombotic events.
Treatment of HIT is currently based on the use of direct throm-
bin inhibitors, lepirudin or argatroban or on danaparoid sodium,
a mixture of anticoagulant glycosaminoglycans with anti-Xa acti-
vity that disrupts PF4-containing immune complexes. Recently,
it was also proposed to use ODSH or 2-O, 3-O desulfated heparin,
a partially desulfated heparin, to prevent the formation of immu-
nogenic PF4/heparin complexes in patients with high risk of HIT.
L18 Drug-induced immune thrombocytopenia:
new observations concerning pathogenesis
Aster R.H.
Blood Research Institute, Blood Center of Wisconsin, Milwaukee,
WI, USA
Many drugs have been implicated as triggers for immune throm-
bocytopenia. With individual drugs, distinctly different mechani-
sms may be responsible. In this presentation, we will review
several cases of drug-induced immune thrombocytopenia (DITP)
selected to illustrate these mechanisms, some of which are briefly
described here.
Quinine. Quinine and numerous other drugs induce antibodies
that bind tightly to platelet membrane glycoproteins only when
drug is present. It was formerly thought that drug reacts with
the target glycoprotein and somehow modifies it so that it beco-
mes immunogenic, However, current evidence suggests the sur-
prising possibility that drug first binds to the antigen-combining
site on the antibody and modifies it so that it acquires specificity
for a glycoprotein target. When antibody binds, drug is trapped
at the antigen-antibody interface. Unidentified compounds in fo-
ods, herbal medicines and other ingested substances also appe-
ar to be capable of triggering this type of antibody.
RGD-mimetic platelet inhibitors. Eptifibatide and other drugs
of this class bind tightly to the RGD recognition site of GPIIb/
/IIIa (aIIb/b3 integrin) and block binding of fibrinogen to the ac-
tivated integrin. Drug binding induces structural changes in IIb/
/IIIa that are recognized by patient antibodies. These “neoepito-
pes” are clustered about the RGD binding site and are distinct
from ligand-induced binding sites (LIBS) recognized by LIBS-spe-
cific monoclonal antibodies.
Abciximab. Abciximab is a murine/human Fab fragment speci-
fic for GPIIIa that inhibits platelet function by blocking the bin-
ding site for fibrinogen. Antibodies causing thrombocytopenia in
patients treated with abciximab appear to recognize murine se-
quence on the Fab immediately adjacent to the residues that de-
termine its specificity (CDR regions). Antibody binding appears
to be accentuated when abciximab is bound to its target epitope.
Clopidogrel. Clopidogrel inhibits platelet function by binding
covalently to the platelet P2Y12 receptor, preventing its reac-
tion with ADP and is one of the most widely used drugs in the
world. Acute thrombocytopenia seen in some patients treated
with clopidogrel appears to be by caused by antibodies that reco-
gnize a metabolite of the drug in a complex with P2Y12.
Protamine. Protamine is widely used to neutralize heparin fol-
lowing surgery. Acute thrombocytopenia following protamine
infusion is a rare complication of treatment. In a patient recently
encountered, we identified an antibody that recognizes protami-
ne in a complex with heparin. Thrombocytopenia in this case
appears to be caused by immune complexes consisting of hepa-
rin, protamine and antibody that form on the platelet surface. The
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close similarity between this antibody and antibodies specific for
heparin/PF4 complexes that cause heparin-induced thrombocy-
topenia/thrombosis (HIT) is apparent.
Autoantibodies. Some drugs are thought to be capable of indu-
cing platelet-specific autoantibodies, leading to a clinical picture
typical of idiopathic immune thrombocytopenia (ITP) but a cau-
se-and-effect relationship is very difficult to prove.
Drug metabolites as triggers for immune thrombocytopenia.
Drug-dependent, platelet-reactive antibodies are not detected in
many patients with apparent DITP. A major reason for this is that
drug metabolites can be the sensitizing agents. Glucuronide-drug
conjugates are particularly likely to cause this complication
O19 Anti-protamine sulphate antibodies
can activate platelets and cause thrombocyto-
penia in patients undergoing cardiac surgery
Bakchoul T., Amiral J., Krautwurst A., Santoso S., Sachs U.J.
Universitatmedizine Greifswald, Greifswald, Germany
Background: Thrombocytopenia is often seen in patients after
extracorporeal circulation (ECC) for heart surgery. Protamine
sulphate (PS) is given for heparin reversal and is associated with
thrombocytopenia for unknown reasons. The aim of the following
study was to investigate the clinical relevance of antibodies re-
cognizing PS in patients with cardiac surgery.
Methods: Sera from patients after cardiac surgery were tested
by ELISA to identify a possible target antigen. Heparin-induced
platelet aggregation assay (HIPA) was modified in order to iden-
tify the antibodies’ capability to activate platelets in vitro. Final-
ly, IgG fractions prepared from these sera were explored for their
ability to remove human platelets in an in vivo NOD/SCID mo-
use model of immune thrombocytopenia.
Results: Workup of the target antigen revealed specific binding
to PS in 9/20 sera. In a modified HIPA, 7/9 sera induced platelet
activation in the presence of PS but not in the presence of hepa-
rin. In a murine model of immune thrombocytopenia, human pla-
telets were cleared from the circulation with an elimination rate
of 18% per hour in the presence of IgG and PS plus heparin, whe-
reas platelet clearance was not above baseline in the presence
of IgG and PS alone (elimination rate, 4% per hour). Platelet
destruction was inhibited by blocking FcgammaRIIa.
Conclusion: We give experimental evidence that antibodies aga-
inst PS induce thrombocytopenia via FcgammaRIIa-induced pla-
telet activation. This finding may be of clinical relevance in patients
undergoing cardiac surgery with PS reversal of heparin.
O20 Furosemide as a cause of immune
thrombocytopenia
Bougie D.W., Nayak D., Aster R.H.
Blood Reseaech Institute, Blood Center of Wisconsin, Milwaukee,
WI, USA
Many drugs have been implicated as triggers for immune throm-
bocytopenia (DITP), but drug-dependent antibodies (DDAb) have
been identified only for a minority of these. Many patients who
are antibody-negative have a history strongly suggestive of DITP.
Likely reasons for failure to detect antibody are low water-solu-
bility of many drugs and specificity of some antibodies for drug
metabolites. In a recent epidemiologic study (Reese 2010) we
identified the widely used diuretic/antihypertensive furosemide
as a likely cause of “antibody-negative” immune thrombocyto-
penia. In standard laboratory testing, 4 of 88 samples from pa-
tients suspected of having furosemide-induced thrombocytope-
nia contained “borderline-positive” DDAbs. Furosemide solubi-
lity increases approximately10-fold at high pH. When furosemide
was dissolved at pH 10 and then neutralized was used for testing,
17 of the remaining 84 samples reacted with platelets when drug
was present. Pathogenicity of the antibodies detected was stu-
died in a NOD/SCID mouse model (Bougie 2010). Of five antibo-
dies studied, four promoted furosemide-dependent destruction
of human platelets in vivo. In addition, two antibody-negative sera
caused platelet destruction in animals given furosemide. Labo-
ratory testing showed that these DDAbs are specific for furose-
mide glucuronide, a known furosemide metabolite.
These findings show that 1) furosemide-dependent platelet an-
tibodies can be detected with much higher yield when drug is
dissolved at alkaline pH before testing is done; 2) the antibodies
detected are capable of causing human platelet destruction in
vivo; 3) some patients produce antibodies specific for the meta-
bolite, furosemide glucuronide; and 4) the NOD/SCID mouse can
be extremely useful in identifying such antibodies.
Key words: platelets, drug-induced thrombocytopenia, furose-
mide, metabolite, NOD/SCID mouse
Platelet transfusions: new insights
— session 8
L19 Effects of immediate or delayed
addition of platelet additive solution on the
in vitro quality of apheresis platelets
Ringwald J.1, Tully S.1, Geier C.1, Hauck B.1, Weiss D.1,
Callaert M.2, Eckstein R.1
1Dpt. of Transfusion Medicine and Hemostaseology, University
hospital of Erlangen, Krankenhausstr. 12, D-91054 Erlangen,
Germany, 2TerumoBCT, Zaventem (Belgium)
Background: Single donor platelets (SDPs) stored in platelet
(PLT) additive solution (PAS) have become a widely used trans-
fusion product. Many studies have focused on the influence of
different PAS on PLT quality. There is still little knowledge how
different hold times of hyperconcentrated PLT suspensions
(HPSs) before the addition of PAS might affect PLT quality.
Aims: We compared the in-vitro quality of SDPs with immedia-
te or delayed (2 hours) PAS addition and studied the quality of
the collected concurrent plasma (CP).
Methods: 31 blood donors underwent PLT apheresis on Trima
Accel® (Version 6.0) system (TerumoBCT) in which a HPS (tar-
get: 6 × 1011 PLTs in 175 mL plasma) and CP was collected. The
volume of CP was automatically limited not to exceed an extra-
corporeal volume of 15% of donor’s blood volume throughout
donation or a total volume of collected units of 650 mL plus anti-
coagulant. The SDP was split into two similar products via gra-
vidity. The system was set to automatically add 162 mL of modi-
fied PAS III (PAS IIIM) to one product (0h-SDP). The same vo-
lume of PAS-IIIM was added to the second product (2h-SDP) after
resting at 22 ± 2°C for 30 and 90 minutes without and with agi-
tation, respectively. This resulted in SDPs with a targeted con-
centration of 1.2 × 106 PLTs/µL and a PAS proportion of 65%.
SDPs were stored for 7 days and samples were taken on days 1,
5, and 7. Lactate, glucose, pH (37°C), P-selectin-expression,
hypotonic shock response (HSR) and extent of shape change
(ESC) were tested. Coagulation factor V (FV) and VIII (FVIII)
activities and D-dimer concentration were determined in the CP
on day 0 and in the donor before donation.
Results: Mean volume of the produced 0h- and 2h-SDPs was
252.1 ± 5.1 and 246.7 ± 5.6 mL with 1.05 ± 0.14 and 1.07 ±
± 0.16 × 106 PLTs/µL resulting in a PLT content of 2.65 ± 0.36
and 2.64 ± 0.42 × 1011 PLTs, respectively. All SDPs contained
less than 1 × 106 residual WBCs with a maximum of 0.126 × 106
WBCs/unit. Metabolic parameters such as glucose utilisation,
lactate increase, and pH were similar throughout storage for both
kinds of products. Furthermore, similarly low values for P-se-
lectin-expression indicated no relevant platelet activation during
storage. Functional parameters such as HSR and ESC were well
preserved during storage with no significant difference between
0h- and 2h-SDP (Table 1). The recovery of FV and FVIII in the
CP was 100.0 ± 14.0 and 98.6 ± 14.9%, respectively. The con-
centration of D-dimers in the donor and the CP was similar with
173.7 ± 90.1 and 177.6 ± 91.2 ng/dL, respectively.
Summary and conclusions: PLT in vitro quality was well ma-
intained up to 7 days of storage in platelets collected as HPSs on
Trima Accel® and diluted with 65% PAS-IIIM. Adding PAS im-
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mediately or 2 hours after collection does not result in different
in-vitro quality of PLTs stored up to seven days. The very good
recovery of FV and FVIII with no signs of activation of the co-
agulation system indicates a good quality of CP.
Table 1. In vitro quality of stored PLTs — comparison
between different hold times (L19)
0h-SDP 2h-SDP
Mean ± SD  Mean ± SD
HSR day 5 (%) 64.8 ± 10.0 64.7 ± 12.0
HSR day 7 (%) 59.9 ± 10.7 60.2 ± 10.6
ESC day 5 (%) 24.4 ± 4.8 25.2 ± 4.8
ESC day 7 (%) 20.3 ± 4.4 19.6 ± 4.9
CD62P day 5 (%)* 2.03 ± 1.02 2.02 ± 0.88
CD62P day 7 (%) 3.03 ± 1.26 2.99 ± 1.23
MPV day 5 (fl) 7.83 ± 0.51 7.84 ± 0.54
MPV day 7 (fl) 7.98 ± 0.50 7.99 ± 0.53
pH at 37°C day 5 7.27 ± 0.07 7.26 ± 0.07
pH at 37°C day 7 7.28 ± 0.09 7.27 ± 0.09
Daily glucose consumption 0.27 ± 0.07 0.26 ± 0.08
until day 5  [mmol/day/1011 PLTs]
Daily glucose consumption 0.31 ± 0.07 0.31 ± 0.08
until day 7  [mmol/day/1011 PLTs]
Daily lactate increase until
day 5 [mmol/day/1011 PLTs] 0.53 ± 0.12 0.52 ± 0.13
Daily lactate increase until
day 7 [mmol/day/1011 PLTs] 0.63 ± 0.11 0.62 ± 0.13
*only n = 30
L20 The Mirasol PRT system,
an alternative to gamma-irradiation
in the prevention of TA-GVHD?
Marschner S.2, Nevola M.1, Tavares J.1, Reddy H.L.2,
Goodnch R.P.2, Fast L.D.1
1IDepartment of Medicine, Rhode Island Hospital/Brown University,
Providence, RI, USA, 2Caridian BCT Biotechnologies, LLC,
Lakewood, CO, USA
Background: During the transfusion of blood products, a reci-
pient can receive allogeneic leukocytes, leading to adverse re-
actions in the recipient inc1uding donor anti recipient responses
such as transfusion-associated graft versus host disease (TA-
GVHD) and cytokine production. To avoid or minimize leukocy-
te mediated reactions, leukocytes can be inactivated by gamma
irradiation and/or depleted prior to administration. Nuc1eic acid
targeted pathogen reduction processes (PRT) are also suited for
leukocyte inactivation. The Mirasol® PRT System uses ribofla-
vin (Vitamin B2) and ultraviolet (UV) light to reduce the active
pathogen load and inactivate residualleukocytes in blood products
used for transfusion.
Aims: The effect of Mirasol treatment on leukocytes was tested
and compared to gamma irradiation.
Methods: Whole blood or separated blood components were
treated with the Mirasol System or received 25 Gy gamma-
irradiation. White blood cells (WBCs) were isolated from tre-
ated blood products and in vitro and in vivo function of the cells
was analyzed. RESUL TS: In vitro studies demonstrated that
this treatment was as effective as gammairradiation in preven-
ting leukocyte proliferation, but was more effective in preven-
ting antigen presentation, cytokine production, and T-cell ac-
tivation. LDA showed that PRTtreatment and gamma-irradia-
tion both reduced the viability of T-cells by 4.7 log. Consistent
with in vitro findings, treatment was as effective as gamma-
irradiation in preventing xenogeneic GVHD, a mouse model
for T A-GVHD.
Conclusions: These results demonstrate that Mirasol treatment
of WBCs may be more effective at preventing the immune con-
sequences of transfusion than gammairradiation. The ability to
effectively inactivate leukocytes in whole blood, prior to separa-
tion into components, provides blood bankers with an alternati-
ve to gammairradiation.
L21 Institute of Hematology and Transfusion
Medicine in Warsaw — experience with
clinical use of platelet concentrates
inactivated with the Mirasol® PRT System
Łętowska M., Pogłód R., Rzymkiewicz L., Lachert E.
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Background: The Mirasol Pathogen Reduction Technology
(PRT) system uses riboflavin (vitamin B2) and ultraviolet light
for the purpose of reducing the amount of infectious pathogens
in blood components as well as inactivating residual white blood
cells. The Mirasol® PRT system relies on two basic mechanisms;
one is the electron transfer induced by the direct interaction of
photoexcited riboflavin with guanosine bases, while the other
makes use of the effect due to action of UV light only. Riboflavin
induces irreversible modifications to the base pairs (mostly in
guanosine bases) and repair and replication of the damaged nuc-
leic acids is hindered. A wide range of bacteria, viruses, parasi-
tes and leucocytes are inactivated in the Mirasol® PRT system
and there is no need to remove riboflavin or photoproducts from
the treated blood components. As a scientific unit involved in
transfusion medicine the Institute of Hematology and Transfu-
sion Medicine (IHTM) has developed and tested numerous in-
activation systems and methods and as a hospital unit with 130
beds for patients with hematological disorders it has performed
a clinical evaluation of the Mirasol® PRT system for both PCs
and plasma. Following this evaluation Mirasol® PRT-treated pla-
telet concentrates are in routine use in our hospital.
Aim: The aim of the study was to analyze the clinical effects of
the Mirasol® PRT-treated platelet concentrates in IHTM patients
with hematological disorders.
Clinical data: The Mirasol® PRT for PCs was first implemen-
ted in the Warsaw Blood Transfusion Center (WBTC) in July 2009
with the installation of six illuminators. Up to December 31, 2011
16,620 Mirasol® PRT-treated therapeutic doses of PCs (8516
apheresis and 8104 from buffy coat) were produced. WBTC is the
main supplier of all blood components for IHTM and the only sup-
plier of Mirasol® PRT-treated PCs. In the two-year study period
(January 2010–December 2011) patients admitted to IHTM were
transfused with 4752 apheresis and 2309 uffy coat PCs (total of
7061 PCs). Within the same period we transfused 1863 Mirasol®
PRT-treated PCs (including 741 apheresis platelet concentrates)
to 329 Institute patients (155 F and 174 M). Among these 329
patients were: 113 AML patients, 30 ALL patients, 13 CML
patients, 29 CLL patients, 21 MDS patients, 13 myelofibrosis,
12 HL patients, 30 NHL patients, 18 myeloma patients, 28 pa-
tients with thrombocytopenia (including 10 with ITP) and 22 with
other disorders. The mean age of patients was 52,95 years (18–
–83), mean platelet count 10,65 × 109/l (0–64 × 109/l) prior to
transfusion and 25.8 × 109/l (0–158 × 109/l) 24 h after/following
transfusion.
Conclusion: We observed no transfusion-related reactions in the
IHTM patients.
L22 PRT Mirasol® System-validation
experience in Poland
Lachert E., Antoniewicz-Papis J., Kubis J., Łętowska M.
Institute of Hematology and Transfusion Medicine, Warsaw,
Poland
Better donor selection, implementation of more sensitive viral
tests, quarantine of plasma, closed-system preparation and es-
tablishment of quality assurance (QA) have much contributed to
the safety of blood and blood components. The next step to fur-
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ther improve this safety is implementation of pathogen reduc-
tion technology. The Polish blood transfusion centers are cur-
rently equipped with 27 illuminators (Mirasol®PRT System) for
routine plasma pathogen inactivation; some of them have also
implemented pathogen inactivation for PCs. This system uses
riboflavin and ultraviolet light to reduce the infectious pathogen
load and to inactivate residual white blood cells in blood compo-
nents. Mirasol®PRT System for plasma and PCs was subjected
to validation at the Institute of Hematology and Transfusion
Medicine (IHTM).
The aim of the validation study was to: 1. evaluate the effect of
Mirasol®PRT System on the functions of PCs during 5 days of
storage, 2. compare the quality of plasma inactivated both befo-
re freezing and after thawing, 3. determine if the Mirasol®PRT
System may be used as alternative to irradiation of blood com-
ponents.
Conclusions: 1. The in vitro results for control and Mirasol-
treated PC groups were comparable for: pH, HSR, aggregation,
CD 42b antigen expression, MPV and platelet count. 2. The re-
sults (markedly higher content of labile coagulation VIII, IX, XIII
and vWF factors in plasma inactivated prior to freezing) con-
firm that the Mirasol inactivation procedure must be applied
before freezing. 3. The significant increase of dead lymphocyte
count (2-fold higher than for gamma-irradiated PCs after 6 days
of storage) as well as decrease in lymphocyte activation during
6 days of storage (activation of lymphocytes/CD69 expression
is lower in PRT-treated units than in irradiated units) confirms
that the Mirasol®PRT System may be used as alternative to
gamma irradiation.
Neonatal alloimmune thrombocyto-
penia mechanisms and prevention II
— session 9
L23 Platelet antibodies may harm more
than platelet - fetal sex and birth weight 
Tiller H., Killie M.K, Husebekk A., Chen P.,
Kjeldsen-Kragh J., Ni H., Øian P., Skogen B.
University Hospital North, Tromsø, Norway
Maternal anti-HPA-1a antibodies are the most common cause of
fetal and neonatal alloimmune thrombocytopenia (FNAIT) in the
Caucasian population. New observations indicate that maternal
anti-HPA-1a antibodies may affect more than platelets. In our
recent study, a strong association between maternal anti-HPA-1a
antibodies and birth weight was observed [1]. Similarly, a signi-
ficant association between neonatal platelet count and birth we-
ight was reported in a murine model of FNAIT [2]. Data also in-
dicate that fetal sex influence how maternal anti-HPA-1a anti-
bodies affected birth weight; only birth weight in boys was
affected by maternal anti-HPA-1a antibodies [1]. Even though the
concept of fetal sex as a risk factor in FNAIT is new and the re-
lated mechanisms currently unknown, it is well known that male
fetal sex is an independent risk factor for adverse pregnancy
outcome in general. The HPA-1a antigen epitope is not restric-
ted to the aIIbb3 integrin complex on platelets. The b chain is
also part of the avb3 integrin complex (vitronectin receptor),
which is present on invasive throphoblasts and syncytiotropho-
blast microparticles (STMP) that are shed into maternal blood.
It has been suggested that STMP carrying the HPA-1a antigen
could be the antigen source of HPA-1 alloimmunization [3], sup-
porting the idea that the placenta play an important part in the
pathogenesis of FNAIT. Existing data on birth weight and fetal
sex in relation with FNAIT will be presented and possible me-
chanisms discussed. These recent findings indicate a broader
impact of maternal anti-HPA-1a antibodies — maybe the term
anti-platelet antibody is too narrow?
References:
1. Tiller H, Killie MK, Husebekk A, et al. Platelet antibodies and fetal
growth: Maternal antibodies against fetal platelet antigen 1a are
strongly associated with reduced birthweight in boys. Acta obstetri-
cia et gynecologica Scandinavica 2011; 91: 79–86.
2. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against
fetal and neonatal alloimmune thrombocytopenia: induction of anti-
body-mediated immune suppression and prevention of severe clini-
cal complications in a murine model. Transfusion 2012; doi: 10.1111/
/j.1537-2995.2011.03480.x. [Epub ahead of print].
3. Kumpel BM, Manoussaka MS. Placental immunology and maternal
alloimmune responses. Vox Sang 2012; 102: 2–12.
L24 Interpretation of the classic screening
criteria in favour of implementing
a screening program for FNAIT
Husebekk A., Skogen B.
University of Tromsø, Tromsø, Norway
Background: Fetal and neonatal alloimmune thrombocytopenia
(FNAIT) is caused by anti-HPA-1a alloantibodies in > 85% of
the cases in Caucasians. The diagnosis is most often recognised
after the birth of a child with bleeding symptoms. 1: 12,500–
–25,000 children are born with devastating intracerebral hemorr-
hage. Identification of pregnancies at risk must be considered in
order to prevent or treat the condition.
Methods: Prospective studies of FNAIT in mice and human have
been performed looking at the natural history of FNAIT and at
the effect of treatment with IVIg.
Results: Prospective studies have shown that FNAIT resem-
bles haemolytic disease of the newborn with most immunizations
in connection with deliveries. Also, both studies in mice and
humans have indicated less mortality and morbidity when tre-
ating with IVIg during pregnancy. There are indications of wor-
se outcome in the first pregnancy where anti-HPA 1a antibodies
are present.
Conclusion: WHO has made a set of criteria which should be met
in order to recommend screening for any condition. Screening for
FNAIT has not been recommended due to lack of prevention or
treatment options which is included in the recommendation from
WHO. Several groups have now recommended screening based
on promising IVIg treatment results. Also, there are attempts to
make a prophylaxis aimed at preventing immunization. HPA-1a
typing in early pregnancy must be introduced in order to identify
pregnancies at risk and it may be time to consider introduction of
HPA 1a typing in standard care for pregnant women.
Key words: fetal and neonatal alloimmune thrombocytopenia,
intracranial haemorrhage, pregnancy, screening
L25 Laboratory and clinical aspects
of FNAIT — Polish experience
Uhrynowska M., Żupańska B.
Department of Immunohematology and Immunology of Transfusion
Medicine Institute of Hematology and Transfusion Medicine,
Warsaw, Poland
Aim: of the lecture is to present our experience and efforts in
solving the difficulties related to diagnosis of fetal/neonatal allo-
immune thrombocytopenia (FNAIT) and also to discuss the me-
thods of improving the efficacy of FNAIT detection.
Ours is the only laboratory in Poland that performs the complex
FNAIT diagnosis. The first NAIT case developed as result of the
presence of anti-HPA1a antibodies was diagnosed in Poland 1985
with the use of platelet suspension immunofluorescence test
(PSIFT) (Maslanka et al.). In the 90s, the diagnostic methods
were improved by implementation of: flow cytometry, the mo-
noclonal antibody immunobilization of platelet antigen (MAIPA)
and HPA 1–5, 15 genotyping. The NAIT incidence rate in Po-
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land was investigated in two large prospective studies. In the
period 1994–1997 the platelet count was determined in more than
26,000 women at delivery and in more than 24,000 newborns;
thrombocytopenia (platelet count < 100,000 platelets/mm3) was
observed in 0.5% and 0.7%, respectively. The serological stu-
dies of these cases determined the prevalence of NAIT at 1:1800
(Uhrynowska et al., 2000). In the 1999–2003 period, HPA 1 phe-
notype was examined by ELISA in 8031 pregnant women, follo-
wed by anti-HPA 1 analysis in HPA1bb women. FNAIT was dia-
gnosed in 1: 2000 (Maslanka et al., 2003). With this in mind we
might expect an annual incidence rate of about 400 FNAIT ca-
ses, as there are annually 450 000 live births and 1500 stillbirths
reported in Poland. As it is, FNAIT is extremely underdiagno-
sed — only 30 cases of severe neonatal thrombocytopenia are
diagnosed each year (4–8 cases with anti HPA 1a) and mostly
(~90%) after birth. Nowadays, the only absolute indication for
FAIT testing is hemorrhage to the fetus central nervous system
visualized in USG.
Screening of all pregnant women for FNAIT is still too costly,
but it is particularly justified in cases with risk factors in history
of the previous pregnancies, mother’s thrombocytopenia in pre-
gnancy and whenever there is need for percutaneous umbilical
cord blood sampling (PUBS).
We are of the opinion that published expert recommendations
would be helpful for dissemination of FNAIT diagnostics.
L26 Current management strategies in
FNAIT
Dębska M.
II Department of Obstetrics and Gynecology, The Centre of Medical
Postgraduate Education, Bielanski Hospital, Warsaw, Poland
Fetal and neonatal alloimmune thrombocytopenia still remains
an underestimated and underdiagnosed clinical problem. This is
a disease, which has to be treated prenatally, because results of
profound thrombocytopenia in the fetus can be devastating. It can
cause spontaneous bleedings in the fetus, including brain hemor-
rhage, and lead to permanent handicap. Because there is no me-
thod of diagnosing asymptomatic fetal thrombocytopenia, we do
not usually observe it until the delivery . In contrast to Rh-dise-
ase, treatment methods are not standardized. Management stra-
tegies differ between centers and countries. Most centers apply
pharmacological treatment, such as IVIG and prednisone, given
in different doses. There is a general trend towards less invasi-
ve methods of diagnosis and treatment. Mostly, intrauterine pla-
telet transfusions are reserved for cases resistant to treatment
or for preventing of bleeding after diagnostic cordocentesis. Ma-
nagement has to be individualized, based on the patient history.
ICH in the older sibling places the fetus in the group of highest
risk of bleeding complications. Regardless of different treatment
strategies, most fetal and neonatal problems arising from allo-
immune thrombocytopenia can be successfully treated.
Poster walks I
Immunological and molecular methods
of platelet and granulocyte investigation
P1 The direct MAIPA revisited for the
detection of platelet autoantibodies
Porcelijn L.1, Oldert G.1, Huiskes E.1,
de Haas M.1, Zwaginga J.J.2
1Sanquin Diagnostic Services, Amsterdam, The Netherlands,
2Leiden University Medical Centre, Leiden, The Netherlands
Introduction: The detection of platelet autoantibodies in the
immunofluorescence (PIFT) technique lacks glycoprotein (GP)
specificity. Autoantibodies against platelets are mostly directed
against the GP complexes IIb/IIIa, Ib/IX and V. The detection of
GP-specific autoantibodies in the direct monoclonal antibody im-
mobilization of platelet antigens (DM) is known to have a > 90%
specificity, but lacks sensitivity (varying from 29 to 54%). We
analysed if the DM could be used for the diagnostic evaluation of
patients with immune-thrombocytopenia (ITP).
Material en methods: In total 462 platelet samples from heal-
thy blood donors and 654 platelet samples from 107 rituximab-
-treated ITP patients were tested in the DM with MoAbs against
GPIIb/IIIa, GPIb/IX, GPV, GPIa/IIa and GPIV. For 66 patients
we received samples drawn before, during or after treatment.
Serial testing, starting before treatment until at least three mon-
ths after treatment, was possible for 41 patients and for 60 pa-
tients pretreatment samples could be tested. DM results were
compared with direct PIFT and eluate PIFT (DPE) results.
Results: For the detection of alloantibodies we used a standard
cut-off value of E = 0.3 but a cut-off value, specific for the detec-
tion of autoantibodies, E = 0.13 (mean + 3std) was based on the
healthy donors DM results. Autoantibodies were detected in 51
(85%) of the 60 pretreatment samples with the DM and in 39
(65%) with the DPE. All but two positive results obtained with
the 654 ITP samples were directed against GPIIb/IIIa and/or
GPIb/IX and/or GPV. There was a significant correlation betwe-
en the DM extinction and the reactivity in the DPE. In addition
42% of the weak positive DPE results were not confirmed in the
DM, whereas 37% of DPE negative samples showed positive
results in the DM.
For the 41 patients of whom follow up samples were tested,
a significant inverse correlation (p < 0.001) was seen between
the DM extinctions and the platelet counts.
Conclusion: Upon defining a new cut-off value, the direct
MAIPA assay is both more sensitive (85%) and more specific
(> 90%) than the PIFT. Therefore the DM (next to the DPE)
adds to the diagnostic evaluation of ITP patients in our routine
ITP diagnostic setup.
P2 Introduction of leukocyte antibody
screening in blood donors
Auvinen M.K., Aspevall-Dietrich B.,
Johnsson A., Taune-Wikman A.
Karolinska University Laboratory Stockholm, Sweden
Background: In Stockholm, 87000 blood units are donated from
43500 donors annually. About 50% are female donors. Male-only pla-
sma was introduced in 2008. To have a sufficient supply of AB pla-
sma, female AB plasma donors are needed. The results from routine
leukocyte antibody screening of the donors for 2011 are reported.
Materials and methods: Blood samples from all blood group AB
female donors as well as males with transfusion after previous do-
nation were tested for antibodies against human leukocyte antigen
class I (HLA I), class II (HLA II) and granulocytes. HLA I and HLA
II antibody screening was done by ELISA-test, and granulocyte an-
tibody screening by granulocyte agglutination test (GAT).
Results: Total of 168/826 donors were initially positive for anti-
bodies. After reanalysis of the same sample or a new sample 126/
/826 (15.2%) were confirmed positive for antibodies (2 males).
42 samples (24.8%) were negative when retested. Granulocyte
antibodies were detected in 3% of the all donors tested.
The positive results in the antibody screening were distributed
as follows:
Positive antibody N % of positive
GAT+HLA I+HLA II 8 6.3
GAT only 1 0.8
HLA I only 45 35.7
HLA II only 40 31.7
HLA I+II 15 11.9
GAT+HLA I 14 11.1
GAT+HLA II 3 2.4
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Conclusion: Introduction of leukocyte antibody screening of
blood donors is considered in many centers. The optimal combi-
nation of tests to an acceptable cost must be chosen. In most of
the cases we detected HLA antibodies. With special electronic
questionnaires the donor population could be further targeted to
only those with previous pregnancies or transfusion history. The
high proportion of positive results in GAT, negative in retesting
needs evaluation as well as the specificities of the antibodies.
P3 Establishment of a cell line panel for the
detection of antibodies against human
platelet antigens 5a and 5b
Hayashi T.
Japanese Red Cross Osaka Blood Center, Osaka, Japan
Background: Antibodies against human platelet antigens
(HPAs) play important roles in thrombocytopenia. A highly sen-
sitive assay using platelets (PLTs) has been developed for the
detection of antibodies against HPAs. However, it is difficult to
obtain PLTs that express rare HPAs that are required for the
assay. Therefore, an alternative method that does not require
PLTs would be helpful for the detection of antibodies against
HPAs. We attempted to establish a cell line panel for the detec-
tion of antibodies against HPA-5a and 5b.
Methods: Using a retroviral vector, CD49b cDNA encoding
HPA-5b, 13b and 18b were co-transduced to K562 cells, which
is a non-adherent cell line that constantly expresses CD29,
a counterpart of CD49 integrin. Transgenic cells were cloned and
termed HP-5b, HP-13b and HP-18b cells according to the HPA
phenotype. To evaluate the sensitivity and specificity of this cell
line panel, we applied it to a minor modified monoclonal antibo-
dy-specific immobilization of platelet antigens (MAIPA) assay.
Result and conclusions: Transgenic products were expressed
in the cultured cells for over 6 months. All serum samples con-
taining HPA-5a and 5b antibodies tested positive, whereas all
other serum samples, including normal serum and that containing
antibodies against the human leukocyte antigen, tested negati-
ve. Our method using the cell line panel demonstrated a higher
sensitivity compared with the MAIPA assay using PLTs. The pre-
sent results indicate that this established cell line panel permits
highly sensitive detection of specific antibodies against HPA-5a
and 5b.
P4 Potential PCR-SSP mistyping of the
HNA-3a allele due to genetic variation
of the SLC44A gene
Flesch B.K., Reil A., Bux J.
German Red Cross Blood Service West Immunogenetics and HLA
Laboratory, Bad Kreuznach and Hagen, Germany
Background: Different genotyping methods have been establi-
shed for HNA-3 allele diagnostics. Recently, we identified an
additional 457C > T SNP (counting from the ATG start codon)
of the HNA-3a allele in about 2.4% of German blood donors which
might provoke mistyping due to incomplete primer annealing,
which should be investigated.
Methods: Two in-house PCR-SSP methods with HNA-3-speci-
fic sense primers, one PCR-SSP with HNA-3-specific anti-sen-
se primers and one commercial assay were applied on seven DNA
samples with a known C457T variation of the HNA-3a allele. Ad-
ditional samples without the 457T variation served as controls.
Results: Four HNA-3aa samples with a heterozygous 457T va-
riation and every control sample tested so far were determined
correctly by each of the four methods. Both, the commercial as-
say and one of the in-house methods with HNA-3 specific sense
primers failed to detect the HNA-3a allele in three HNA-3ab sam-
ples with the additional 457T variation and falsely reported an
HNA-3b homozygous result. However, after changing the cycle
protocol of the in-house procedure, these samples resulted in
weak HNA-3a specific bands like those produced by the second
in-house method with HNA-3 specific sense primers. The anti-
sense primer method produced clear and correct results.
Conclusions: PCR-SSP mistyping of the HNA-3a allele is po-
ssible in samples with the additional 457T variation when the
allele-specific primers are constructed as sense-primers. We
suggest to either re-type DNA samples with an HNA-3bb result
by an HNA-3a 457T specific PCR method or to use an assay with
HNA-3 specific anti-sense primers.
P5 Detection of antibodies against HNA-1a,
-1b and -1c by rapid ELISA
Werth S., Bayat B., Tjahyono Y., Eskandar J.,
Berghöfer H., Sachs U.J., Santoso S.
Clinical Immunology and Transfusion Medicine, Giessen, Germany
Background: Antibodies to human neutrophil antigens (HNAs)
are responsible for immune-mediated neutropenia and transfu-
sion related acute lung injury. Several methods exist for the iden-
tification of neutrophil antibodies, but most methods require fresh
neutrophils. In this study, a rapid ELISA using recombinant HNA-1
antigens was developed for the detection of HNA-1a, -1b and
-1c alloantibodies.
Methods: Soluble recombinant HNA-1a, -b, and -1c were isola-
ted from cell culture supernatant of allele-specific transfected
insect cells. Purified recombinant HNA antigens were immobili-
zed on microtiterwells using mab against V5-Tag protein. Sera
were added, and bound antibodies were detected by enzyme la-
beled secondary antibodies. In parallel, MAIGA was performed
and the results from both methods were compared.
Results and conclusions: In total, 30 MAIGA positive sera
containing HNA-1a (n = 15) or HNA-1b alloantibodies (n = 15)
were tested in ELISA. 13/15 (86.7%) reacted with HNA-1a, but
not with recombinant HNA-1b. Interestingly, four HNA-1a sera
showed additional reaction with HNA-1c peptide. This result
could be confirmed by MAIGA using HNA-1c transfected cell line.
In ELISA, 13/15 (86.7%) showed a specific positive reaction with
recombinant HNA-1b, and 12/15 (80.0%) cross-reacted with
HNA-1c protein. Immunoprecipitation analysis of all ELISA ne-
gative HNA-1a and -1b sera with phenotyped neutrophils did not
show any specific band indicating false positive reaction of these
sera in MAIGA assay. These results suggested that rapid ELISA
using recombinant neutrophil antigens might provide a valuable
method for rapid characterization of human antibodies against
HNA-1a, -1b, and -1c in patients with neutropenia.
P6 A modified immunocomplex capture
fluorescence analysis for the detection
of human platelet antigen antibodies
Miyagi T., Ichihara T., Kashiwase K.,
Uchikawa M., Nakajima K.
Japanese Red Cross Tokyo Blood Center, Tokyo, Japan
Background: Immunocomplex capture fluorescence analysis
(ICFA) is a new method for the detection of human platelet anti-
gen (HPA) antibodies (Fujiwara et al. 2009 Vox Sanguinis). Ho-
wever, high background fluorescence occasionally impedes the
detection of anti-HPA-2b. Therefore, we developed a modified
ICFA protocol that reduces the background fluorescence.
Methods: Microbeads (Luminex) were separately coupled with
monoclonal antibodies specific for GPIIb, GPIIIa, GPIba, GPIa,
GPIV and human leukocyte antigen (HLA) class I. Platelets re-
acted with serum were lysed and the solubilized antigen-antibo-
dy complexes were captured with the beads. Beads are labeled
with phycoerythrin-conjugated anti-human IgG during the cap-
ture reaction at 37°C in the original ICFA protocol. On the other
hand, beads were washed after the capture reaction at 37°C and
then labeled at room temperature in the modified ICFA proto-
col. Median fluorescence intensities (MFI) of the beads were
measured using a Luminex100 system.
Results: We analyzed background MFI observed with the anti-
GPIba bead, which is used to detect anti-HPA-2b. In this case,
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MFI of the serum samples with and without anti-HPA-2b were
266 and 239 fluorescent units, respectively. The nonspecific re-
action occurred even when phosphate-buffered saline was used
instead of serum, but not in the absence of platelet. The nonspe-
cific reaction was markedly reduced in the modified protocol; MFI
of the serum samples with and without anti-HPA-2b were 11 and
166 fluorescent units, respectively.
Conclusions: We have developed a modified ICFA protocol that
reduces nonspecific reactions. This modified ICFA assay is use-
ful for the detection of HPA antibodies.
P7 Preliminary findings on how ECMO
disrupts haemostasis: an ovine model
Fung Y.L., Foley S.R., Simonova G., Solano C.,
Spanevello M., Fraser J.F.
University of Queensland & The Prince Charles Hospital,
Brisbane, Australia
Background: Extracorporeal membrane oxygenation (ECMO)
is a vital treatment modality for patients with respiratory failure
refractory to standard ventilation. However, the extended con-
tact of patients’ blood with an artificial circuit, routinely leads to
bleeding and clotting complications. Defining what factors disrupt
haemostasis is difficult in ECMO patients because of their com-
plex underlying pathologies. We sought to overcome this with
an in vivo ovine ECMO model.
Methods: Ten healthy female merino sheep were placed on veno-
venous ECMO. Seven were supported for 2hr, and 3 for 24hr. Sam-
ples were collected for FBC, routine coagulation (PT, APTT, Clauss
Fibrinogen) and rotational thromboelestometry (ROTEM), pre-
ECMO (0 hr) and post-ECMO (0.25, 1, 2, 6, 7, 12, 18 and 24 hr).
Results: ECMO induced a quick and significant decrease in
EXTEM maximum clot firmness (MCF) (Fig A) which endured
for 2 hours. Correspondingly PT increased initially but was tem-
poral (Fig B). Fibrinogen levels decreased initially but not signi-
ficantly (Fig D), this was reflected in FIBTEM MCF (Fig C). No
significant changes to INTEM or platelet number and function
were detected (data not shown).
Discussion and conclusions: This preliminary data confirms
that even in a healthy host, ECMO disrupts haemostasis imme-
diately. The EXTEM data correlated with the PT, but may be
more sensitive as it detected a decreased MCF over a longer
period. The decrease in EXTEM MCF suggests that the quality
of the clot is compromised.
As the platelet count and function remained unchanged this may
reflect the fall in fibrinogen. These haemostatic imbalances war-
rant further investigation.
P8 The effectiveness of magnetic mixed
passive hemagglutination assay (M-MPHA)
for the detection of anti-HNA antibodies
Matsuhashi M., Tsuno N.H., Takahashi K.
The University of Tokyo, Japan
Background: Antibodies against human neutrophil antigens
(HNA) are involved in the pathogenesis of a variety of clinical
conditions, including neonatal immune neutropenia (NIN), febrile
transfusion reactions and transfusion-related acute lung injury
(TRALI). The detection of anti-HNA antibodies is essential for
their diagnosis. The IGIW recommends the use a combination of
the GIFT and GAT for HNA-antibody detection, and the monoc-
lonal antibody-specific immobilization of granulocyte antigens
(MAIGA) for the determination of antibody specificity. Mixed
passive hemagglutination (MPHA) is largely applied in Japan for
the detection of anti-platelet antibodies, and the magnetic (M) —
MPHA is a modification, in which magnetic microbeads coated
with anti-human or anti-mouse antibodies are used as the indi-
cator cells instead of sheep red cells.
Aim: Here, we aimed to analyze the sensitivity of the M-MPHA
for the detection of anti-HNA antibodies, and compared with that
of GIFT. Also the specificity of M-MPHA was confirmed using
human sera and HNA-specific monoclonal antibodies.
Methods: M-MPHA was applied for the detection of anti-HNA
antibodies. Human sera containing HNA-specific antibodies were
tested by M-MPHA and compared with GIFT.
Results: The sensitivity of M-MPHA was found to be similar to
that of GIFT, and it could clearly detect the HNA-1a, 1b, 3a and
3b antibodies with high specificity.
Conclusion: In MPHA, a large number of samples can be manipula-
ted in a single assay, and the panel cell plates can be frozen prese-
rved. Thus, it is an ideal method for the screening of HNA antibo-
dies, and is also effective for the identification of antibody specificity.
Key words: HNA antibodies, Granulocyte immunofluorescence
test, Mixed passive hemagglutination assay.
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P9 Family immune neutropenia in Russian
children
Vasilyeva M.N.1, Finogenova N.A.2, Mamedova E.A.3,
Polovzeva T.V.3, Golovkina L.L.1
1Hematological Research Center, Moscow, Russian Federation,
2Federal Research Center of Pediatric Hematology, Oncology and
Immunology, Moscow, Russian Federation, 3Morozov Children’s
City Clinical Hospital, Moscow, Russian Federation
Background: immune neutropenia (INP) is one of the most com-
mon variant of neutropenia in infants. Initial autoimmune neu-
tropenia of new-born children is rare disease with variable clini-
cal picture: from asymptomatical to livethreating pyo-septic and
necrotic complications.
Material and method: serums and neutrophils of 9 infants and
their parents of 4 families have been studied in complement de-
pended granulocytotoxic test.
Results: INP has been diagnosed in two 7 month old heterooval
girls of first family. Child T. had sepsis, osteomyelitis of left fe-
mur, abscesses of soft tissues, minimal neutropenic index (MNI)
0.02 × 109/l. Titer of antigranulocytotoxic antibodies (AGCA) 1:
32. Other girl K. has abscesses of soft tissues, pyo lymphadeni-
tis, MNI 0.2 × 109/l, AGCA 1: 8. Long-term follow-up is done
more than 5 years. Second family has two suffering INP sisters.
The old one was sick since age 8 month. Neutropenia was mild
during 5 years, MNI 0.36 × 109/l, AGCA 1: 32. The younger si-
ster had neutropenia since age 4 month and persisted in 10 month.
MNI 0.5 × 109/l, AGCA 1: 8. Neutropenia in both sisters was
asymptomatic. Third family has three kids. Older son suffered
with INP since age 6 month. In clinical picture — mastitis, re-
curring otitis, MNI 0.04 × 109/l, AGCA 1: 4. Complete remis-
sion have been achieved in 4.5 years. Two other children had neu-
tropenia since age 2 and 8 month without clinical manifestations,
MNI 0.4 × 109/l and 0.2 × 109/l. AGCA have never been detec-
ted. Remission have been achieved in 2 and 1.5 years after pro-
phylactic and symptomatic treatment of infections complications
(PSTIC). In fourth family the older girl became sick since age
8 month without pyo-infections, MNI 0.05 × 109/l, AGCA 1: 8.
Remission has been achieved in 3 years. Neutropenia has been
diagnosed in younger brother since age 2.5 month, MNI 0.3 × 109/l,
no AGCA have been detected. Remission have been achieved in
1 year after PSTIC. All data are summarized in the Table 1.
No AGCA have been detected in parents’ serums in all families.
Conclusions:
1. Neutrophils level doesn’t related to antibody activities.
2. Similar anamnestic data and clinical picture in younger siblings
with neutropenia but without antibodies (families 3 and 4)
allowed diagnosing INP. Prophylactic and symptomatic tre-
atment of infections complications in those children allowed
achieving early clinical and hematological remission and pre-
venting severe infection complications.
3. Some genetic factors predispose to family neutropenia.
P10 Resolving a complex granulocyte
serology problem with the aid of
cell lines expressing rHNA-3
Lucas G.1, Hopkins M.1, Wozniak M.2, Calvert A.1,
Ridgwell K.2, Green A.1, Cole S.3, McNicholl F.3
1Histocompatibity & Immunogenetics, NHSBT, Bristol, UK,
2Bristol Institute for Transfusion Sciences, NHSBT, UK,
3Haematology Department, Altnagelvin Hospital, Londonderry, UK
Background: A 44 year old multiparous woman presented with
an influenza like illness that resolved after a week. Haematological
indices were normal except for a low neutrophil count (0.22 × 109/
/L), which had previously always been normal. A transient facial rash
and knee and shoulder joint pains were noted. Bone marrow exa-
mination was normal. A diagnosis of SLE was excluded but there
was elevated rheumatoid factor. The neutropenia persisted (0.06
to 0.42 × 109/L) and several episodes of folliculitis required anti-
biotic treatment. A diagnosis of autoimmune neutropenia was made
and samples were referred for investigation.
Methods: Antibody investigations were performed using the
granulocyte chemiluminescence test, immunofluorescence tests
with granulocytes (GIFT), lymphocytes and cell lines expressing
rHNA-3a and -3b together with antigen capture (MAIGA) assays.
HLA antibodies were determined by Luminex. HNA typing was
performed by PCR-SSP and SBT.
Results: Serological investigations revealed the presence of
granulocyte and lymphocyte reactive antibodies without apparent
HNA specificity. HLA class II antibodies were detected by Lu-
minex. MAIGA assays for CD16b and CD11/18 antibodies were
negative. Elevated granulocyte membrane bound IgG and IgM
was detected by direct GIFT. Testing with cell lines expressing
rHNA-3 revealed the presence of HNA-3a antibodies. The pa-
tient typed as HNA-1a (+), 1b (–), 1c (+), 3a (–), 3b (+), 4a (+),
4bw (–), 5a (+), 5bw (–).
Conclusions: These investigations revealed the presence of
granulocyte autoantibodies and a coincidental finding of HNA-3a
alloantibodies. Elucidation of these antibodies required the use
of traditional granulocyte immunology techniques and rHNA-3
cell lines together with HNA genotyping. rHNA proteins are li-
kely to have an increasing role in resolving complex mixtures of
granulocyte reactive antibodies.
Table 1. Data summary (P9)
Families Children Minimal Antigranulo- Age of Duration of Prophylactic Severe infection
neutropenic cytotoxic diagnostic neutropenia and sympto- complications
index  (109/l)  antibodies   INP matic
(month) treatment
I 1a 0,02 1: 32  7 More than – +
1b 0,2 1: 8 5 years – +
II 1  0, 36 1: 32 8 5 years – –
2  0, 5 1: 8 4 10 month – –
III 1 0,04 1: 4 6 4.5 years – +
2 0,4 – 2 2 years + –
3 0,2 – 8 1.5 years + –
IV 1 0,05 1: 8 8 3 years – –
2 0,3 – 2,5 1 year + –
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P11 Molecular and cytogenetic methods
in the evaluation of chimerism after
HLA-identical related bone marrow
transplantation in oncohematological patients
Golovkina L.L.1, Vinogradova O.A.2, Kutina R.M.2,
Savtchenko V.G.2
1National Hematological Research Center, Moscow, Russian
Federation, 2National Hematological Research Center of Russia,
Moscow, Russian Federation
Background: Monitoring of engraftment after HSCT is carried
out by molecular and cytogenetic markers. HLA-identical siblings
have distinctions on HPA (Human Platelet Antigens), caused by
various chromosomal localization of HLA and HPA genes.
Aim: to compare results of molecular (HPA-marks) and cytoge-
netic researches in patients undergoing HLA-identical related
BMT.
Material: 54 DNA samples of 15 hematological patients and
15 siblings DNA samples.
Methods: PCR-ASP on HPA-1-6w, differentiated G-colorings of
the chromosomes, XY-FISH in 10 sex mismatched pairs, S-FISH
with probes for ABL and BCR genes in CML patients.
Results: the distinctions of HPA-genes have allowed watching
the occurrence of donor’s and disappearance of recipient’s mar-
kers after BMT, and cytogenetic methods — occurrence of cells
with donor’s karyotype after sex mismatched BMT and disappe-
arance of bcr/abl positive cells. All researches carried out by pro-
tocol after BMT. In 38 cases we found complete donor chime-
rism by HPA and the presents of cells with donor’s karyotype
after sex mismatched BMT and absence of bcr/abl positive cells,
in 10 cases the mixed chimerism by HPA and about 3% of reci-
pient’s cells by X/Y-FISH method, that corresponded to cytoge-
netic remission, in 6 cases — the presents of recipients sex cells
till 46% and bcr/abl positive cells till 60%, and relapse of disease
was established. By molecular method the appearance of reci-
pients HPA-markers was established after their absence in the-
se six patients.
Conclusions: the evaluation of chimerism after BMT by HPA-
-genes allows diagnosing molecular remission or the relapse con-
terminous to criteria of identification of these conditions on cy-
togenetic markers.
Immune thrombocytopenic purpura
P12 Platelet autoantibodies against GPV
in patients with ITP
Stoy J., Bein G., Santoso S., Sachs U.J.
Justus Liebig University Giessen, Giessen, Germany
Background: Increased platelet destruction by the reticulo-
endothelial system following platelet sensitization by antiplate-
let autoantibodies is a major pathomechanism in ITP. Sensitivi-
ty of platelet autoantibody tests, however, is low, and the question
has been raised whether glycoproteins (GP) IIb/IIIa and Ib/IX are
the only relevant target proteins.
Objectives: To evaluate immunization rates against GPV.
Patients/methods: 273/704 patients with a suspected diagno-
sis of ITP matched the international consensus criteria for the
diagnosis of ITP and were evaluated for the presence of plate-
let-bound autoantibodies against GPIIb/IIIa, GPIb/IX, and GPV
by a direct glycoprotein specific assay. 351 patients who did not
match the criteria were also assessed.
Results: 92 patients (36%) tested positive; 41 had antibodies
against a single GP, and 51 against more than one GP. Detected
specificities were: anti-GPIIb/IIIa = 71, anti-GPIb/IX = 56 and
anti-GPV = 44. Anti-GPV was the only autoantibody detected in
5 patients. Due to limited material, antibodies against GPV co-
uld not be analyzed in 17/54 patients. Analysis of the patients’
clinical data did not reveal any significant differences between
the different antibody-positive groups. Out of 351 non-ITP pa-
tients, 5 tested positive (1.4%). Test characteristics calculated
from these results are: sensitivity, 33.8% (including GPV, 35.8),
specificity, 98.6% (98.6), PPV 94.6% (94.9), and NPV 67% (67.7).
Conclusion: Immunization against GPV is a frequent phenome-
non in ITP. Most of the patients with antibodies against GPV are
also immunized against GPIIb/IIIa and GPIb/IX. However, 2% of
ITP patients are immunized against GPV only; these patients may
benefit from extended testing.
P13 A retrospective data analysis using
the PakAuto assay for the detection
of platelet autoantibodies in AITP
Matteocci A., Collaretti A., Castagna K., Spaccino C.,
Damiani L., Tudini M., Pierelli L.
Transfusion Medicine Service — s. Camillo Hospital, Rome, Italy
Background: The detection of platelet autoantibodies has a hi-
ghly positive diagnostic value for primary immune thrombocy-
topenia (AITP). The antibodies recognize platelet glycoproteins
(GPs), especially IIb/IIIa, Ib/IX and Ia/IIa. We have reviewed the
tests which were carried out in the last two years.
Methods: We analyzed all the sera and platelet eluates from 254
patients with suspected AITP, 112 male/142 female with mean
age 51 yrs. We used the PakAuto (GTI, Brookfield, WI USA)
which is a qualitative solid phase ELISA for the detection of the
platelet bound and serum/plasma autoantibodies reactive against
GPs IIb/IIIa, Ib/IX or Ia/IIa.
Results: Of all the 254 patients 165 (65%) were positive for pla-
telet bound autoantibodies. The glycoprotein specificities were:
N.120 (73%) anti-GPs IIb/IIIa, Ib/IX, Ia/IIa, N.13 (8%) anti-GPs
IIb/IIIa, N.32/ (19%) anti-GPs IIb/IIIa, Ib/IX, anti-GPs IIb/IIIa, Ia/
/IIa, anti-GP Ia/IIa and anti-GP Ib/IX. Fifty-five (33%) of the pa-
tients were also positive for sera autoantibodies. The platelet
counts were: the mean was 95 × 109/L, the median 85 × 109/L in
anti-GPs IIb/IIIa, Ib/IX, Ia/IIa; the mean was 70 × 109/L, the me-
dian 75 × 109/L in anti-GPs IIb/IIIa, Ia/IIa; the mean and the me-
dian were 18 × 109/L in anti-GP Ib/IX.
Conclusions: The GP IIb/IIIa was implicated in 161 (37%) ca-
ses, the GP Ib/IX in 127 (30%) and the GP Ia/IIa in 142 (33%).
We also noted that the patients with antibodies against only GP
Ib/IX or multiple GPs (GPs IIb/IIIa, Ib/IX, Ia/IIa; GPs IIb/IIIa, Ia/
/IIa) had lower platelet counts, more severe bleeding symptoms
and a poorer response to steroids.
Key words: autoimmune thrombocytopenia, platelet glycopro-
teins, PakAuto assay
P14 Platelet autoantibodies in patients
with chronic liver disease
Stissing T., Rasmussen A., Taaning E.
Rigshospitalet, Copenhagen, Denmark
Background: Patients with chronic liver disease (CLD) often
present with thrombocytopenia i.e. platelet concentration < 150 ×
× 109/L. Studies have shown a high prevalence of platelet auto-
antibody anti-GPIIb-IIIa and anti-GPIb-IX in these patients. It re-
mains controversial whether these platelet autoantibodies are se-
condary to an autoimmune-induced liver disease and nonfunc-
tional or contribute to the development of thrombocytopenia. The
present retrospective study examined the prevalence and type
of platelet autoantibodies in patients with CLD. Furthermore, the
associations between platelet autoantibodies and autoimmune-
induced liver disease and thrombocytopenia were analyzed.
Methods: From 2009–2011, patients with CLD who were ana-
lyzed for the prevalence of platelet autoantibody with ELISA (Pak
Plus, GTI diagnostics, WI, USA) was included. The etiologies of
the CLD and the platelet counts were collected from the elec-
tronic patient record system. Data were analyzed with Fisher’s
exact test. P values < 0.05 were statistically significant.
Results: Platelet antibodies were detected in 33 (40%) of 82
screened patients. Most frequent were anti-GPIa-IIa (33%), anti-
GPIIb-IIIa (29%) and anti-GPIV (18%) whereas anti-GPIb-IX only
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was found in 7 patients (9%). Platelet autoantibodies were not
more frequent in patients with autoimmune-induced CLD (auto-
immune hepatitis, primary biliary cirrhosis and primary sclero-
sing cholangitis) (p = 0.8). There was not any significant asso-
ciation between the presence of platelet autoantibodies and
thrombocytopenia (p = 0.35).
Conclusions: Platelet autoantibodies are often seen in patients
with CLD of diverse origin. The effect of these platelet autoanti-
bodies on the development of thrombocytopenia needs further
investigations.
P15 Chronic peadiatric ITP patients with
a strong bleeding tendency and low platelet
counts show decreased aggregation capacity
via the GPIIbIIIa activation route
Laarhoven A.1, 2, Heitink K.2, Bruin M.2, Porcelijn L.1,
de Haas M.1, Vidarsson G.1, van der Schoot C.E.1
1Department of Experimental Immunohaematology, Sanquin
Research Amsterdam and Landsteiner Laboratory, Academic
Medical Center, University of Amsterdam, Amsterdam, the
Netherlands, 2Center for Molecular and Cellular Intervention
(CMCI),Department of Paediatric Immunology, Wilhelmina
Children’s Hospital, University Medical Center Utrecht (UMCU),
Utrecht, the Netherlands
Background: Chronic immune thrombocytopenia (ITP) in chil-
dren is characterized by an isolated thrombocytopenia
(< 100.000/ul) for over a year. ~70% of patients have autoanti-
bodies against platelets, mainly directed against GPIIbIIIa, the
fibrinogen binding site. These patients express a wide range in
bleeding tendency that doesn’t directly correlate with platelet
count. One explanation could be that autoantibodies might inter-
fere with platelet function rather than causing platelet destruc-
tion, as described for acquired Glanzmann patients. If true, then
it may be used to select optimal treatment regimens, and pre-
vent invasive treatments proving futile, such as splenectomy.
Methods: 20 chronic ITP patients and 20 healthy controls (HCs)
were included. Patients’ platelets, and HC as control, were isola-
ted and stained with PKH and mixed with HC platelets stained
with CFSE. Platelet mixes were stimulated with PMA (activates
GPIIbIIIa), Ristocitine (activates GPIbIX) or no stimulator, to di-
stinguish between GPIIbIIIa and GPIbIX activation pathways. Sam-
ples were taken at different timepoints after stimulation and fixed
in 0.5% (w/v) PFA. Aggregation was assessed by FACS analysis.
Results: Patients with a high bleeding tendency scored 1/3 lo-
wer when stimulated with PMA, compared to HCs and patients
with a low bleeding tendency. A control with Glanzmann patients
showed a decrease in aggregation of > 70% upon PMA stimula-
tion, compared to HCs.
Conclusion: Patients with a high bleeding tendency show a de-
crease in aggregation in the GPIIbIIa pathway, suggesting dys-
function of platelets next to a low platelet count. No functional
defects were observed in patients with a low bleeding tendency.
P16 Health related quality of life
in children with acute immune
thrombocytopenia and their parents
Heitink-Polle K.M.J., Shep S.J., Haverman L.,
de Haas M., Bruin M.
UMC Utrecht/Wilhelmina Children’s Hospital, Utrecht, the Netherlands
Background: Children with acute immune thrombocytopenia
(ITP) are restricted in their activities by doctors and parents due
to the fear of severe bleeding during thrombocytopenia. We hy-
pothesized that these restrictions and fear of bleeding have an
important impact on health related quality of life (HRQoL) of both
children and parents. However, HRQoL studies in childhood ITP
are scarce. Therefore, as part of the TIKI study (Therapy with
or without Intravenous Immunoglobulin for Kids with acute ITP,
a Dutch multicenter randomized trial) HRQoL was measured.
Methods: Children aged 3 months-16 years with newly diagno-
sed acute ITP were included in the TIKI study. HRQoL was eva-
luated at diagnosis, after 1 week, 1 month, 3 months, 6 months
and 12 months. All parents and children ≥ 7 years completed the
generic Pediatric Quality of Life Inventory (PedsQL) questionna-
ires and the Kids’ ITP Tools (KIT). Additionally, parents comple-
ted the KIT for parents regarding their own HRQoL. The KIT is
a validated ITP specific questionnaire recently developed in Ca-
nada by Klaassen and colleagues. We compared HRQoL scores of
1) children diagnosed with acute ITP versus healthy children, 2)
children with persisting thrombocytopenia beyond 6 months and
children with other chronic conditions, 3) parents and children that
received intravenous immunoglobulin versus parents and children
randomized to the observational arm and 4) parents and children
that recovered within 6 months versus parents and children with
persisting thrombocytopenia beyond 6 months.
Results: We will present the results of the first 60 patients inc-
luded in the study.
Key words: idiopathic thrombocytopenic purpura, quality of life,
intravenous immunoglobulins
P17 Primary immune thrombocytopenia
in pregnancy
Kopeć I.1, Teliga-Czajkowska J.2, Uhrynowska M.1,
Zwoliński J.3, Guz K.1, Maślanka K.1,
Brojer E.1, Warzocha K.1
1Institute of Haematology and Transfusion Medicine, Warsaw,
Poland, 2Second Department of Obstetrics and Gynecology, Warsaw
Medical University, Warsaw, Poland, 3Obstetrics and Maternity
The Holy Family Hospital, Warsaw, Poland
Objective: A retrospective analysis of 121 pregnancies of 105
patients with primary immune thrombocytopenia (ITP), who
delivered 123 children (2 twins).
Results: Median age at delivery — 28 years. 85 (69%) cases were
diagnosed prior to pregnancy and 37 (31%) during pregnancy.
Platelet count of < 50 × 109/l was observed in 74 (61%) pregnan-
cies. Antiplatelet antibodies were detected in 25 cases, in 7 ca-
ses they were anti-HPA5b alloantibodies. In 60 pregnancies
(50%) women required treatment to increase platelet count (cor-
tycosteroids in 38, intravenous immunoglobulin (IgG IV) in 3 and
cortycosteroids with IgG IV in 19 cases). Median gestational age
at delivery was 38 weeks. The mean platelet count at delivery
prednisone
— Type of delivery — obstetrical indication
— IgG IV  administration before delivery — may be proposed for  women
who are at   risk of delivering thrombocytopenia babies  (eg. first baby
with trombocytopenia < 50 × 10 /l; splenectomy before pregnancy)
— Cesarean section — coexistent of alloimmune fetal/newborn
thrombocytopenia;  fetal thrombocytopenia < 50 × 10 /L confirmed
by cordocentesis, earlier delivery of child with thrombocytopenia
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Therapeutic considerations for pregnant patients with ITP
Figure 1. Therapeutic considerations for pregnant patients
with ITP (P17)
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was 81 × 109/l (range 10 — 335 × 109/l ), in 31 women — < 50 ×
× 109/l. 82 (68%) deliveries were vaginal and 39 (22%) by cesa-
rean section (for obstetrical indication). Platelet transfusion was
administered to 22 women with platelet count < 50 × 109/l. At
delivery 68 women were treated with corticosteroid and/or IgG
IV. No woman had major hemorrhagic complication.
Platelet counts measured at the time of birth were available for
118 babies. The median birth platelet count 170 × 109/l (range
23 — 403 × 109/l). Neonatal thrombocytopenia with platelet co-
unt < 100 × 109/l occurred in 38 (32%) neonates, 15 infants had
platelet count < 50 × 109/l. 22 newborns were treated for throm-
bocytopenia — 3 were treated with corticosteroids, 18 with in-
travenous immunoglobulin, 2 received platelet transfusion. The
platelet counts for infants who received treatment ranged from
23 — 77 × 109/l. No bleeding complications occurred in any of
the neonates. The mean thrombocytopenia duration time was
20 days. Two fetal deaths occurred; one fetus was stillborn at
38 weeks (the mother diagnosed with thrombophilia), the other
death was caused by rubella infection (myocarditis).
Conclusion: No serious bleeding event was observed in either
the mothers or infants. No correlation was noted between mo-
thers’ platelet count, antiplatelet autoantibodies in maternal sera
and neonatal platelet count.
Neonatal alloimmune
thrombocytopenia
P18 Two cases of human platelet antigen
21b-associated neonatal alloimmune
thrombocytopenia in Japan: establishment
of a cell line panel for detecting antibodies
against the human platelet antigen 21b
Hayashi T., Koh Y.
Japanese Red Cross Osaka Blood Center, Osaka, Japan
Background: Neonatal alloimmune thrombocytopenia (NAIT)
is a neonatal disorder characterized by maternal alloimmuniza-
tion against foetal platelet (PLT) antigens inherited from the fa-
ther. Two healthy Japanese women gave birth to neonates with
petechiae; the PLT count of these neonates was 9 × 103/µL and
10 × 103/µL. We suspected anti-PLT antibody involvement and
subsequently aimed to detect and identify these antibodies to
elucidate the maternal cause of NAIT in these infants.
Methods: Exon-specific PCR was performed for the genomic
DNA of both fathers and products were sequenced. ITGA2B and
ITGB3, including the human platelet antigen (HPA) 21b, were
co-transduced to K562 cells using retroviral vectors. The clo-
ned cell was termed as the HP-21b cell and cultured. A modified
and rapid monoclonal antibody-specific immobilization of plate-
let antigen test was performed using the mothers’ serum and the
fathers’ PLTs or HP-21b cells. A retrospective study using the-
se HP-21b cells was performed for the determination of antibo-
dy specificity in NAIT cases with unidentified causes.
Result and conclusions: Sequencing analysis revealed that the
fathers’ genomic DNA encoded HPA-21b antigens. The mother’s
serum clearly reacted with the father’s PLTs and HP-21b panel
cells in both cases. On the other hand, the serum of both mo-
thers did not react with any of the known HPA antigens. We iden-
tified an HPA-21b antibody using HP-21b cells in the retrospec-
tive study; this indicates that the HP-21b cell line panel may re-
tain the potential to detect and identify HPA-21b antibodies.
Although the HPA-21b antibody was first identified in the USA,
these results suggest that the HPA-21b antigen plays an impor-
tant role in the pathogenesis of NAIT in Japan as well.
P19 Neonatal alloimmune thrombocytopenia
and neutropenia in two consecutive twin
pregnancies
Kølbæk M.D.1, Nielsen K.R.2, Nielsen B.W.1
1Department of Pediatrics, Regional Hospital Herning, 2Department
of Clinical Immunology, Arhus University Hospital, Aalborg,
Denmark
Background: The rare occurrence of both neonatal alloimmu-
ne thrombocytopenia (NAIT) and subsequent neonatal neutro-
penia in both twins in two consecutive twin pregnancies is pre-
sented and discussed.
Methods: Case report — premature twins were born by a healthy
mother in 2004. Twin A had hydrocephalus due to a severe prena-
tal intracranial hemorrhage, and died within a few days. Platelet
count was 10 × 109 m/L. Twin B appeared well with platelet count of
70 × 109 m/L. During the second twin pregnancy in 2010, the mother
received steroids and IVIG due to increasing HPA-1a titers. The
twins both showed thrombocytopenia on day one (counts of 8 × 109 m/L
and 11 × 109 m/L, respectively), both received platelet transfusions
and recovered without serious hemorrhage. At day 10 both twins
had normal platelet counts, but subnormal neutrophil counts. Neutro-
phil nadir was at 2–3 months of age (lowest counts of 0.63 × 109 m/L
and 0.56 × 109 m/L respectively) with concomitant thrombocytosis
(628 × 109 m/L and 711 × 109 m/L, respectively). At 4–5 months of
age, the neutrophil count was > 1.5 × 109 m/L in both twins, altho-
ugh thrombocytosis persisted until 7 months of age.
Results: Maternal serum contained a high titer anti-HPA-1a
antibody and mater was typed HPA-1 (a-b+). Neither neutrophil
specific nor anti-HLA antibodies in the maternal serum could be
demonstrated two months post partum, parental granulocyte
cross-match analysis is ongoing.
Conclusion: NAIT with high titers of antibody to HPA-1a is well
documented in these siblings, with fatal outcome in one child.
Although NAIT resolved within two weeks in the second twin
pair, neutropenia and thrombocytosis persisted for months, as is
regularly seen in neonatal alloimmune neutropenia. The combi-
ned occurrence of thrombo- and granulocytopenia in neonates is
rarely seen and the very different time-course of the two condi-
tions merit further study.
P20 Alloimmune thrombocytopenia due
to anti HPA-1a in a mother also immunized
with anti-HPA-5b
Malcata C.1, Virella D.2, Duran J.A.3
1Centro Regional de Sangue de Lisboa/IPS, Portugal, 2Serviço de
Neonatologia — Hospital Dona Estefânia, Portugal, 3Centro
Regional de Sangue do Porto/IPS, Portugal
Background: Fetal/Neonatal Alloimmune Thrombocytopenia
(FNAIT) is caused by the presence of maternal antibodies aga-
inst antigens in fetal platelets which were inherited from the fa-
ther, inducing the immune destruction of fetal platelets. The most
frequently platelet antigen involved in FNAIT is HPA-1a, follo-
wed by HPA-5b, although in rare cases other antigens like HPA-
-3a and HPA-1b may also be found. We present a case of FNAIT
caused by anti HPA-1a in a newborn with petechiae, subconjunc-
tival hemorrhage and platelet count of 20.000/µl. This was the
third child of this mother but the first of this father.
Methods: Antiplatelet antibodies were studied by the ELISA
technique (PAKPLUS® and PAKAUTO®, GTI, USA). Platelet
crossmatch and platelet antibody screening of the child were
performed by solid phase technique (MASPAT®, Sanquin, The
Netherlands). Genotyping was performed by real time PCR.
Results: In the serum and plasma of the mother there were an-
tibodies against the glycoprotein IIb/IIIa and the glycoprotein Ia/
/IIa. The platelet crossmatch between platelets from the father
and serum and plasma from the mother was positive. The anti-
bodies in platelets child were positive, and in the serum of the
77www.jtm.viamedica.pl
Abstracts of the XII European Symposium on Platelet and Granulocyte Immunobiology
child antibodies against the glycoprotein Ia/IIa were found, with
specificity HPA-5b. Genotyping showed: Mother: HPA 1bb, 5aa;
Father: HPA 1aa, 5aa; Child: HPA 1ab, 5aa, consistent with the
existence of anti HPA-1a mediated FNAIT.
Conclusions: FNAIT was caused by anti HPA-1a, although the
mother had anti HPA-5b from previous pregnancies.
Key words: Fetal/Neonatal Alloimmune Thrombocytopenia,
Antiplatelet antibodies, HPA-1a
P21 Alloimmune thrombocytopenia due
to anti HPA-5a in a gipsy girl
Malcata C.1, Rodrigues C.1, Moser I.1, Gonçalves L.2
1Centro Regional de Sangue de Lisboa/IPS, Portugal, 2Serviço
de Neonatologia — Hospital de Faro, Portugal
Background: Fetal/Neonatal alloimmune thrombocytopenia
(FNAIT) is caused by maternal alloantibodies against fetal pla-
telet antigens inherited from the father. In the setting of an anti-
gen-negative mother, transplacental passage of maternal immu-
noglobulin G (IgG) antibodies results in the accelerated destruc-
tion of fetal platelets expressing the corresponding antigen. The
platelet antigen most frequently involved in FNAIT is HPA-1a.
FNAIT caused by anti HPA-5a is rare. We present a case of FNAIT
caused by anti HPA-5a in a newborn gipsy girl with platelet
count of 20.000/µl. This was the seventh child of this mother.
Methods: Antiplatelet antibodies were studied by the ELISA
technique (PAKPLUS® and PAKAUTO®, GTI, USA). Platelet
crossmatch and platelet antibody screening of the child were
performed by solid phase technique (MASPAT®, Sanquin, The
Netherlands). Genotyping was performed with HPA-SSP kit
(Inno Train®, Germany).
Results: In the serum and plasma of the mother there were an-
tibodies against the glycoprotein Ia/IIa with HPA-5a specificity.
Platelet crossmatch between platelets from the father and se-
rum and plasma from the mother was positive. The antibodies in
platelets child were positive. Genotyping showed: Mother: HPA
1aa, 2aa, 3bb, 4aa, 5bb, 15aa; Father: HPA 1aa, 2aa, 3ab, 4aa,
5aa, 15ab; Child: HPA 1aa, 2aa, 3ab, 4aa, 5ab, 15ab consistent
with the existence of anti HPA-5a mediated FNAIT.
Conclusions: FNAIT related to HPA-5a is rare with only a few
cases reported. The frequency of HPA antigens in the gipsy po-
pulation is unknown, and it would be interesting to know more
of their genetic background.
Key words: FNAIT, Antiplatelet antibodies, HPA-5a
P22 Immunohematological investigations
for neonatal alloimmune thrombocytopenia:
accurate diagnosis for a good clinical
management
Revelli N.R., Villa M.A., Fantini N.N., Portella G.,
Manazza A., Cormaci G.R., Marconi M.
IRL — Centro Trasfusionale e di Immunohematologia, Milano, Italy
Background: The diagnosis of Neonatal-Alloimmune-Thrombo-
cytopenia (NAIT) requires laboratory demonstration of parental
platelet antigen incompatibility and the detection of maternal
antibodies directed to discordant paternal alloantigen.
Methods: We use a solid-phase technique to detect antibodies
bound to platelets or in the serum and to type the HPA-1a anti-
gen (Capture-P or Capture P Ready Screen, Immucor, Norcross,
GA, USA) by NeoGalileo (Immucor). Platelet crossmatch is per-
formed with same technology. To distinguish HLA from platelet
antibodies, we use ELISA by PAKPLUSR/PAK1 (GTI Diagno-
stics, Waukesha, WI, USA). The genotype is performed by PCR-
SSP (ThrombotypeR, GTI Diagnostics) or by microarray (HPA
BeadChipTM, Immucor). The study analyzes data from 39 conse-
cutive suspected NAIT cases during 2008–2011.
Results: Antibodies were detected in 20 of the 39 patients:
8 HPA-1a, 2 HPA-5b, 4 HPA-1a+HLA, 4 HLA, 1 GPIa/IIa and
1 GPIIb/IIIa. Ten patients were follow-up in our hospital: all had
previous pregnancies with suspect NAIT. Of these, 5 had anti-
bodies: 4 HPA-1a and 1 HPA-5b+HLA. Only the women with
HPA-1a antibodies were treated with IVIg. Three neonates were
born at 38-39 weeks, one neonate at 34 weeks for maternal in-
trahepatic cholestasis. No newborns show hemorrhagic diathe-
sis and required platelet transfusions.
Conclusions: Our data illustrate the need to use multiple labo-
ratory techniques to identify the antibodies, the IVIg-therapy and
the follow-up during pregnancy.
Key words: immunoglobulins, neonatal alloimmune thrombo-
cytopenia, pregnancy
P23 Comparison of various noninvasive
HPA-1a fetal genotyping methods
— preliminary results
Guz K., Orzińska A., Krzemienowska M.,
Baran P., Dębska M., Kopeć I., Maślanka K.,
Uhrynowska M., Brojer E.
The Institute of Hematology and Transfusion Medicine, Warsaw,
Poland
Background: Noninvasive HPA-1a genotyping of fetal DNA is
an important method of risk prediction for fetal and neonatal
thrombocytopenia (FNAIT) in HPA-1a-alloimmunised pregnan-
cies. Up to date false positive results were observed due to non-
specific amplification from maternal HPA-1b. These difficulties
have been recently overcome by introducing HPA-1a-specific
primer with a mismatch (Nogues et al, 2010) or by pre-PCR di-
gestion of HPA-1b (Scheffer et al, 2011). In our study we asses-
sed the accuracy of such methods of HPA-1a fetal genotyping
while introducing our own modifications.
Methods: Plasma DNA was isolated from 22 HPA-1b/b pregnant
women (19–37 week of gestation) by EasyMag extractor (Bio-
merieux) and used for HPA-1a fetal genotyping by RQ-PCRs with
Nogues’s MBG probe: Method 1 (Nogues’s primers); Method
2 (Msp1 digestion, Nogues’s primers) and Method 3 (Msp1 dige-
stion, Scheffer’s primers). Appropriate control RQ-PCRs: CCR5
and SRY (undigested DNA) and control DNAs (HPA-1b/b, HPA-
-1a/b) digested by Msp1 were performed.
Results: In 14 HPA positive child cases all three methods were
found to have properly genotyped the fetal status. Msp1 digestion
did not reduce the sensitivity of HPA-1a detection by RQ-PCR
(mean Ct: 34.4 v. 34.1; Method 2 v. 1). In 8 HPA-1a negative child
cases the results obtained by Method 2 and 3 confirmed the HPA-
-1a negative result, while Method 1 gave false positive results
in 3/8 cases. The presence of fetal DNA was confirmed by SRY
detection in 5/8 HPA-1a negative cases; in the remaining cases
total DNA was estimated by CCR5 level.
Conclusions: Digestion of maternal HPA-1b allele by Msp1 is
an effective method of improving the specificity of noninvasive
HPA-1a assays. It does not effect the sensitivity of HPA-1a de-
tection.
Key words: noninvasive HPA-1a genotyping, FNAIT
P24 Fetal blood sampling by cordocentesis
in FNAIT — risk analysis and prevention
by intrauterine platelet transfusion
Dębska M.1, Kretowicz P.1, Uhrynowska M.2,
Antoniewicz-Papis J.2, Guz K.2, Maślanka K.2,
Brojer E.2, Dębski R.1
1II Department of Obstetrics and Gynecology, The Centre of Medical
Postgraduate Education, Bielanski Hospital, 2The Institute of
Hematology and Transfusion Medicine, Warsaw, Poland
Background: Fetal blood sampling (FBS) by cordocentesis is the
only method of estimating the fetal platelet count and fetus ge-
notype to confirm the alloimmune thrombocytopenia (AITP) dia-
gnosis as well as to monitor therapy. There is however some
concern for the safety of this invasive procedure as literature re-
ports cases of higher bleeding risk related to umbilical vein punc-
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ture in thrombocytopenia fetuses. We decided to present our own
experience in cordocentesis FBS in AITP patients.
Material and methods: In 1999–2012 we performed 86 diagno-
stic FBS in 48 patients with suspected AITP: 75 — due to anti-
HPa-1a, 1 — anti-HPa-5b, 1 — anti-HLA, 1 — anti-HPA-3b,
1 — anti-HLA and anti-HPA-5b, 1 — anti-HLA and HPA-1 in-
compatibility and 6 patients with no antibodies but HPA-1 incom-
patibility (mother HPA-1bb, father HPA-1aa). Usualy we perfor-
med 2 punctures per pregnancy; at 26 and 33 week mean gesta-
tional age. The mean platelet count in fetuses with platelet
transfusion at first and second cordocentesis was 46 G/L, and
72 G/L respectively. In 6 FBS cases (1999–2001 ) there was no
platelet transfusion. In 75 cases we transfused platelet concen-
trates (PCs) from mother platelet rich plasma collected by ma-
nual plasmapheresis and in 5 cases from HPA compatible alloge-
nic donors (apheresis). The mean PC volume: 18–20 ml; platelet
count: 0,3–0,4 × 1011 .
Results: In 2/6 severe fetal thrombocytopenia cases (PLT < 10 G/L)
of cordocentesis but no platelet transfusion, fetal death occur-
red due to prolonged bleeding from umbilical vein. No fetal de-
aths were reported for 80 FBS followed by intrauterine platelet
transfusions. We observed only 4 cases (5%) of prolonged fetal
bradycardia which occurred in 2/5 fetuses transfused with con-
centrates from allogenic donor and in 2/75 transfused with con-
centrates from their own mothers. In 2/4 cases of prolonged
fetal bradycardia we decided on immediate pre-term cesarean
section; in 1 case following maternal PCs transfusion (1/75) and
in 1 after transfusion of PCs from allogenic donor (1/6).
AITP diagnosis was confirmed by platelet genotyping when the
father was heterozygous regarding HPA antigens.
All mothers with antiplatelet antibodies and confirmed fetal
thrombocytopenia were treated with IVIG and/or steroids. The
mean gestational age at birth was 38 weeks and the mean plate-
let count at delivery — 173 G/L. There was one neonate with
small ICH, but the development of all babies was normal.
Summary and conclusions:
1. There is a higher risk of fetal death from exsanguinations fol-
lowing FBS in AITP fetuses. AITP screening of pregnant
women is not a universal recommendation but it should be
considered when intrauterine invasive procedures are indi-
cated.
2. Intrauterine platelet transfusion following FBC is safe and
effective for preventing bleeding complications. Fetal brady-
cardia after PC transfusion was the only adverse reaction
observed and this is typical after FBS and IUT.
3. Fetal bradycardia occurred more frequently when PCs of al-
logenic donors were transfused.
Diagnosis and etiology of TRALI
P25 TRALI — priming of neutrophils
increases reactivity with antibodies
against the HNA-3a
Muschter S., Berthold T., Schubert N., Wesche J., Fürll B.,
Bagemühl J., Teumer A., Reil A., Bux J., Greinacher A.
Universitätsmedizin Greifswald/Abteilung für Immunologie und
Transfusionsemedizin, Greifswald, Germany
Aim: Patients with comorbidities (e.g. sepsis) have an increased
susceptibility to transfusion-related acute lung injury (TRALI) cau-
sed by antibodies against human neutrophil alloantigens (HNAs).
We investigated primed and naive neutrophils using the granulocy-
te aggregation test (GAT) with increasingly diluted anti-HNA-3a-
-plasmas and by measurement of the activation marker CD11b.
Methods: Isolated neutrophils (healthy donors, HNA-3a/a) were
preincubated with various concentrations of either lipopolysac-
charide (LPS) or N-formyl-methionyl-leucyl-phenylalanine
(fMLP) or buffer (control). Aggregation capability of primed and
naive cells was determined in the GAT with two serially diluted
anti-HNA-3a plasmas. Neutrophil activation was evaluated com-
paratively by measurement of CD11b surface-exposition using
flow cytometry.
Results: Primed neutrophils aggregated at 1-2-fold higher HNA-
-3a-plasma dilutions (max. 1: 512) in the GAT, compared to naive
cells. CD11b exposition increased with activator concentration
and HNA-3a-ab-treatment resulted in a further increase. Howe-
ver, the influence of HNA-3a-abs on CD11b exposition of primed
neutrophils was not different from that on control cells. Concen-
trations of fMLP and LPS enhancing the aggregation capability
differed between donors.
Conclusion: Primed neutrophils aggregate with less HNA-3a-
-abs, supporting the two hit hypothesis of TRALI induction. The
transfusion of a red blood cell concentrate (~10 mL plasma) into
a recipient (5 L blood) corresponds to a 1: 512 dilution and may
induce TRALI, if the patient is sensitized. There was no supra-
additive effect of HNA-3a-ab-treatment on neutrophil activation
marker CD11b on primed neutrophils. However, it seems that
a distinct activation level must be exceeded to increase aggre-
gation ability. In vivo, this activation threshold is probably exce-
eded by several and combined minor priming factors.
Key words: neutrophil granulocytes, two hit hypothesis, TRALI,
HNA-3a, priming, CD11b, granulocyte agglutination test, flow
cytometry
P26 Detection of antibodies against human
neutrophil antigens among cases of
transfusion-related acute lung injury:
screening test in Japanese Red Cross
Society, from 1998 to 2011
Hashimoto S., Kamada H., Nakajima F., Watanabe Y.,
Okazaki H., Satake M., Tadokoro K.
Japanese Red Cross, Tokyo, Japan
Background: Leukocyte antibodies in blood products are one
of the causes of transfusion-related acute lung injury (TRALI).
In Japan, antibody detection tests for human neutrophil antigens
(HNA) have been performed to determine the cause of dyspnea
since 1998. In the present study, we demonstrate comprehensi-
ve results of the examination.
Methods: Blood samples from recipients with non-hemolytic
transfusion reactions (NHTR) cases (TRALI, 316 cases; other
NHTR, 385 cases) and donors associated with NHTR cases
(TRALI, 338 cases; other NHTR, 390 cases) were tested for HNA
antibodies. Granulocyte immunofluorescence test — flow cyto-
metry (GIFT-FCM) was performed as a screening test. In order
to identify antibody specificities, GIFT-FCM, monoclonal anti-
body-specific immobilization of granulocyte antigens (MAIGA),
immunocomplex capture fluorescence analysis (ICFA), and LAB-
-Screen Multi (OneLambda Inc.) were performed.
Results: HNA antibodies were detected in 8% of the recipients
with TRALI and 9% of those with other NHTR. Among the do-
nors, HNA antibodies were detected in 11% of the cases asso-
ciated with TRALI and 5% of those associated with other NHTR.
In 10 out of 37 donors with TRALI cases, HNA antibody specifi-
cities were determined (CD16, 3 cases; HNA-1a, 1 case; HNA-
1b, 3 cases; HNA-3a, 3 cases). The detection rate of antibo-
dies in donors associated with TRALI cases was higher than that
in donors associated with other NHTR cases (p < 0.01).
Conclusion: HNA antibodies were detected at a higher rate in
donors associated with TRALI cases compared to other NHTR
cases, although the specificities of HNA antibodies weren’t de-
termined in many cases.
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P27 Incidence of leukocyte reacting antibodies
in patients with dyspnea-associated non-
-hemolytic transfusion reactions and in the
transfused blood components
Maślanka K., Uhrynowska M., Łopacz P., Guz K.,
Sak-Budzisz J., Wróbel A., Ostas A., Żupańska B., Brojer E.
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Background: Leukocyte antibodies involved in pathogenesis
of dyspnea-associated non-hemolytic transfusion reactions
(d-NHTRs) are patient or donor origin.
Aim: Analysis of lymphocyte and granulocyte reacting antibo-
dies in 250 patients with d-NHTRs (June 2006–December 2011)
and in 470 blood components transfused to them.
Materials: Patients: 13 with transfusion-related acute lung in-
jury (TRALI), 15 with probable TRALI (p-TRALI), 211 with trans-
fusion reactions and dyspnea (TRD) where the lung tissue was
not the most affected site and 11 with transfusion-associated cir-
culatory overload (TACO). Blood component units: 328 — red
blood cell concentrates (RBCs), 44 — leukoreduced RBCs
(L-RBCs), 25 — platelet concentrates (PCs), 64 — fresh frozen
plasma (FFP), 8 — cryoprecypitates, 1 — granulocyte concentrate.
Methods: Screening assays used for anti-HLA and anti-granulo-
cyte antibodies detection in recipients and donors of blood compo-
nents: LCT (Lymphocytotoxicity Test), ELISA (Enzyme-Linked
Immuosorbent Assay), GAT (Granulocyte Agglutination Test),
GIFT (Granulocyte Immunofluorescence Test) and MAIGA (Mo-
noclonal Antibody specific Immobilization of Granulocyte Antigens).
Results: Leukocyte antibodies in patients and in donors of trans-
fused blood components (Table 1).
Conclusions. Leukocyte reacting antibodies are more often de-
tected in d-NHTRs patients than in donors of the transfused blo-
od components. The percentage of blood components with leu-
kocyte antibodies transfused to TRALI and p-TRALI patients was
statistically higher than that of blood components received by
TRD patients.




P28 HPA-4 incompatibility may cause rejec-
tion reactions in solid organ transplantation
Tsuno N.H., Matsuhahi M., Hasegawa K., Tamura S.,
Kawabata M., Kaneko J., Aoki T., Sugawara Y.,
Kokudo N., Takahashi K.
University of Tokio, Japan
Background: Human platelet antigen (HPA) systems have been
implicated in neonatal alloimmune thrombocytopenia (NAIT),
post-transfusion purpura (PTP) and platelet transfusion refrac-
toriness (PTR). Recently, HPA incompatibility has been asso-
ciated with poor prognosis in kidney as well as bone marrow
transplantation, suggestive of their role as the minor histocom-
patibility antigens in transplantation.
The patient and the donor: The live-donor liver transplantation
was performed to a 56 year-old women, with diagnosis of primary
biliary cirrhosis, from her oldest son. Both were blood group type B,
but the HPA-4 incompatibility (the mother: HPA-4a/a, the donor:
HPA-4a/b) was observed and anti-HPA-4b detected in the mother’s
serum. The lymphocyte cross-match was negative and anti-HLA
antibodies were not detected. Pre-operatory plasmapheresis redu-
ced the antibody titer, and corticosteroid administration was started.
Clinical course: The operation was successful, but on the POD7,
hepatic enzyme levels and the anti-HPA-4b antibody titers increased.
Liver biopsy was negative for acute cellular rejection, and the pla-
smapheresis significantly decrease the antibody titer, with improve-
ment of hepatic function. Mycophenolate mofetil was started on
POD12, and anti-HPA-4b alloantibody was not detected thereafter.
Discussion: The case was a HPA-4 incompatible child to mother
live-donor liver transplantation, in which the anti-HPA-4b alloanti-
body present in mother’s serum was reactivated by the organ trans-
plantation. In conclusion, anti-HPA-4 alloantibodies may cause re-
jection reactions against transplanted liver, possibly by reacting with
antigenic determinants expressed on endothelial cells of the ves-
sels of the transplanted organ. Therefore, HPA-4 compatibility sho-
uld be carefully checked prior to solid organ transplantation.
Key words: human platelet antigen, liver transplantation, minor
histocompatibility antigen, transplantation rejection
Table 1. Leukocyte antibodies in patients and donors of transfused blood components (P27)
Diagnosis       Antibodies in
(no. of cases)
Patients (n = 250) Donors (n = 439)
Specificity Positive/Total Specificity Positive/Total
no. of patients (%) no. of patients
or donors (%)
TRALI & p-TRALI 10 — anti-HLA 11/28  (39.3%) RBCs: 2 — anti-HLA 6/28  (21.4%)
(28)*  class I or II class I
1 — anti-HNA-1a 1 — anti-granulocyte
non-specific
FFP: 3 — anti-HLA
classes I&II
TRD  (211)* 68 — anti-HLA 70/211 (33.2%)  RBCs: 2 — anti-granulocyte 4/211  (1.9%)
class I or II non-specific
2 — anti-granulocyte L-RBCs: 1 — anti-HLA
non-specific class I&II
FFP: 1 — anti-HLA
classeS I&II
TACO (11) 3 — anti-HLA  class I or II 3/11  (27.3%) 0 0
Total (250) 81 — anti-HLA 84/250 (33.6%)  7 — anti-HLA
2 — anti-granulocyte 3 — anti-granulocyte 10/250 (2.3%)
non-specific non-specific 10/439 (4%)
1 — anti-HNA-1a
*In 1 case antibodies were detected in both the donor and the patient
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P29 Retyping with complementary
methods of Danish individuals previously
found to be HPA-1a negative
Shah B.S.H., Taaning E., Schejbel L.,
Madsen H.O., Larsen R.
Rigshospitalet, Copenhagen, Denmark
Background: Accurate human platelet antigens (HPA)-typing
is important for diagnosing in clinical situations, and screening
of blood donors.
HPA-1a false negative results using PCR-SSP with primers de-
scribed by Skogen et al., 1994 have previously been described in
3/70 (4%) Polish individuals (Guz et al. 2010).
Aim: To compare results of HPA-1 genotyping performed by
PCR- SSP using the Skogen primers and Sanger sequencing, and
to compare HPA-1a phenotyping with genotyping.
Methods and materials: DNA samples from 343 Danes pre-
viously typed as HPA-1a negative were available. They were
divided into 2 groups. One group consisted of 24 blood donors,
32 FNAIT cases and 5 other patients initially genotyped as HPA-
-1bb by SSP-PCR. The other group consisted of 276 blood do-
nors and 6 FNAIT cases initially typed as HPA-1a negative with
a commercial ELISA kit for phenotyping (BioRad, CA, USA).
Results: The 61 individuals initially typed as HPA-1bb by PCR-
-SSP, were retyped as HPA-1bb in all cases by sequencing.
Genotyping by sequencing of 282 phenotyped individuals confir-
med HPA-1bb in 275 of the cases, while 5 individuals were typed
HPA-1aa and 2 individuals were typed HPA-1ab using sequencing.
Conclusions: Compared to the results of HPA-1 genotyping
using sequencing, false HPA-1a negative results were found in
2.5% of the individuals using a commercial phenotyping kit.
The polymorphism causing false negatives in HPA-1a typing
using PCR-SSP with primers from Skogen et al does not seem to
occur frequently in the Danish population. However further stu-
dies based on a larger group of individuals are required.
P30 Activated platelets may dispose for
thromboembolic disease in patients with
inflammatory bowel disease
Eichelberger B.1, Schmid W.2, Papay P.3,
Novacek G.3, Panzer S.1
1Department for Blood Group Serology and Transfusion Medicine,
Medical University Vienna, 2Department of Anaesthesia, Medical
University Vienna, 3Department for Internal Medicine II, Division
of Gastroenterology and Hepatology, Medical University Vienna,
Austria
Background: Platelets activation may explain an increased risk
for thromboembolic disease in patients with inflammatory bowel
disease (IBD).
Methods: We studied by flow cytometry P-selectin expression
and platelet-monocyte aggregates (PMA) in 36 patients with IBD
(f/m 21/15, median age 36 years, range 19–72 years) and in 25
patients with non-active celiac disease (CD, f/m 18/7, median age
35 years, range 20–64 years).
Results: P-selectin expression was not different in IBD patients
from patients with a history of CD (p > 0,05). Further, P-selectin
levels were not different in 8 IBD patients with active disease
compared to P-selectin at their remission. PMA levels, however,
where significantly higher in IBD patients then in CD patients
(p < 0,02). PMA levels were not different in IBD patients with
active disease compared to PMA levels at their remission.
Conclusion: Elevated PMA levels in patients with IBD may in-
dicate their increased risk for thromboembolic disease.
Key words: platelet activation, P-selectin, platelets adhering to
monocytes, inflammatory bowel disease, celiac disease
P31 Streptococcus sanguinis-induced
cytokine release from platelets
McNicol A.1, 2, Agpalza A.1, Jackson E.C.1,
Hamzeh-Cognasse H.3, Garraud O.3, Cognasse F.3
Departments of : 1 Oral Biology and Pharmacology & Therapeutics,
University of Manitoba, Winnipeg, MB, 2The International Centre
for Oral Systemic Health, University of Manitoba, Winnipeg, MB,
Canada, 3Etablissement Français du Sang (EFS) Auvergne-Loire,
Saint-Etienne; GIMAPEA3064, Université de Saint-Etienne —
membre de l’Université de Lyon, Faculté de Médecine,
Saint-Etienne, France
Background:There is increasing evidence that both chronic and
acute infections play a role in the development and progression
of atherothrombotic disorders. One potential mechanism is the
direct activation of platelets by bacteria. The oral micro-organism
S. sanguinis stimulates platelet aggregation in vitro in a strain-
dependent manner, although there are no reports of associated
cytokine production.
Methods: The present study was to determine whether plate-
let activation by S. sanguinis involved the release of pro-inflam-
matory and immune modulating factors (specific ELISA) and
whether activation was enhanced by epinephrine (specific ELISA
and platelet aggregation).
Results: Four strains of S. sanguinis and one of S. gordonii sti-
mulated the release of RANTES, PF4, sCD40L and PDGF-AB,
whereas only one S. sanguinis strain caused the release of
sCD62p. Epinephrine enhanced S. sanguinis-induced platelet
aggregation and phosphorylation of phospholipase Cc2 and Erk,
but inhibited RANTES, PF4, sCD40L and PDGF-AB release.
Wortmannin inhibited S. sanguinis-induced aggregation and re-
lease; however, only aggregation was partially reversed by epi-
nephrine.
Conclusions: The present study demonstrates that platelets
respond to S. sanguinis with both prothrombotic and pro-inflam-
matory/immune-modulating responses. Epinephrine, potential-
ly released in response to infection and/or stress, can significan-
tly enhance the prothrombotic response, thereby providing
a putative link between bacteraemia and acute coronary events
during stress. In contrast, epinephrine inhibited the pro-inflam-
matory/immune-modulating response by an undetermined me-
chanism.
Key words: platelets, bacteria, inflammation, cytokines/chemo-
kines
P32 Platelet participation to inflammation
in HIV-1 infected patients is affected
by HAART
Damien P.1, Cognasse F.1, 2, Lucht F.1, 3, Pozzetto B.1, 4,
Garraud O.1, 2, Hamzeh-Cognasse H.1
1GIMAP-EA3064, Université de Saint-Etienne-membre de
l’Université de Lyon, Faculté de Médecine, Saint-Etienne, France,
2EFS Auvergne-Loire, Saint-Etienne, France, 3Service des
maladies infectieuses, CHU de Saint Etienne, France, 4Service de
microbiologie et hygiène, CHU de Saint Etienne, France
Background: Chronic HIV infection is associated with an im-
mune activation state and inflammation, which contributes to
cardiovascular disease. Platelet-related inflammatory molecules,
which have been somewhat neglected so far, were investigated
in this study.
Methods: HIV+ patients who had been receiving stable HAART
for at least 1 year (n = 41); untreated HIV+ patients (n = 30); and
HIV-blood donors were recruited. Peripheral blood was collected
on sodium citrate to prepare platelet-free and platelet-rich plasma
(PRP) samples. Freshly isolated platelets were then stimulated with
thrombin receptor-activating peptide (TRAP). Levels of IL-27,
sCD62P, RANTES, GRO-a and sCD154 were analyzed in plasma
samples and PRP supernatants by Luminex technology.
Results: We observed, as shown in Table 1, that while plasma
levels of IL-27 were comparable between the 3 groups, there was
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a significant increase in sCD40L, GRO-a, RANTES and sCD62P
in HIV+ compared to HIV– patient plasmas. However, sCD62P
was significantly untreated vs HAART patients, suggesting an
effect of HAART. We also observed that TRAP-stimulated pla-
telets from HAART patients, were able to significantly release
sCD40L, GRO-a, and RANTES in higher amounts than those of
HIV-controls, but this was not the case for sCD62P.
Conclusion: These results suggest that platelets from HIV+ patients
remain able to release inflammatory molecules, and even in higher
amounts than controls, which could maintain HIV-associated inflam-
mation. However, it appears that platelets from HAART are affected
in their ability to release RANTES and sCD62P. Therefore, HIV in-
fection affects platelet physiology and notably increases their ability
to release inflammatory factors and HAART treatment could reduce
their participation to HIV-associated inflammation.
Key words: platelet, inflammation, cytokines/chemokines,
HIV-1, HAART
Granulocyte immunobiology
P33 Expression of the SLC44A2/CTL2
isoforms in peripheral blood cells
Flesch B.K.1, Wesche J.2, 3, Berthold T.3, Hundt M.2, Bux J.1
1German Red Cross Blood Service West, Bad Kreuznach and
Hagen, Germany, 2Innovation Center — Humoral Immune
Responses in Cardiovascular Disorders (ZIK HIKE), Greifswald,
Germany, 3Institute of Immunology and Transfusion Medicine,
University Hospital, Greifswald, Germany
Background: The HNA-3a/-3b epitope is encoded by the choline
transporter like protein 2 (CTL2) gene [1], which exists in two iso-
forms differing by the upstream promotor and coding region. The
resulting shorter glycoprotein TV2 (NM_001145056.1) with 704
amino acids differs from the longer TV1 (NM_020428.3) glycopro-
tein with 706 amino acids in the first N-terminal 10–12 amino acids.
Only TV1 has been demonstrated to enable choline transport across
the cell membrane [2]. The aim of this study was to determine the
CTL2 transcript pattern in human peripheral blood cells.
Methods: RNA was isolated from human whole blood, isolated
neutrophils, mononuclear blood cells and leukocyte-depleted pla-
telets. After reverse transcription, the single-stranded cDNA was
amplified using primer combinations specific for the respective
transcript. Plasmids containing the entire CTL2 coding cDNA of
the TV1 transcript variant (pCTV1L-3a) or the TV2 transcript
(pCTV2k-3a) served as controls. Amplicons were sequenced to
confirm the amplification of the correct transcript variant.
Results: The shorter TV2 transcript was demonstrated in each
RNA sample derived from human peripheral blood tested so far,
whereas the longer TV1 transcript was only detected in the
pCTV1L-3a control plasmid. In a mixture of the plasmids pCTV1L-
-3a and pCTV2k-3a the two isoforms could be detected in parallel.
Conclusion: Up to now in human peripheral blood we only fo-
und the shorter CTL2 transcript which seems to be inefficient
in choline transport. Whether these findings are relevant in the
context of TRALI, remains to be investigated.
References:
1. Greinacher et al. Nat Med 2010; 16: 45.
2. Kommareddi et al. Protein J 2010; 29: 417.
P34 TRALI — neutrophil aggregation
by HNA-3a antibodies occurs in a plasma
free environment
Schubert N., Berthold T., Muschter S., Wesche J.,
Fürll B., Reil A., Bux J., Greinacher A.
Universitätsmedizin Greifswald; Abt. Transfusionsmedizin,
Greifswald, Germany
Background: Antibodies against the human neutrophil alloanti-
gen-3a (HNA-3a) are involved in severe cases of transfusion-re-
lated acute lung injury (TRALI). Currently, the granulocyte ag-
gregation test (GAT) is the method of choice to detect HNA-3a
antibodies. Performance of the GAT in a plasma free environment
leads to a lack of typical anti-HNA-3a induced neutrophil clusters,
suggesting a participation of additional factors necessary for ag-
gregation. Using the GAT we investigated whether HNA-3a-anti-
body-induced neutrophil aggregation is dependent on plasma.
Methods: HNA-3a/a granulocytes were isolated from anticoagu-
lated whole blood by dextran sedimentation and density gradient
centrifugation and resuspended in plasma, phosphat buffered
saline (PBS), or PBS containing 0.5% bovine serum albumin
Table 1. Illustration of P32
HIV negative healthy HIV positive Untreated HIV
blood donors  patients with ART  positive patients
n 40 41 30
Mean age (years; [IQR]) 43 [36–51] 50 [43–57]* 41 [35–50]
Men (n; (%)) 21 (53) 34 (82) 25 (83)
Mean platelet count (G/l; [IQR]) 245 [201–276] 208 [166–245]* 214 [180–253]*
Mean white cell count (G/l; [IQR]) 6.02 [5.12–6.52] 5.82 [4.64–6.85] 5.61 [4.92–6.81]
CD4+ T–cell count (/µl; [IQR]) 678 [575–749] 587 [412–722] 523 [410–630]*
Mean levels of inflammatory cytokines in plasma
Plasma IL–27 (ng/ml; [IQR]) 9.0 [3.4–8.2] 9.7 [5.9–13.2] 10.1 [6.8–13.4]
Plasma RANTES (ng/ml; [IQR]) 19.7 [14.7–23.7] 44.1 [39.8–47.0]* 10.8 [6.8–13.4]*
Plasma GRO–á (ng/ml; [IQR]) 0.7 [0.4–0.8] 1.2 [0.8–1.4]* 1.3 [0.9–1.5]*
Plasma sCD40L (ng/ml; [IQR]) 2.3 [1.5–3.1] 5.4 [2.7–6.1]* 5.6 [2.6–6.9]*
Plasma sCD62P (ng/ml; [IQR]) 28.0 [19.6–29.7] 82.3 [64.0–99.3]* 43.3 [38.3–47.1]*#
HIV-specific data
Mean HIV RNA (copies/ml ; [IQR]) – <50 200970 [3430–31525]*#
< 50 copies/ml ((n; (%)) – 41 (100)* 0 (0)#
On NNRTI ((n; (%)) – 19 (46) –
On protease inhibitor ((n; (%)) – 22 (54) –
*p < 0.05 v. HIV negative healthy blood donors; #p < 0.05 v. HIV positive patients with ART
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(BSA), milk powder, or commercially available blocking reagent.
Alternatively, Terasaki plates were blocked with the same solu-
tions before granulocytes were added. The GAT was performed
as previously described.
Results: Neutrophil aggregation in the GAT failed, when HNA-
-3a/a granulocytes in PBS were incubated with plasma-free IgG-
-fractions of HNA-3a plasma. However, when granulocytes were
resupended in plasma, PBS containing BSA, milk powder, or bloc-
king reagent, or when the Terasaki plate was blocked before in-
cubation, the HNA-3a-IgG-fraction induced aggregation of granu-
locytes in PBS. In none of the experiments neutrophils aggrega-
ted after the incubation with control plasma or control IgG-fraction.
Conclusion: HNA-3a antibody induced neutrophil aggregation is
not dependent on plasma, as it takes place even in an optimized
plasma free environment. For functional experiments with
HNA-3a-antibodies and granulocytes in a plasma free environment
tubes and plates must be blocked to avoid false negative results.
Key words: TRALI, HNA-3a, GAT, PMN, neutrophil granulo-
cytes, blood transfusion
P35 A case of neonatal neutropenia (ANN)
induced by HNA-3a alloantibodies
and HNA-3 allelic frequencies
in the Spanish population
Canals C., Velez R., Tarragó M., Panizo C., Gracia M.,
Vinyets I., Alzina V., Nogués N., Muńiz-Diaz E.
Banc de Sang i Teixits, Barcelona, Spain
Background: HNA-3 antigens have been characterized as a sin-
gle nucleotide change in the CTL2 gene. We have investigated
the allelic frequencies in the Spanish population. HNA-3 antibo-
dies are exceptionally involved in ANN. We have recently stu-
died a case induced by maternal HNA-3a antibodies.
Methods: A male was born at term after a normal pregnancy.
It was the mother’s first pregnancy and she had never received
transfusions. Mild omphalitis developed on the first week of life
and the absolute neutrophil count (ANC) dropped to 280 cells per
µL. He responded adequately to rhG-CSF. At present, he is
5 months old, no additional infections have been observed, and
ANC have ranged from 600 to 900 cells per µL.
Investigation of neutrophil antibodies was performed by immu-
nofluorescence test (IF), granulocyte agglutination test (GAT)
and monoclonal antibody immobilization of granulocyte antigens
(MAIGA) assay. The maternal serum was also tested for HLA
Class I antibodies. HNA-1 and 3-5 were genotyped by PCR-SSP.
Results: No HLA antibodies were detected and IF tests were
negative. The maternal serum induced agglutination of HNA-3a+
granulocytes in the GAT. HNA genotypes: mother 3b3b/newborn
3a3b. There were no other incompatibilities. In a group of 219
blood donors genotyped we found: 57.5% 3a3a, 4.1% 3b3b and
38.4% 3a3b. The frequencies of HNA-3a and 3b alleles were 0.767
and 0.233, respectively.
Conclusions: HNA-3 allelic frequencies in the Spanish popula-
tion are similar to the reported in other populations. Despite
being infrequent, HNA-3 antibodies can be involved in ANN, even
in a 1st pregnancy.
P36 Neonatal neutropenia: investigation
of human neutrophil alloantibodies
in a series of 51 cases
Canals C., Toll T., Guinovart G.I., Zambudio S., Ester A.,
Ramiro L., Julià M.R., Gracia M., Ibanez M., Vinyets I.,
Farsac E., Nogués N., Muniz-Diaz E.
Banc de Sang i Teixits, Barcelona, Spain
Background: Neutropenia in the neonate can be the result of
antibodies transferred to the fetus from the maternal circulation.
Alloimmune neonatal neutropenia (ANN) is associated with si-
gnificant infection-related morbidity.
Methods: From 2005 to 2011, 51 neonatal neutropenia studies
were referred to our laboratory from different hospitals in Spa-
in. Investigation of maternal neutrophil antibodies was perfor-
med by immunofluorescence, granulocyte agglutination and mo-
noclonal antibody immobilization of granulocyte antigen assays.
When possible, cross-match between maternal serum and pater-
nal neutrophils was performed. The maternal serum was also
tested for HLA antibodies (ELISA). HNA-antigens were pheno-
typed or genotyped by PCR-SSP.
Results: Most of the patients were studied soon after birth.
Neutrophil counts (ANC) were 500–1.000/µl in 30% of the ca-
ses, 200–500/µl in 40% and < 200/µl in 30 %. Fever and/or in-
fections were present in 32%. All serological studies were nega-
tive in 23 cases (45%); in 2 mothers IgG autoantibodies were
detected; in 13 (25.5%) only HLA class I antibodies were pre-
sent; and in 13 (25.5%) HNA alloantibodies were found, 5 with
HLA antibodies. The specificities identified were: 5 anti-HNA-
-1a, 4 HNA-1b, 2 HNA-1c, 1 HNA-2a and 1 HNA-3a. The pre-
sence of neutrophil specific antibodies in maternal serum was as-
sociated with significantly lower ANC and higher incidence of fe-
ver and/or infectious events.
Conclusion: HNA specific antibodies were found in 25% of the
cases, being anti-HNA-1a and 1b the most frequent. HLA anti-
bodies might also be implicated in some of the cases. The reco-
gnition of ANN may be of importance for the management of the
patients.
P37 Evaluation of a Luminex based assay
for neutrophil antibody detection
Nielsen K.R.1, Kølbæk M.D.2, Haunstrup T.M.1,
Jensen A.N.1, Baec J.1, Nielsen B.W.2, Steffensen R.1
1Department of Clinical Immunology, Aalborg Hospital, Aarhus
University Hospital, Aalborg, Denmark, 2Department of Paedia-
trics, Herning Hospital, Aarhus University Hospital, Herning,
Denmark
Background: Antibodies with HNA reactivity are linked to se-
veral clinical disorders. The LABScreenMULTI assay (LSMUTR)
(One Lambda, Inc.) allows for rapid detection of HNA-1a, -1b,
-1c and -2 allo-antibodies even in the presence of HLA antibo-
dies. The aim of this study is to compare the LSMUTR assay with
a standard flow cytometric granulocyte immunofluorescence test
(flow-gift) for detection of neutrophil auto-antibodies in children
with suspected autoimmune neutropenia (AIN)
Methods: Fifty-six sera from neutropenic children with suspec-
ted AIN were analyzed using both the flow-gift and the LSMUTR
assay. For evaluation of assay sensitivity, we initially performed
titration studies with sera containing anti-HNA-1a, -1b and -2 re-
spectively.
Results: The flow-gift method was more sensitive compared to
the LSMUTR for the detection of antibodies with HNA-1a, -1b,
and -2 specificity. One serum containing an allo-HNA-1a antibo-
dy was detectable at a titer of 1: 16.384 with flow-gift however
was found negative with the LSMUTR when tested in a 1: 32 di-
lution. In the AIN setting the overall concordance between tests
were 75%. Four sera were positive by the LSMUTR assay but
were negative by flow-gift and ten sera were negative with
LSMUTR but positive by flow-gift.
Conclusion: Titration studies revealed that the LSMUTR as-
say was less sensitive compared to the flow-gift method for
detection of HNA-1a, -1b, and -2 allo-antibodies. When eva-
luated on a cohort of suspected AIN patients concordance be-
tween the two tests were 75%. The LSMUTR is a promising
screening assay for neutrophil auto-antibodies, but needs to
be evaluated further in the clinical setting on more patient
samples.
Key words: HNA, antibodies, luminex, autoimmune, neutropenia
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P38 Genotype/phenotype discrepancy
of HNA-1a antigen typing in blood
donor involved in TRALI leads to
the identification of FCGR3B variant
Guz K., Maślanka K., Skulimowska J., Orzińska A.,
Baran P., Uhrynowska M., Brojer E.
The Institute of Hematology and Transfusion Medicine, Warsaw,
Poland
Background: The FCGRB3 alleles (*01,*02,*03) responsible for
formation of alloantigen epitope on the neutrophil FcgRIIIb
(HNA-1a, -1b, -1c) and their variants with nucleotide exchange
(141, 147, 227, 266, 277, 349) have been described. However the
participation of such variants in TRALI has not yet been obse-
rved. We present a case of TRALI after RBCs transfusion from
a blood donor with discrepant results of HNA-1a phenotyping/
/genotyping because of 2 atypical FCGRB3 alleles.
Methods: A patient with suspected TRALI and a donor of RBCs
transfused directly before occurrence of TRALI symptoms (No.
4) as well as 3 donors of RBCs transfused 13 and 9 days earlier
with no adverse reaction were examined using: anti-HNA-1 (MA-
IGA); HNA-1 phenotypes (GIFT and MAIGA); HNA-1 genotype
(PCR-SSP according to Bux et al. 1995, 1997); direct sequencing
of FCGRB3 coding region (PCR-SSP for 147C/T and/or 266A/C)
of cDNA from mRNA of granulocytes from donor No.4.
Results: Anti-HNA-1a, reactive with all 4 donors, were identi-
fied in patient’s plasma (anti-HNA-1c excluded). The phenoty-
pe/genotype results were as follows: patient HNA-1a (–) b (+)/
/FCGR3B*02; donors: No.1 HNA-1a (+) b (–) /FCR3B*01; No.2
and No.3 HNA-1a (+) b (+)/FCGR3B*01,*02. Donor No.4 was
HNA-1a (+) b (+) /FCGR3B*02,*03. Two FCGRB3 variants:
141G, 147C, 227G, 266A, 277A, 349A and 141G, 147C, 227G,
266C, 277A, 349A have been detected by sequencing besides
FCGR3B*02 and *03 in this case.
Conclusions: The FCGRB3 variants found in the blood donor
with HNA-1a phenotype/genotype discrepancy lack the Asn65
and Asp82 (227A; 277G) considered to be responsible for HNA-
1a epitope formation. His granulocytes were recognized by anti-
HNA-1a antibodies which suggests that the presence of Arg36
is effective for epitope formation. The investigation of FCGRB3
variant expression will be continued.
Key words: FCRG3B gene variants; HNA-1 antigen, HNA-1
antibody, TRALI — transfusion related acute lung injury
Heparin-induced thrombocytopenia
P39 A lateral-flow immunoassay for rapid
and reliable exclusion of heparin-induced
thrombocytopenia
Sachs U.J., von Hesberg J., Bein G., Santoso S., Bakchoul T.
Justus Liebig University Giessen, Germany
Background: Heparin-induced thrombocytopenia (HIT) is an
adverse complication of heparin caused by HIT antibodies (abs)
recognizing platelet factor 4-heparin (PF4/hep) complexes. Se-
veral laboratory tests are available for the confirmation or refu-
tation of HIT. A reliable and rapid single-sample test is pending.
Objectives: To evaluate a new lateral-flow immunoassay based
on nanoparticle technology.
Patients/methods: A cohort of 452 surgical and medical patients
suspected of having HIT was evaluated. All samples were tested
in two IgG-specific ELISAs, in a particle gel immunoassay (Pa-
GIA) and in a newly developed lateral-flow immunoassay (LFI-
HIT) as well as in a functional test (HIPA). Clinical pre-test pro-
bability was determined using 4T’s score.
Results: Platelet-activating antibodies were present in 34/452
patients, all of whom had intermediate to high clinical probabili-
ty. PF4/hep abs were detected in 79, 87, 86, and 63 sera using
the four different immunoassays. The negative predictive valu-
es (NPV) were 100% for both ELISA tests and LFI-HIT but only
99.2% for PaGIA. There were less false positives (n = 29) in the
LFI-HIT compared to any other test. Significantly less time was
required to perform LFI-HIT (median, 11 min 30 sec) than to
perform the other immunoassays.
Conclusion: A newly developed lateral-flow assay, LFI-HIT, was
capable of identifying all HIT patients in a cohort in a short period
of time. Beside an NPV of 100%, the rate of false-positive signals
is significantly lower with LFI-HIT than with other immunoassay
(s). These performance characteristics suggest a high potency in
reducing the risk and costs in patients suspected of having HIT.
P40 Lateral flow immunoassay (LFIA)
to detect heparin-induced IgG antibodies
against PF4/polyanion-complexes
Machek M.1, Steinlechner B.2, Psihoda G.1,
Eichelberger B.1, Panzer S.1
1Department for Blood Group Serology and Transfusion Medicine,
Medical University Vienna, Austria, 2Department of Anaesthesia,
Division of Cadio-Thoracic-Vascular Surgical Anaesthesia
and Intensive Care, Medical University Vienna, Austria
Background: Heparin-induced thrombocytopenia (HIT) requ-
ires rapid laboratory confirmation.
Methods: We investigated consecutive samples from 41 patients
(f/m 13/28; median age 55 years; range 20–85 years) for detecta-
ble HIT antibodies. The 4T score was median 5; range 2–8. All
samples were investigated by Zymutest HIA IgG ELISA (Hy-
phenBioMed), Heparin/PF4-antigen Particle Gel Immuno Assay
(PaGIA, BioRad), and Lateral Flow Immunoassay (LFIA, Mile-
nia Quickline). LFIA detects IgG antibodies that are captured by
biotinylated PF4/polyanion-complexes and bind to immobilized
anti-human IgG Fc on the membrane of the test unit. Biotin re-
acts with gold nanoparticles coated with anti-biotin antibodies via
immunochromatography and a coloured test line becomes visi-
ble. IgA or IgM antibodies are not detected.
Results: The 4T score was available for 35 patients. The 4T
score was 2–4 (n = 13), 5–6 (n = 20), and ± 7 (n = 2). ELISA+
samples (OD ≥ 800) were associated with a 4T score of 2–4
in n = 6; a 4T score of 5–6 in n = = 5; and a 4T score ≥ 7 in
n = none. ELISA+ (n = 12) were PaGIA+ n = 11; ELISA
(n = 29) were PaGIA+ (n = 13). ELISA+ were LFIA+ n = 5.
No ELISA was LFIA+. Plasma samples from healthy controls
spiked with dilutions of 4 HIPA+ sera were LFIA+ up to dilu-
tions of 1: 2 to 1: 8.
Conclusion: LFIA requires minimal amounts of serum (5 ml)
and provides results within 10 minutes. Its specificity is higher
than that of PaGIA, possibly without false negative results if HIT
is suspected.
Key words: heparin-induced thrombocytopenia, antibody detec-
tion, lateral flow immunoassay
Platelet transfusions
P41 Range of hematological disorders on the
alloimmunization frequencies to HLA and
HPA in Russian multitransfused patients
Golovkina L.L., Atroshchenko G.V., Krasnikova N.A.,
Kutyina R.M., Isaev V.G., Mikchaylova E.A.
Hematological Research Center, Moscow, Russia
Background: Multiple platelet transfusions result in antibody
formation to HLA and HPA and posttransfusion nonhemolitic
complications.
Aim: to determine frequencies of antiplatelet alloimmunization
in some hematological patients.
Method: Serums of 226 multitransfused patients with hemato-
logical disorders (HD) — 100 with aplastic anemia (AA), 76 with
acute myeloid leukemia (AML), 50 with acute lymphoid leuke-
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mia (ALL), received transfusions of platelet concentrates (pooled
random-donor PCs or single-donor apheresis PCs). Lymphocy-
totoxicity test and ELISA (by Santnicolos) with native and modi-
fied without HLA after processing by phosphate buffer pH3 tre-
ated platelets were used for antibody identification.
Result: The frequencies of alloimmunization to HLA and HPA
in multitransfused patients with HD are presented in Table 1.
Isolated anti-HLA has never been found in ALL patients. Allo-
immunization frequency did not depend on transfusion quantity.
Thirty percent of patients with anti-HPA have antibodies with
high and broad reactivity to donor’s platelets. Platelet transfu-
sion immune refractoriness has been observed in those patients.
Conclusion: Hematological disorders have been ranged on allo-
immunization frequency as AA-AML-ALL. Low frequency of anti-
body formation in ALL patients may be because on high block level
of lymphoid differentiation and immature of immune system cells.
P42 Antiplatelet antibodies in multiple
recipients of blood components
— personal experience
Szafranek E., Gryba P., Nadłonek K.
Regional Blood Transfusion Centre, Lublin, Poland
Introduction: Refractoriness to transfused platelet concentra-
tes (PCs) is often observed in hematological  patients. Anti-HLA
antibodies are usually implied as the  cause of refractoriness, and
for such patients  it is routine practice to transfuse  platelets from
a HLA compatible donor or platelets  from  donors compatible in
the cross match in lymphocytotoxicity test (LCT). However,  pla-
telet specific antibodies may  also be responsible for refractori-
ness.  The  anti-HPA antibody detection test  has recently been
introduced in our center.
The aim of the study is to analyze  the incidence rate for antibo-
dies to platelet glycoprotein’s in a  group of  hematolgical patients.
Material: 146 patients  were tested for  lymphocytotoxic  anti-
HLA  antibodies with LCT and  for anti-platelet antibodies and
non-complement binding anti- HLA antibodies with  ELISA PAK-
PLUS  test (GTI DIAGNOSTICS).
Results: Results of antibody detection in 146 patients are pre-
sented in the Table 1.
Anti-HLA in LCT were detected in 12% of patients;  in 2.7% of
them anti-HPA were also detected.  In the group of 129 patients
with negative  LCT  in 15 cases anti-platelet antibodies were
detected (10.3%) and non complement binding anti-HLA antibo-
dies in one case.  They were mostly  (13 recipients) anti-GPIIb/
/IIIa antibodies and in 8 cases — GPIa/IIa antibodies. GPIV anti-
bodies were detected in one recipient.
Conclusion: GTI ELISA test  helps to determine the cause of
refractoriness to transfused PCs. Detection of the antibodies in
recipient  should be followed by HPA antigen identification in  pa-
tients as well as  transfusion of HPA compatible platelets from
HPA donor registry.
P43 A new model for the identification of
refractoriness to platelet transfusion
Quaglietta A., Carinci L., Di Saverio M., Iacone A.
Department of Transfusion Medicine, Pescara Civil Hospital, Italy
Background: The identification of refractoriness in onco-hema-
tological patients undergoing platelet transfusion can help pre-
vent serious hemorrhagic events. Since the incidence of refrac-
toriness is often underestimated, we evaluated the impact of
a computerized model incorporated into the transfusion mana-
gement system, allowing a rapid detection of refractoriness thro-
ugh the automated calculation of post-transfusion absolute incre-
ment (AI). The system provides an alert after two consecutive
transfusions with an AI < 10.500 × 109/L.
Methods: Between September — October 2010 we evaluated
620 transfusions performed in 108 patients before the system
was implemented and between September and October 2011, 636
transfusions were performed in 137 patients after the implemen-
tation of the system. Patient and transfusion characteristics as-
sociated with an AI ≥ 10.500 × 109/L were evaluated through
multiple logistic regression analysis.
Results: No difference between the two years were detected in
the number of days of storage, type of platelet transfused, and
patients characteristics. The average (± SD) AI was of 13,045 ±
± 15,453 × 109/L in 2010 and 18,467 ± 23,538 × 109/L in 2011
(p = 0.03). The proportion of patients with immunological re-
fractoriness identified in 2010 and 2011 were 7,4% and 12%, re-
spectively (p = 0.19). At multivariate analysis, the likelihood of
a satisfactory response to transfusion was 70% greater in 2011
as compared to 2010 (OR = 1.7; 95% CI 1.2–2.4).
Conclusions: The adoption of an automated system allowed the
identification of a larger number of patients with immunological
refractoriness, thus leading to more effective platelet transfusions.
Table 1. Frequencies of alloimmunization to HLA and HPA (P41)
Hematological disorders Frequencies of alloimmunization (%) to Total alloimmunization
HPA HLA HPA + HLA
frequency (%)
AA 34 18 18 70
AML 18,42 2,63 14,47 35,52
ALL 8 0 4 12
Table 1. Results of antibody detection (P42)
Anti-HLA in LCT (n = 146 patients)
Detected  17 (12%) Undetected  129 (88%)
Antibodies in GTI test
Anti-platelet Anti-HLA Anti-platelet Anti-HLA
Detected Undetected Detected Undetected Detected Undetected Detected Undetected
N = 4 N = 13 N=17 N = 0 N = 15 N = 114 N = 1  N = 128
2.7% (11.6%) (10.3%) 0.7%
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P44 Platelet refractoriness and
lymphocytotoxic crossmatch
Matejkova E., Bolckova H.T., Sklenarova M.,
Zuckova M., Simackova J., Zlabova J.
Inst. of Hematology and Blood Transfusion Prague, Czech Republic
Background: The complement-dependent cytotoxicity (CDC)
crossmatch is used as an alternative method to find compatible
platelet donors for HLA alloimmunized patients with platelet
refractoriness if HLA identical donors are not available. New
sensitive techniques for the detection of donor specific HLA an-
tibodies are introduced (solid-phase assays, Luminex, FAX) but
are not standardized.
Methods: We tried to utilize a time prolonged CDC crossmatch
due to the necessity to increase the assay sensitivity. We compa-
red results of standard CDC crossmatches (standard NIH lympho-
cytotoxicity assay) and crossmatches with longer incubation time
(45 v. 30 minutes serum incubation with lymphocytes followed by
90 v. 60 minutes incubation with rabbit complement). We used con-
currently sera undiluted and diluted 1:1 with physiologic solution.
Results: We investigated crossmatches in 100 hematological
potentially HLA alloimunized patients. After the test time pro-
longation 34/100 crossmatches (34.0%) tended to have higher
reactivity scores. 10/34 crossmatches (29.4%) turned from ne-
gative to positive score and in total 15/34 tests (44.1%) incre-
ased positivity score. The reactivity score was not decreased in
any case. The serum dilution (1:1) did not significantly impact
the reaction positivity.
Conclusion: The prolongation of crossmatching time influenced
34% of reactions towards an higher reactivity score. The exten-
sion of CDC test time could in relevant cases of refractoriness
prophylaxis refine the search for a HLA compatible platelet do-
nor until standardization of more sensitive methods will be esta-
blished.
This study was supported by grant CEZ 237360001 UHKT.
P45 Cytokine and chemokine-mediated
adverse reactions in single donor apheresis
platelet component transfusions reveal
novel platelet associated-products and
likely functions
Nguyen K.A.1, Hamzeh-Cognasse H.1, Arthaud C.A.1,
Eyraud M.A.1, Chavarin P.2, Absi L.2, Pozzetto B.1,
Cognasse F.1, 2, Garraud O.1, 2
1Université de Lyon, F-42023, Saint Etienne, France. Université
de Saint Etienne, Jean Monnet, F-42023, Saint Etienne, France.
GIMAP, EA3064, F42023A, Saint Etienne, France, 2EFS
Auvergne-Loire, Saint-Etienne, France
Background: Despite being indispensible therapeutic products,
allogeneic platelets transfused in patients in need still lead to
adverse immunological effects and acute transfusion reactions
(ATR), in a frequency largely over than the other two labile blo-
od products. A part of ATRS is recapitulated by acute inflamma-
tory symptoms which may be severe. The present investigation
revealed novel cytokines associated with immune ATRs, and
specific cytokine associations in such immune ATRs.
Methods: This prospective study carried on a two-year period,
reported 59 ATR cases where the causative product was single
donor aphaeresis obtained platelets: we excluded platelet pools
to ease the interpretation of data.
Results: We here discovered novel proteins to be secreted by
platelets and associated with ATR and foremost that 6 products
were found only in association with ATR. We crossed individual
data and evidenced statistically significant associations of cyto-
kine profiles, in a donor dependent manner as we could exclude
here the patients’ relative conditions. We then calculated the risk
of association of platelet cytokine products in immune ATRs as
possible predictors of pathology.
Conclusions: This is the first demonstration of platelet secre-
tion “programs” in pathology.This work has recapitulated a num-
ber of cytokines and related products that are clearly associated
with immune ATR and adverse effects. Meanwhile, we could
chart a map of predictors of pathology by associations of cytoki-
nes first, and by the measurement of non physiological — pro-
pathological — concentrations of certain products in the PC bags
(once more, the most certain being sCD40L).
Key words: transfusion, inflammation, acute transfusion reac-
tions, cytokines/chemokines
P46 Do manual and automated processes
with distinct additive solutions differentially
affect whole blood derived platelet
components?
Nguyen K.A.1, 2, Chavarin P.1, Arthaud C.A.1,
Eyraud M.A.1, Cognasse F.1, 2, Garraud O.1, 2
1EFS Auvergne-Loire, Saint-Etienne, France, 2Université de Lyon,
F-42023, Saint Etienne, France. Université de Saint Etienne, Jean
Monnet, GIMAP-EA3064, F42023, Saint Etienne, France
Background: Platelet component (PC) transfusions are still
major contributors to adverse events, and avoiding storage le-
sions and the production of inflammatory products is a major
concern with PC preparation.
Methods: We compared PC production by manual (m) procedu-
res and automated (a) procedures using the TACSI platform with
regard to the induction of inflammatory platelet storage lesions,
and for each procedure compared platelet additive solutions
(PAS) (i.e., PASIII v. PASIIIM) with a mean range of 35% resi-
dual plasma. The comparison study involved five pooled (p) whole
blood buffy-coat-derived platelets (pPCs). We focused, 24h after
whole blood collection, on two markers, the activation platelet
surface markers CD62p and CD40L (cytometry), along with their
soluble counterparts (ELISA), which were measured under each
condition. For reference values we used TRAP, an analogue of
thrombin.
Results: Slight differences in total CD40L and CD62p platelet
surface expression was measured between ‘a’ and ‘m’ proces-
sing, irrespective of PAS. Secreted products were also signifi-
cantly different between ‘m’ and ‘a’ preparations. Platelets from
all four preparations maintained the ability to express and secrete
CD62p and CD40L following TRAP stimulation, demonstrating
their viability and the absence of detrimental storage lesions.
Conclusions: These findings validate the use of automated PC
processing with commercially available PAS, an advantage for
homogenizing the production of PCs and increasing the produc-
tion of pBCs compared to single donor aphaeresis platelet col-
lection, which that is currently considered advantageous for the
donor and recipient.
Key words: platelet, transfusions storage lesions, inflammation,
cytokines/chemokines
P47 HLA antibodies in polytransfused
hematological patients
Bolckova H.T.1, Matejkova E.1, Zuckova M.1, Simackova J.1
1Institute of Haematology and Blood Transfusion, Prague, Czech
Republic
Blood transfusions comprise an important part of a hematologi-
cal patient’s treatment. One of side effects of this therapy is
a possible recipient’s alloimmunization to antigens of donor’s blo-
od cells that might complicate following transfusion therapy.
The retrospective analysis of 100 multiply transfused hematolo-
gical patients was done in order to establish a prevalence of anti-
HLA antibodies in these patients.
The standard complement-dependent lymphocytotoxicity test
(CDC — NIH) and ELISA techniques were used for HLA anti-
bodies detection. The ELISA kits QuikScreen and B-Screen
[GTI] were employed to detect antibodies HLA class I (IgG as
well as IgM) and II (IgG).
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